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This work explores novel approaches towards pharmacological enhancement of motivated 
behaviour. A loss of motivation remains a severe unmet clinical need in a number of 
neuropsychiatric and neurodegenerative disorders. 
 
The work described in this thesis, can be divided into two sections. Initially, a series of 
experiments were conducted that aimed to increase the likelihood of cross-species translation 
of motivation research. This was achieved by firstly optimising and validating a battery of tasks 
to assess effort-related behaviour, a preclinical measure of motivation, in rats for use within an 
operant touchscreen platform. This will allow tasks to be performed with high face validity, 
across species. Secondly, we applied a highly translatable functional imaging measure, in vivo 
oxygen amperometry, to explore whether a neural correlate of motivated behaviour could be 
detected in rats. 
 
The second section describes the identification and exploration of a novel pharmacological 
target for treating apathy. By using a progressive ratio (PR) schedule of reinforcement,  
muscarinic acetylcholine receptor antagonists were found to facilitate motivated behaviour in 
intact mice. Furthermore, through the application of several compounds, these actions appeared 
to be driven by the M1 receptor subtype. Subsequently, nonpathological aging was examined 
as a potential model of impaired motivation, based upon previous reports. However, the deficit 
was found not to be reliable. Therefore, the effects of the muscarinic acetylcholine receptor 
antagonist biperiden was tested following administration of the dopamine receptor antagonist 
haloperidol, a well-validated model of impaired motivation. Biperiden was able to successfully, 
reverse the effects of haloperidol on effort-based behaviour. This suggests that the drug 
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Chapter 1. General Introduction 
 
1.1 What is apathy 
 
1.1.1 Defining apathy 
The ability to initiate and maintain goal-directed behaviour is crucial to everyday functioning. 
This ability, loosely referred to as motivation, encompasses a range of cognitive processes that 
govern how we interact with our environment to obtain key goals. The loss of motivation, 
commonly known as apathy or amotivation, is a severe unmet clinical need in a number of 
disorders. Apathy, as a clinical term, has received several definitions. Marin (1990) defined 
apathy as a disturbance of motivation that cannot be attributed to cognitive impairment or 
emotional distress. This definition was subsequently operationalised to suggest apathy was the 
loss of voluntary goal-directed behaviour (Levy & Dubois 2006). A further definition 
suggested that apathy may arise from deficits in three distinct processes, in which apathy could 
consist of auto-activation, cognitive and emotional-affective types (Levy & Dubois 2006). The 
auto-activation, or behavioural domain refers to a loss of self-initiated behaviour or a loss of 
response to externally driven behaviour. The cognitive domain refers to a loss of curiosity, 
routine or ideas both self-initiated and externally stimulated. Finally, the emotional domain 
refers to the loss of spontaneous emotions or emotional reactivity (Robert et al., 2009). 
 
One important distinction is the difference between apathy and depression. Depression and 
apathy share a high degree of co-morbidity as apathy itself is a prevalent symptom in major 
depressive disorder (Treadway & Zald, 2011). Apathy and depressive symptoms also 
frequently co-occur in a number of neurodegenerative disorders (Rovner et al. 1989; 
Cummings 1992; Paulsen et al. 2005; Kirsch-Darrow et al. 2011). Furthermore, apathy and 
depression share a number of  clinical features such as a loss of interest and psychomotor 
retardation (Landes et al. 2001). Given this close association, it is important to distinguish 
between these two syndromes as conventional treatments for major depression have little effect 
on apathy (Nutt et al. 2007). However, it is possible to distinguish apathy and depression in 
clinical samples. For example, some characteristics of depression, such as dysphoria are not 
observed in apathy (Levy et al. 1998; Lanctôt et al. 2017). Furthermore, apathy and depression 
have been associated with differential clinical outcomes in neurodegenerative diseases 
(Naarding et al. 2009).  Apathy and depression show dissociable neuroimaging correlates 
(Starkstein et al. 2009; Dan et al. 2017) and across neurodegenerative disorders, high rates of 
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apathy are observed in non-depressed patients (Levy et al. 1998; Paulsen et al. 2005; Starkstein 
et al. 2001). Perhaps the key distinction between the two constructs is that apathy is an 
emotionally neutral state, whereas depression occurs in a severely negative emotional state 
(Radakovic et al. 2015). 
 
A separate distinction is the relationship between apathy and anhedonia. Anhedonia, an 
inability to experience pleasure, is also commonly observed in a number of disorders associated 
with apathy (Der-Avakian & Markou 2012). Distinguishing the two constructs in clinical 
samples can be difficult as a loss of an ability to experience pleasure is a diagnostic symptom 
of emotional apathy (Landes et al. 2001; Robert et al. 2009). This means that apathy and 
anhedonia will likely share a high degree of overlap, as anhedonia will likely also contribute 
to a loss of goal directed behaviours. Consequently, in both the general population and 
neurodegenerative disease samples, apathy and anhedonia are highly correlated (Pluck & 
Brown 2002; Kaji & Hirata 2011; Ang et al. 2017). However, the lack of a complete overlap 
suggests some features may be separate. Apathy can be observed in the presence of otherwise 
intact reward processing in Schizophrenia and Parkinson’s disease (Lee et al. 2015; Leentjens 
et al. 2008). Furthermore, in a study of healthy subjects, apathy was shown to be dissociable 
from both anhedonia and depression (Bonnelle et al. 2015). Rodent studies have also 
demonstrated that apathy and anhedonia have at least partially distinct neural substrates 
(Salamone et al. 1994; Der-Avakian & Markou 2012). Together, these studies suggest in spite 
of the overlap in clinical samples, apathy and anhedonia represent two distinct constructs, that 
may respond differentially to pharmacological interventions. An example of the overlap of 
neuropsychiatric symptoms observed in AD can be seen in figure 1.1. 
 
1.1.2 Apathy prevalence and severity 
The presence of symptoms of apathy is  observed in neurodegenerative diseases, such as 
Alzheimer’s disease (AD, Starkstein et al. 2001), Parkinson’s disease (PD, Pedersen et al. 
2009), Huntington’s disease (HD, Naarding et al. 2009), frontotemporal dementia (FTD, Chow 
et al. 2009), vascular dementia (Staekenborg et al. 2010) and amyotrophic lateral sclerosis 
(Radakovic et al. 2016); as well as following both traumatic (Kant et al. 1998) and nontraumatic 
brain injury (Brodaty et al. 2005). Additionally, apathy is a common symptom in 
neuropsychiatric disorders such as Schizophrenia (Foussias et al. 2014) and major depressive 
disorder (Treadway & Zald 2011). The prevalence of motivational impairments in these diverse 
clinical groups is consistently high. Studies have reporting rates of apathy of up to 72% in AD 
(Mega et al. 1996); 38%-42% in PD (Starkstein et al. 1992; Pedersen et al. 2009), 28% in HD 
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(van Duijn et al. 2014) and 50% in cases of Schizophrenia (Bortolon et al. 2017). Across 
disorders, the presence of apathy is associated with significantly lower quality of life and 
increased caregiver burden (Ho et al. 1998; Boyle et al. 2003; Starkstein et al. 2006; Aarsland 
et al. 2007; Barone et al. 2009; Strauss et al. 2013; Spalletta et al. 2015; Dauphinot et al. 2015; 
Hongisto et al. 2018). AD patients with apathy show accelerated rates of cognitive decline and 
increased mortality rates (Starkstein et al. 2006; Spalletta et al. 2015). Together, these studies 
highlight the prevalence and severity of a loss of motivation. 
 
Several studies have also suggested that apathy may emerge early in neurodegenerative 
diseases. For example, the presence of apathy is often noted several years prior to formal 
diagnosis of HD (Tabrizi et al. 2013; Epping et al. 2016). The presence and severity of apathy 
is also associated with a greater risk of developing AD in those with mild cognitive impairment 
(Robert et al. 2006). Finally, individuals with rapid eye-movement sleep behaviour disorder, 
who are likely to develop a neurodegenerative disorder such as PD or dementia with Lewy 
bodies (Iranzo et al. 2013) show significantly higher rates of apathy than control subjects 
(Barber et al. 2017; Barber et al. 2018). Together, these studies suggest that the presence of 
apathy can precede full disease diagnosis, highlighting the importance of understanding apathy 
in the context of diseases. 
 
Figure 1.1: Example of the overlap and prevalence of symptoms in Alzheimer’s disease (AD). 
1Mega et al., 1996. 2Husain & Roiser 2018. 3 (Reichman & Coyne 1995) 
 
1.1.3 Methods of assessment of apathy in humans 
The majority of clinical studies assess apathy using questionnaire-based measures. These can 














consist of subsets of more general scales such as the Neuropsychiatric Inventory (Cummings 
et al. 1994). They are also scales that have been validated for specific clinical populations such 
as the Lille apathy rating scale for PD (Sockeel et al. 2006). Although, such specific scales do 
not exist for a number of neurodegenerative disorders (Radakovic et al. 2015).  
 
There are a number of considerations in the use of questionnaire-based apathy scales. Firstly, 
such measures may overlook any multidimensional aspects of apathy that can exit within a 
clinical population.  Although certain scales that probe apathy subtypes do exist, (Radakovic 
& Abrahams 2014), they have not yet been widely used in large scale clinical populations. 
Secondly, scales may be confounded by a lack of self-awareness caused by the cognitive 
impairments that co-occur with apathy in many disorders (Lanctôt et al. 2017). A number of 
scales also rely on responses from caregivers; however, the agreement between self-report and 
caregiver ratings can be low (Zanetti et al. 1999; Chatterjee et al. 2005; McKinlay et al. 2008).  
For example, caregiver ratings on the severity of apathy appear to be  heavily influenced by 
the burden placed on the caregiver (Mangone et al. 1993; Zanetti et al. 1999). It is possible that 
the responses given may be biased to reflect caregiver burden rather than apathy per se. The 
large variation in the quality of each scale may also confound comparison between studies that 
employ different questionnaires (Radakovic et al. 2015). Finally, it is not clear how well 
questionnaire based measures compare to the behavioural tasks used preclinically (see below, 
Luther et al. 2018).  
 
1.1.4  Neuroimaging correlates of apathy 
A number of studies have used structural and functional neuroimaging methods to determine 
the neural correlates of apathy. Recent in-depth reviews (Kos et al. 2016; Moretti & Signori 
2016) highlight, that disruptions to fronto-striatal circuitry have been consistently associated 
with the presence of apathy, across disorders. Magnetic resonance imaging (MRI) studies of 
stroke patients with apathy have identified higher rates of frontal and prefrontal cortex damage 
compared to non-apathetic stroke patients (Kang & Kim 2008; Brodaty et al. 2005; Hama et 
al. 2007). Studies of post-stroke apathy have also implicated lesions within the basal ganglia 
as being predictive of the presence of apathy (Onoda et al. 2011; Hama et al. 2007). Similar 
findings have been reported in studies of neurodegenerative diseases. Studies using both 
structural and functional MRI techniques have associated abnormalities within the frontal lobe 
with apathy in PD (Reijnders et al. 2010; Skidmore et al. 2013), as well as reduced fronto-
striatal resting state connectivity (Baggio et al. 2015). Apathy in PD has also been associated 
with reduced ventral striatum volume (Carriere et al. 2014). The association between structural 
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MRI-measured brain changes in AD and apathy is less clear. Some studies have reported an 
association between medial frontal lobe volume (Bruen et al. 2008; Tunnard et al. 2011) 
whereas others have not (Starkstein et al. 2009). Neuroimaging studies of  frontotemporal 
dementia (FTD) have linked atrophy within the frontal lobe to motivational impairments 
(Rosen et al. 2005; Bertoux et al. 2012; Zamboni et al. 2008). Ventral striatal volume within 
FTD patients has also been linked to the prevalence of apathy (Rosen et al. 2005). However, 
no association between apathy and structural MRI measures was found in patients with HD 
(Scahill et al. 2013).  
 
The neural correlates of motivational impairments have been widely studied in Schizophrenia. 
Like neurodegenerative samples, apathy in schizophrenia has been associated with reduced 
frontal volumes (Roth et al. 2004; Mørch-Johnsen et al. 2015) and hypoactivation of the ventral 
striatum during anticipation of rewards (Kirschner et al. 2016; Simon et al. 2010; Waltz et al. 
2009; Wolf et al. 2014). Furthermore, the degree of this hypoactivation has been correlated 
with the severity of motivational impairments (Kirschner et al. 2016; Wolf et al. 2014) 
 
To summarise, a loss of apathy is clearly present in a number of disorders including AD, PD 
and schizophrenia. Aberrant fronto-striatal function and structure have been consistently linked 
with the presence of apathy in these disorders. This suggests an approach, in line with RDoC, 
in which we bypass traditional diagnostic categories and instead focus on understanding the 
neurobiology of specific symptoms that exist across disorders (Insel et al. 2010; Cuthbert & 
Insel 2013). By understanding the biological basis of apathy, we may be able to treat it across 
a range of disorders.  
 
1.2 Assessment of motivation in rodents 
 
1.2.1 Parcellation of apathy 
A great deal of work has focused on defining and operationalising motivation for preclinical 
assessment. Motivation can be divided into appetitive/anticipatory and consummatory 
processes (Craig 1918; Ikemoto & Panksepp 1996).  The appetite-anticipatory phase refers to 
behaviours involved in approaching a goal; whereas the consummatory components are 
involved in the terminal phase of behaviour, governing the direct interaction with the goal 




Another partition of motivation divides motivated behaviours into directional and activational 
processes (e.g. Duffy 1941; 1957; Bindra 1968). Directional components of motivation, which 
contain some aspects of reward seeking or approach behaviour, allow behaviour to be directed 
towards and away from appropriate goals. Activational aspects of motivation provide an 
organism with the vigour or energy required to overcome any costs or obstacles to obtain key 
stimuli. This governs the ability to initiate and maintain goal-directed behaviour (Salamone & 
Correa 2012). In humans, the presence of apathy appears to reflect  changes in activational 
behaviours, rather than a deficit in directional or consummatory processes (Treadway et al. 
2012; Wolf et al. 2014; Barch et al. 2014; Chong et al. 2015). Although much of the research 
has focused on effort exertion for appetitive rewards, a number of preclinical studies have 
suggested that activational behaviours are also necessary to avoid negative outcomes, such as 
footshocks (McCullough et al. 1993; Sokolowski et al. 1994). These studies suggest that it is 
possible to disrupt the ability of rodents to overcome the costs to needed to avoid  an aversive 
event but leave the basic reactivity to the outcome intact (Salamone 1994). Deficits in  exerting 
effort to avoid negative outcomes have also been reported in apathetic PD patients (Porat et al. 
2014). 
 
1.2.2  Preclinical assays to measure effort 
In laboratory rodents, activational aspects of motivation can be probed through examining the 
expenditure of effort for food rewards (Salamone & Correa 2012; Salamone 1988). A number 
of behavioural assays have been developed to study effort, a number of which are outlined in 
table 1.1. One of the most commonly used assays of effort expenditure involves studying 
behaviour under a progressive ratio (PR) schedule of reinforcement (Hodos 1961). PR 
schedules probe the ability to maintain instrumental responding (such as lever-pressing) for 
rewards under escalating work demands. As the work requirement for each reward grows, an 
animal will eventually cease responding – which is known as the breakpoint. Breakpoints, 
therefore, can provide a measure of how much effort an animal is willing to exert for a given 
reward (Stewart 1975). This has been widely interpreted as giving a reflection of the 
motivational state of the organism. A drug-induced increase or decrease in breakpoint suggests 
that the compound is able to facilitate or disrupt motivated behaviour respectively. PR 
schedules were originally developed for use in the rat (Hodos 1961), however they have since 
been utilised across an number of nonhuman species including mice, pigeons and nonhuman 




Preclinical Assay Advantages Disadvantages 
Progressive ratio (PR) Highly sensitive to bi-directional 
modulations in performance 
 
Human equivalent 
Could be confounded by 




Can dissociate changes in 
motivational and hedonic processes 
 
Human equivalent 
Subject to ceiling effects. 
 
Typically requires the 
use of a deficit-model 
Progressive Choice 
(PR Choice) tasks 
Can dissociate changes in 
motivational and hedonic processes 
 
Does not require the use of a 
motivational-deficit model 
Less widely used 
Table 1.1: Overview of some of the assays used to probe effort-based behaviour in rodents 
 
One disadvantage with the use of PR schedules is that a number of psychological processes 
other than a disruption in motivation could affect performance. For example, any manipulation 
that causes a disruption to motoric function or appetite could suppress breakpoint.  
Alternatively, any animal that was hyperactive, or compulsive may show elevated breakpoints. 
However, the risk of these potential confounds can be mitigated through the use of a battery of 
control tasks that test for potential mediating behaviours, such as change in hedonic state 
(Bailey et al., 2015) 
 
An alternative  or complementary approach is to employ effort-based decision-making tasks to 
probe activational processes of motivation (Salamone, Yohn, et al. 2016).  The major 
advantage is these tasks can dissociate changes in motivational (i.e. effort exertion) and 
hedonic state (Salamone et al. 1997). The first effort related choice (ERC) task was developed 
for operant chambers (Salamone et al. 1991). During this task, rats can choose between 
performing an action (pressing a lever a given number of times) for a highly palatable reward 
(sucrose pellet) or consuming a freely available, but less preferred reward (such as standard lab 
chow). During these conditions, rats would readily respond for the highly preferred reward and 
consume little lab chow (Salamone et al., 1991). Crucially, perturbations that are believed to 
suppress effort-exertion result in a behavioural shift away from lever pressing to the low-effort, 
low-reward option (Salamone et al. 1991; Cousins et al. 1994).This is in contrast to the effects 
of appetite suppressant drugs, which result in a suppression of both lever pressing and chow 
consumption (Sink et al. 2008). ERC tasks have also been developed for use in T-mazes, where 
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animals are given a choice between entering one maze arm for a small reward, or scaling a 
barrier in the other arm to receive a larger reward (Salamone et al. 1994).   
 
A potential limitation with the use of standard ERC tasks to test for enhancements in motivation 
is that ceiling effects may obscure a facilitation in performance following drug administration. 
This is because, at baseline, healthy animals choose the higher effort, high reward option, in 
the majority of trials. Therefore, many studies have tested the efficacy of pharmacological 
interventions in rescuing a deficit model. These deficit models include pre-treatment with the 
dopamine receptor antagonist haloperidol, or tetrabenazine, a vesicular monoamine transport 
inhibitor, both of which shift behaviour to the low-effort option without causing any significant 
change in appetite or motor function (Salamone et al. 1991; Nunes, Randall, Hart, et al. 2013). 
An alternative approach has been to combine the PR and ERC tasks into PR choice tasks 
(Schweimer & Hauber 2005; Randall et al. 2012). In these tasks, the work requirement for the 
valued reward increases throughout the experimental session. The escalating work requirement 
reduces ceiling effects but still allows for the dissection of hedonic and activational processes.  
 
1.2.3 Performance based tasks in humans 
In recent years some of the behavioural tasks used in rodents have been translated for use in 
humans. Several human versions of PR tasks exist that require participants to complete an easy 
but mundane task to emulate operant responding (e.g. Roane et al. 2001; Wolf et al. 2014; 
Strauss et al. 2016; Bland et al. 2016). Like the rodent PR the number of times this task is 
required for trial completion escalates throughout the session. This allows for the calculation 
of breakpoint in human participants. However, the same caveats apply for the use of PR with 
clinical samples, as with rodent versions. For example, patients with frontal lobe damage are 
known to show high rates of apathy (Eslinger & Damasio 1985) as well as high rates of 
perseverative responding on computerised tests (Owen et al. 1993). This perseverative 
responding would be expected to produce high breakpoints in this clinical population, in spite 
of the presence of apathy.   
 
Like PR, versions of effort-based decision-making tasks have been translated for used for use 
in humans. One widely used assay is the Effort Expenditure for Rewards Task (EEfRT, 
Treadway et al. 2009). The task involves rapid button pressing for monetary rewards, with 
participants able to select from hard or easy versions of the task on each trial that yield larger 
or smaller rewards respectively. Other behavioural tasks manipulate effort through exerting 
hand grip force (Chong et al. 2015).  Although such performance based tasks are promising, 
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and have been used to probe motivational deficits in clinical populations (Treadway et al. 2012; 
e.g. Barch et al. 2014; Treadway et al. 2015; Hershenberg et al. 2016; Wolf et al. 2014), there 
have been no large-scale studies to date using such measures to test pharmacological 
interventions in humans. Therefore, the findings reviewed below rely on traditional, 
questionnaire-based assessments of motivation. In spite of this, there appears to be good 




1.3 Apathy as an unmet clinical need: Pharmacological approaches to enhancement of 
motivated behaviour 
 
1.3.1 Neurocircuitry of effort-based behaviour 
The neurocircuitry of effort-related behaviour has been widely characterised. Regions 
including the anterior cingulate cortex (Walton et al. 2003); medial orbitofrontal cortex 
(Münster & Hauber 2017); basolateral amygdala (Floresco & Ghods-Sharifi 2007) and 
hippocampus (Schmelzeis & Mittleman 1996) have all been shown to be involved in effort-
expenditure for appetitive rewards.  One system that has been extensively relative to effort-
based behaviour studied is the mesolimbic dopamine (DA) pathway. The mesolimbic pathway, 
one of the major DAergic pathways of the brain, consists of DA neurons projecting from the 
ventral tegmental area to the striatum. Dopaminergic depletions or local receptor blockade 
within the nucleus accumbens (NAc) region of the ventral striatum impairs PR performance 
(Aberman et al. 1998; Hamill et al. 1999; Bari & Pierce 2005).   In contrast, excitotoxic lesions 
to the NAc increase PR breakpoints (Bowman & Brown 1998); whereas lesions to dorsal 
regions of the striatum do not affect breakpoint (Eagle et al. 1999).  
 
Similar (but not identical) findings have been observed using effort-based decision-making 
tasks (reviewed in Bailey, Simpson, et al. 2016). Dopamine depletions of the NAc or local DA 
receptor blockade shift performance from the higher-effort high-reward options, to the low-
cost less preferred choices in ERC tasks (Salamone et al. 1991; Cousins & Salamone 1994; 
Nowend et al. 2001). The NAc can be further subdivided into the core and shell sub-regions 
(Záborszky et al. 1985). The effects of DAergic manipulations on effort-related behaviour 
appear to driven by the core, not the shell, sub-region of the NAc (Sokolowski & Salamone 




A number of brain regions beyond the nucleus accumbens have also been implicated in 
supporting effort exertion. As reviewed above, human imaging studies have implicated altered 
activity within the prefrontal cortex (PFC) in patients displaying apathy. In rodents, an 
appreciation of the neural circuitry supporting behaviour can be gained through disconnection 
lesion-based approaches, where asymmetric unilateral lesions or infusions of GABA agonists 
are administered. In mice, lesions to the prelimbic region of the PFC significantly reduces PR 
breakpoint (Gourley et al. 2010). Numerous studies have also implicated the anterior cingulate 
cortex (ACC) in effort-based behaviour. Excitotoxic lesions to the ACC shift behaviour from 
preforming a high-effort high-reward behaviour to a lower effort smaller reward option, in both 
maze- and lever-based ERC tasks (Walton et al. 2003; Schweimer & Hauber 2005; Walton et 
al. 2009). The ACC has strong projections to the NAc core (Brog et al. 1993). Disconnecting 
the ACC and the NAc Core significantly impaired ERC performance, demonstrating a 
necessary role of the ACC-NAc circuitry in effort-based behaviour (Hauber & Sommer 2009). 
Like the ACC, lesions to the basolateral nucleus of the amygdala (BLA), disrupts effort-based 
decision making (Floresco & Ghods-Sharifi 2007; Ghods-Sharifi et al. 2009). The BLA also 
projects to the NAc (McDonald 1991) and receives projections from the ACC (Mcdonald et al. 
1996). Disconnecting this BLA and ACC circuit through asymmetric lesions impairs 
performance (Floresco & Ghods-Sharifi 2007). Effort-based behaviour can also be disrupted 
through interfering with the output projections from the NAc.  Disconnecting the NAc from 
the ventral pallidum also shifts behaviour to the low effort, low reward action (Mingote et al. 
2008), mirroring the effects of DAergic lesions to the NAc. Taken together, these studies 
demonstrate an extended network of brain regions involved in supporting effort-based 
behaviour. 
 
1.3.2 Dopaminergic based approaches 
As disruptions to DA function impair effort-based behaviour, manipulations that enhance NAc 
DA function may facilitate motivated behaviour. Neurotransmission of DA can be enhanced 
with psychostimulants. For example the indirect catecholamine agonist d-amphetamine, which 
enhances DA release within the striatum (Westerink et al. 1987), facilitates PR performance in 
rodents. Infusions of amphetamine into the nucleus accumbens (NAc) region of the striatum 
enhances PR breakpoints (Zhang et al. 2003; Wirtshafter & Stratford 2010). Furthermore, 
systemic administration of amphetamine facilitates PR performance in rats and mice (Poncelet 
et al. 1983; Bensadoun et al. 2004; Heath et al. 2015). Amphetamine can also facilitate selection 
of high-effort high-reward options in some effort-related decision-making tasks (Floresco et 




In healthy human subjects, amphetamine facilitates high-effort selection in the EEfRT task 
(Wardle et al. 2011), particularly in trials where the likelihood of reward was low. There have 
also been a number of amphetamine studies investigating the effects in clinical samples using 
observational and questionnaire-based measures. Amphetamine has been reported to be 
effective in reducing apathy in small group of patients with FTD (Huey et al. 2008). 
Furthermore, in elderly subjects residing in care homes, amphetamine was effective at 
significantly reducing rates of apathy in the majority of subjects (Clark & Mankikar 1979). 
 
Other psychostimulant compounds have also demonstrated efficacy in facilitating motivated 
behaviours in rodents. The dopamine reuptake inhibitor methylphenidate, (Ferris & Tang 1979) 
is typically prescribed as a treatment in attention deficit hyperactivity disorder as well as 
narcolepsy (Wenthur 2016), Like amphetamine, one of the major physiological actions of 
methylphenidate is to increase the levels of dopamine within the NAc (Kuczenski & Segal 
1997). Systemic administration of methylphenidate to rats increases PR breakpoints (Poncelet 
et al. 1983; Mayorga et al. 2000). Furthermore, methylphenidate is able to rescue an induced 
deficit in ERC performance following pre-treatment with the pro-inflammatory cytokine, 
interleukin-6 (Yohn, Arif, et al. 2016). The ability to facilitate effort exertion in intact rodents, 
and rescue a motivational deficit provides strong preclinical evidence for pro-motivational 
efficacy.  
 
A number of clinical studies have reported that methylphenidate has been successful in 
reducing symptoms of apathy, across a number of disorders. Single patient or small scale case 
reports have noted that motivational deficits were improved following methylphenidate 
treatment, patients with subcortical infarcts (Watanabe et al. 1995), PD (Chatterjee & Fahn 
2002), hydrocephalus (Keenan et al. 2005), major depression (Padala et al. 2005), and acquired 
brain injuries (Spiegel et al. 2009). The effects of methylphenidate on apathy have also been 
studied in larger randomised control trials (RCTs). An initial small study of patients with AD 
reported a significant reduction in the severity of apathy (Galynker et al. 1997). Subsequent 
larger RCTs, investigating the effect of methylphenidate treatment on apathy in AD patients 
have replicated this finding (Herrmann et al. 2008; Rosenberg et al. 2013; Padala et al. 2017).  
Together, these studies present strong support for the use of methylphenidate in AD to treat 






Bupropion also acts as a dopamine reuptake inhibitor  (Dwoskin et al. 2006), and has been used 
as a treatment for depression as well as a smoking cessation aid (Stahl et al. 2004). Bupropion 
has been shown to produce a dose-dependent increase in PR breakpoints (Bruijnzeel & Markou 
2003).  Furthermore, systemic administration of bupropion increases selection of the high-
effort, high reward option in a PR-choice task in rats (Randall, Lee, Podurgiel, et al. 2014). 
Bupropion is also effective at rescuing motivational impairments in rodents. Administration of 
bupropion  can rescue deficits in effort-related decision-making induced by pre-treatment with 
tetrabenazine (Randall, Lee, Nunes, et al. 2014; Nunes, Randall, Hart, et al. 2013) and the pro-
inflammatory cytokine interleukin-6 (Yohn, Arif, et al. 2016).  
 
Bupropion has been reported to improve symptoms of apathy in cases of acquired brain injury, 
major depression (Corcoran et al. 2004) and frontotemporal dementia (Lin et al. 2016). 
However, several larger placebo-controlled studies suggest only limited effects of bupropion. 
In a study of 40 patients with schizophrenia, bupropion was found to have no significant effect 
on apathy or negative symptoms as a whole (Yassini et al. 2014). Furthermore,  in a  recent 
RCT of bupropion in HD, apathy was not significantly affected by the drug (Gelderblom et al. 
2017). It is not clear whether bupropion lacks clinical efficacy, or whether bupropion as a whole 
is not affective at treating motivational impairments, or simply not effective in the clinical 
populations tested 
 
Novel dopamine reuptake inhibitors have also been demonstrated to facilitate motivated 
behaviour indexed by PR and PR Choice tasks in healthy rodents (Sommer et al. 2014) and are 
able to rescue a tetrabenazine deficit model (Yohn, Gogoj, et al. 2016). Another compound 
which may act,  as a weak dopamine reuptake inhibitor is the wakefulness promoting drug 
modafinil (Minzenberg & Carter 2008). In rodents, modafinil has been shown to increase 
extracellular DA within the NAc (Murillo-Rodríguez et al. 2007). However, the evidence for 
motivational enhancing effects of modafinil in rodents is mixed. One study suggested 
modafinil produced a small but significant increase in PR breakpoints in mice  (Young & Geyer 
2010). Whereas, another study has reported no effects on either PR or PR choice performance 
in rats (Sommer et al. 2014). However, modafinil has been reported to partially reverse a ERC 
deficit (Yohn, Gogoj, et al. 2016). Together, this suggests that modafinil may be more effective 




Like the mixed preclinical results, it is not clear if modafinil is a useful therapeutic option for 
apathy in clinical cases. There are several single case reports suggesting that modafinil can 
improve symptoms of apathy in elderly subjects (Padala et al. 2007; Camargos & Quintas 
2011). A systematic review of five RCTs in schizophrenia concluded that modafinil or 
armodafinil (the R-enantiomer of modafinil) may be effective at reducing negative symptoms 
(Andrade et al. 2015). However, it is not clear whether these effects are linked to changes in 
motivated behaviour specifically. The RCTs in question all employed composite measures of 
negative symptoms as endpoints – the subscale of the Positive and Negative Syndrome Scale 
(PANSS-N) or the Scale for Assessment of Negative Symptoms (SANS), rather than a specific 
measure of apathy. Although apathy is a subdomain of both of these rating scales (Kay et al. 
1987; Andreasen 1989), both scales consist of a number of other domains independent from 
apathy, that may underlie the global change in negative symptoms score. In particular, several 
domains are linked to inattentiveness across both scales (Kay et al. 1987; Andreasen 1989). 
Given the stronger association between modafinil and attention in schizophrenia (Morein-
Zamir et al. 2007). It is possible that the effects reported here are primarily driven by a domain 
other than apathy. Furthermore, a small RCT of the efficacy of modafinil at treating apathy in 
AD, found no significant difference from placebo on symptoms of apathy (Frakey et al. 2012). 
Overall, the mixed evidence for the efficacy of modafinil may be due to its weaker effect on 
DA function compared to other psychostimulants such as methylphenidate. 
 
Several studies have investigated the effects of monoamine-oxidase (MAO) inhibitors on effort 
expenditure in rodents. The MAO-B inhibitor deprenyl (also known as selegiline)  is used as a 
treatment in Parkinson’s disease and depression (Miklya 2016) Although it is not clear whether 
administration of deprenyl is sufficient for an increase extracellular DA levels (Kato et al. 
1986; Butcher et al. 1990; Yohn et al. 2018), the compound does potentiate stimulant induced 
DA release (Schiffer et al. 2003). Acute administration of deprenyl has been shown to partially 
rescue a tetrabenazine-induced deficit on both ERC and PR choice tasks (Randall, Lee, Nunes, 
et al. 2014; Contreras-Mora et al. 2018). Deprenyl is also able to facilitate high effort selection 
on a PR choice task in intact rats (Yohn et al. 2018). Together, these studies suggest that DAT 
inhibition as well as MAO-B inhibitors can increase effort expenditure in intact rodents as well 
as reverse pharmacological-induced motivational deficits.  
  
The MAO-B inhibitor deprenyl has been linked to positive changes in motivation in clinical 
samples. Case reports suggest deprenyl may be effective at treating apathy in cases of traumatic 
brain injury (Newburn & Newburn 2005; Moutaouakil et al. 2009). An initial open-label study 
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suggested deprenyl may also be effective at reducing negative symptoms in schizophrenia 
(Bodkin et al. 1996), which has since been replicated in a placebo controlled RCT (Amiri et al. 
2008). Furthermore, deprenyl is able to significantly reduce symptoms of apathy in patients 
with schizophrenia relative to placebo (Bodkin et al. 2005). However, there is no clear evidence 
of any benefit of deprenyl administration to those with AD (Birks & Flicker 2003, for a review). 
 
Many of the effective compounds described above (e.g. amphetamine, methylphenidate, 
bupropion) act on the noradrenaline system (Kuczenski & Segal 1997). However, tests of 
selective noradrenaline reuptake inhibitors atomoxetine and desipramine suggest that the 
effects of psychostimulants on motivated drugs are not driven by affecting noradrenaline 
function. In rats, atomoxetine does not affect effort-related decision making (Hosking et al. 
2015) nor affect responding in a PR choice task (Yohn, Errante, et al. 2016). Furthermore, 
desipramine does not rescue a tetrabenazine-induced deficit in ERC (Yohn, Collins, et al. 
2016). In line with preclinical evidence, atomoxetine does not reduce symptoms of apathy in 
PD (Weintraub et al. 2010).  
 
Taken together there is clear evidence that enhancing dopamine neurotransmission can 
facilitate effort-related behaviour in rodents and improve symptoms of apathy on clinical 
samples. However, it is also important to note that there may be several problems with the use 
of dopaminergic therapy, particularly in clinical groups. These include exacerbation of pre-
existing symptoms, particularly in the case of schizophrenia (Janowsky & Davis 1976; 
Janowsky et al. 1973; Lindenmayer et al. 2013); abuse liability (Morton & Stockton 2000); and 
increasing maladaptive behaviours such as impulsivity (Cools et al. 2003).  
 
1.3.3 Effects of serotoninergic compounds 
Research has also investigated the therapeutic potential of non-dopaminergic targets in 
motivated behaviours. Compounds that affect the activity of another monoamine, serotonin (5-
HT) can also affect effort exertion in rodents. Serotonin reuptake inhibitors (SSRIs) are 
amongst the most common forms of antidepressant medication (Jakobsen et al. 2017). 
However, in laboratory animals, administration of SSRIs has been shown to either reduce PR 
breakpoints or have no effect (Cilia et al. 2001; Sanders et al. 2007; Mathes et al. 2013).  
Additionally, SSRIs are not effective at reversing pharmacological-induced deficits on effort-




Different 5-HT receptor subtypes appear to have differential roles in motivated behaviour. For 
example, 5-HT6  stimulation can facilitate PR breakpoint, whereas 5-HT1/7 receptor stimulation 
reduces breakpoints (Pratt et al. 2012). A number of studies have focused on the 5-HT2c 
subtype, due to a relationship with dopamine transmission (Di Giovanni et al. 1999; Alex et al. 
2005). Micro-dialysis studies have allowed for the investigation of the effects of 5-HT2c ligands 
on dopamine release. In particular several studies have investigated the effects of such drugs 
on NAc dopamine efflux. Systemic and local administration of 5-HT2c agonists results in a 
decrease in NAc levels (Alex et al. 2005). Conversely, 5-HT2c receptor agonists can result in 
an increase in dopamine influx. Studies with genetic KO mice have confirmed this relationship 
(Huang et al. 2011). Similar 5-HT2c – DA associations have been observed within the dorsal 
striatum and prefrontal cortex (Bailey et al. 2018; Di Giovanni et al. 2000).. Due to this 
relationship it would be anticipated that 5-HT2c agonists and antagonists would decrease and 
increase effort expenditure respectively. In line with this, activation of 5-HT2c receptors 
reduces PR breakpoints (Fletcher et al. 2010; Bezzina et al. 2015; Wolff & Leander 2000). 
Conversely, PR performance can be facilitated by the 5-HT2c receptor antagonist SB242084 
(Simpson et al. 2011; Bailey, Williamson, et al. 2016). Furthermore, SB242084 also facilitates 
high effort choices on a modified ERC task (Bailey, Williamson, et al. 2016).  
 
Much of the research in humans has investigated the efficacy of SSRIs on apathy. In line with 
the preclinical evidence, these studies suggest SSRIs have little effect on the symptoms of 
apathy and may even exacerbate motivational impairments. SSRIs typically do not affect rates 
of apathy present in major depression (Nutt et al. 2007). In elderly patients, SSRI use is 
associated with higher levels of apathy (Wongpakaran et al. 2007) (Padala et al. 2012; Barnhart 
et al. 2004). Similar findings have been reported in other clinical populations. A number of 
RCTs have reported that SSRIs do not reduce apathy in AD patients (Pollock et al. 2002; 
Siddique et al. 2009; Porsteinsson et al. 2014). The use of SSRIs as an add-on to antipsychotic 
medication appear to have no effect on symptoms of apathy in schizophrenia (Hayashi et al. 
1997), or HD (Beglinger et al. 2014). Whereas, SSRI use is associated with greater levels of 
apathy in PD (Zahodne et al. 2012). Together, these studies suggest that SSRIs have little 
positive impact on apathy in clinical populations. There is however, evidence is evidence to 
suggest that 5-HT2c antagonists may be able to treat apathy, in line with the preclinical findings. 
Agomelatine is a nonselective 5-HT2c antagonist (Millan et al. 2003), used as an antidepressant 
treatment. In a case report, agomelatine was reported to reduce SSRI-induced apathy (Callegari 
et al. 2016). Furthermore agomelatine was found to reduce apathy in a group of non-depressed 
patients with FTD (Callegari et al. 2016). This early result suggests that 5-HT2c receptors may 
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be a viable target for treating motivational impairments; however, this finding should be fully 
explored with the use of larger -scale RCTs. 
 
One caveat with the therapeutic use of 5-HT2c agonists are the effects of this class of drugs on 
appetite. In rodents, activation of 5-HT2c receptors facilitates the onset of satiety and reduces 
free food consumption (Hewitt et al. 2002; Clifton et al. 2000). Conversely genetic deletion of 
5-HT2c increases feeding behaviour in mice (Heisler & Tecott 1999). This may potentially 
confound the rodent studies of effort, reviewed above, which used food-reinforced assays to 
measure motivation. Although some studies have utilised sucrose consumption tests as a 
control (Bailey, Williamson, et al. 2016), the results on breakpoint should be interpreted with 
caution due to a potentially mediating effect of appetite. In humans, long-term use 
pharmacotherapies with of 5-HT2c antagonist properties are associated with alterations in 
appetite regulation (Reynolds & Kirk 2010). This is believed to underlie the significant weight-
gain associated with atypical antipsychotic use (Lord et al. 2017); a hypothesis that is supported 
by preclinical studies (Kirk et al. 2009).  Together, this may limit the potential therapeutic 
benefit of targeting the 5-HT2c receptor for the treatment of apathy. 
 
1.3.4 Effects of adenosinergic compounds 
Another pharmacological target that has been linked with effort-based behaviour is the 
adenosine system. The widely used psychostimulant caffeine acts as a nonselective adenosine 
receptor antagonist (El Yacoubi et al. 2000).  In rodents, caffeine increases effort expenditure 
for food reward. When administered prior to PR testing, acute and chronic administration of 
caffeine increases breakpoint (Poncelet et al. 1983; Sheppard et al. 2012; Retzbach et al. 2014). 
In intact rats, a moderate dose of caffeine can produce a small but significant facilitation of 
PR-choice performance (SanMiguel et al. 2018).  Furthermore, caffeine can partially rescue 
the effort-related decision-making deficit induced by the D2 receptor antagonist haloperidol 
(Salamone, Farrar, et al. 2009).  
 
Studies investigating the effects of caffeine on effortful behaviour in humans date back over a 
century (Rivers & Webber 1907). A small observational study of elderly patients with dementia 
reported a significant negative correlation between the quantity caffeine consumption and 
severity of apathy (Kromhout et al. 2014).  This finding suggests that caffeine may reduce the 
severity of apathetic symptoms. Although a recent case study suggests that caffeine may not 
work as a direct intervention for apathy (Kromhout et al. 2017), a larger study of elderly 
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subjects aims to investigate the therapeutic potential of caffeine (the BeCAF study), which 
remains an ongoing trial, with no results yet published (Kromhout et al. 2018).  
 
Many of the behavioural actions of caffeine may be driven primarily through actions at the 
adenosine A2A receptor subtype (El Yacoubi et al. 2000). Within the striatum, adenosine A2A 
receptors are colocalised with DA receptors  on D2-like MSNs (striatopallidal neurons) where 
they exert opposing effects on the adenylyl cyclase signalling pathway (Ferré et al. 2008). 
Antagonism of adenosine A2A receptors with systemic administration of the compound MSX-
3, can reverse a motivational deficit defect on ERC tasks induced by systemic haloperidol 
(Farrar et al. 2007; Mott et al. 2009) and tetrabenazine (Nunes, Randall, Hart, et al. 2013). 
Systemic administration of MSX-3 also facilitates high effort choices in a PR choice 
performance in intact rats (Randall et al. 2012).  Other A2A receptor antagonists are also able 
to reverse the motivational deficits induced by dopamine D2 receptor blockade (Nunes et al. 
2010; Collins et al. 2012). Together, these results suggest a possible therapeutic benefit of A2A 
receptor blockade in the treatment of motivational impairments.  
 
Several studies have investigated adenosine antagonists as pharmacological treatments for 
Parkinson’s disease. A recent RCT investigated the effect of caffeine in Parkinson’s patients 
(Postuma et al. 2017). Although apathy was not specifically examined, the authors reported 
that caffeine did not produce any benefit on quality of life, cognitive function or mood 
(Postuma et al. 2017).  Selective A2A receptor antagonists appear effective at treating motoric 
symptoms of Parkinson’s Disease (Sako et al. 2017). Several case reports suggest that A2A 
receptor antagonists may benefit mood and fatigue in Parkinson’s disease (Nomoto et al. 2014). 
However, there is currently no studies specifically examining the effects of adenosine A2A 
receptor antagonists on apathy in Parkinson’s disease. Further research is needed to investigate 
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Further research needed 
Table 1.2: Overview of the effects of the effects of pharmacological interventions for apathy.  
 
1.3.5 Resistance to current treatments 
The typical front-line treatments for many neuropsychological and neurodegenerative 
disorders have little impact on apathy. In schizophrenia, neither typical nor atypical 
antipsychotics are effective in treating motivational impairments (Fusar-Poli et al. 2015; 
Fervaha et al. 2015). Furthermore, there is some evidence to suggest antipsychotic treatment 
may in fact exacerbate symptoms of apathy in patients (Artaloytia et al. 2006) and induce 
impairments in healthy subjects (Mas et al. 2013). Symptoms of apathy arising during cases of  
major depression are also resistant to traditional pharmacological treatments (Nutt et al. 2007), 
and may be exacerbated by serotoninergic-based antidepressant medication (Barnhart et al. 
2004). In AD, there is no clear evidence whether the acetylcholinesterase inhibitors (AChEIs) 
used to treat cognitive impairments can produce clinically meaningful effects on rates of apathy 
(Ruthirakuhan et al. 2018). Apathy also appears resistant to the non-AChEI treatment, 
memantine (Kishi et al. 2017). Likewise, the only approved pharmacological treatment for HD, 
tetrabenazine, does not help reduce the severity of apathy (Mestre et al. 2009).  These studies 
highlight how conventional treatment approaches However, one possible exception arises in 
PD, where treatment where dopaminergic-based treatments, such as levodopa, may reduce the 




As the foregoing review indicates, apathy remains an unmet clinical need. However, there is 
clear therapeutic promise with a number of pharmacological approaches, in particular 
methylphenidate. Further work is needed to fully explore the potential benefits of 5-HT2c and 
adenosine A2A receptor antagonists in treating motivational impairments. In spite of differences 
in the way motivation is assessed in laboratory animals and clinical groups, the similarity in 
the efficacy in a number of compounds suggests that examining effort exertion can model the 
motivational processes that occur in humans. This strengthens the case for clinical studies to 
build on future preclinical work discovering new targets.   
 
1.4 The Muscarinic system 
 
1.4.1 Muscarinic receptors location and pharmacology 
As reviewed above, there is a clear association between DA function and motivated behaviour.  
Furthermore, both 5-HT2c and adenosine A2A receptor antagonists are able to modulate DA 
function ((Salamone, Farrar, et al. 2009; Valencia-Torres et al. 2017). A separate 
neurotransmitter that can act as a neuromodulator is acetylcholine (ACh) (Picciotto et al. 2012). 
In particular, ACh plays a key role in modulating striatal circuitry and function (for reviews 
see: Cragg 2006; Exley & Cragg 2008; Picciotto et al. 2012). ACh receptors consist of 
muscarinic (mAChR) and nicotinic (nAChR) types. Of the muscarinic type, there are five 
receptor subtypes, M1-M5(Dörje et al. 1991; Bonner et al. 1987). Based on morphology and 
function these have been divided into M1-type (M1, M3, M5) and M2- type (M2, M4) mAChRs 
(Caulfield & Birdsall 1998). mAChRs are expressed in peripheral and central locations (Hulme 
et al. 1990).  In peripheral tissue, mAChRs are expressed within the gut, heart and bladder 
(Caulfield 1993). Centrally, some degree of regional localisation of receptor subtypes has been 
found within the rodent brain (table 1.3).  The M1 receptor is the most common mAChR in the 
CNS (Langmead et al. 2008). M1 receptors  are  the highest expressed subtype in the cortex and  
hippocampus, (Levey et al. 1991; Levey et al. 1995). M1 receptors are also widely expressed 
in both dorsal and ventral regions of the striatum (Weiner et al. 1990) and to a lesser extent the 
thalamus and hindbrain (Levey 1993). M2 receptors are also located within the striatum, along 
with high expression within thalamus and  cortex (Levey et al. 1991; Levey 1993). Unlike the 
other subtypes, M3 receptors show far lower levels of CNS expression; however, M3 receptors 
are expressed within the cortex and hippocampus (Wall et al. 1991). M4 receptors, like the M1 
subtype are expressed throughout the brain, particularly within the striatum where they are the 
most widely expressed mAChR (Bernard et al. 1992). Finally, M5 receptors are the most 
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discretely localised receptor, with expression largely confined to the substantia nigra and 
ventral tegmental area (Vilaró et al. 1990). M1  receptors show similar levels of expression in 
both the dorsal and ventral striatum, whereas M2 and M4 receptors are expressed in higher 
levels in the ventral striatum (Tayebi et al., 2004, table 1.3). 
 
Table 1.3: Outline of the localisation and signalling pathways of centrally-located muscarinic 
acetylcholine receptors. CIN: cholinergic interneurons; CNS: Central Nervous System; DA: 
dopamine; MSN: Medium Spiny Neurons. 
 
Muscarinic receptors also differ according to their pharmacological profile. Muscarinic 
receptors are G-protein coupled receptors (GPCRs) M1-type (M1, M3, M5) receptors couple to 
the Gq/11 protein, and M2- type (M2, M4) receptors couple to the Gi/o protein.  Figure 1.2 shows 
how the stimulatory M1 class of receptor activates phospholipase c, which causes the generation 
of the second messengers diacylglycerol and inositol 1,4,5-triphosphate (Felder 1995). Inositol 
1,4,5-triphosphate subsequently mobilises intracellular calcium and  diacylglycerol activates 
protein kinase C (Felder 1995). Activation of M2- type receptors inhibits adenylyl cyclase, 
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which reduces the availability of the second messenger cyclic adenosine monophosphate 
(cAMP, table 1.3, figure 1.2). 
 
Figure 1.2 Visualisation of the signalling pathways of M1 and M2 type muscarinic receptors. 
M1 type receptors activate phospholipase C .M2 receptors inhibit adenyl cyclase. PLC: 
phospholipase C; IP3: inositol 1,4,5-triphosphate; DAG: diacylglycerol activates; PKC: protein 
kinase C; AC: adenylyl cyclase; cAMP: cyclic adenosine monophosphate 
 
Striatal levels of ACh, as well as acetylcholinesterase expression are amongst the highest of 
anywhere in the brain (Macintosh 1941; Weiner et al. 1990). Throughout the striatum, 
cholinergic tone is governed by tonically active cholinergic interneurons (CINs, Zhou et al. 
2002). CINs only comprise of 1-2% of the striatal neuron population (Phelps et al. 1985; Bolam 
et al. 1984); however, they have been heavily implicated in modulating striatal function 
(Goldberg et al. 2012; Gonzales & Smith 2015).  CINs express presynaptic M2 and M4 receptors 
(Bernard et al. 1992), where they function as autoreceptors. Activation of these receptors has 
been shown to supress ACh release from CINs (Zhang et al. 2002). The majority of the 
remaining striatal neurons (90-95%) are GABAergic medium spiny neurons (MSNs, Goldberg 
et al. 2012). These MSNs are the primary output neurons of the striatum and have been divided 
into two pathways. The dopamine D1 receptor expressing striatonigral MSNs (also known as 
the direct pathway) and the dopamine D2 receptor expressing striatopallidal  MSNs (also 
known as the indirect pathway, Gerfen et al. 1990). M4 receptors appear largely co-expressed 
with D1 receptors on striatonigral MSNs, where they exert opposing effects to D1 receptors 
which activate adenylyl cyclase, and subsequent cAMP signalling (Girasole & Nelson 2015).  
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In the striatum, D1 receptor dependent cAMP signalling is mediated by the Gaolf protein, unlike 
in cortical areas where D1 receptors are  believed coupled to Gas proteins, due to the clear 
regional distribution of the expression of these G-protein subunits (Hervé et al. 1993; Hervé 
2011; Yano et al. 2018). 
 
M1 receptors, in contrast to M4 receptors , are expressed on both MSN types (Goldberg et al. 
2012). M1 receptors increase MSN excitability through promoting the closure of potassium 
channels (Shen et al. 2005). Interestingly, M1 receptor modulation of dendritic excitability by 
Kir2 potassium channels is found almost exclusively in striatopallidal MSNs, due to elevated 
expression of the Kir2.3 subunits in these neurons  (Shen et al. 2007). This raises the possibility 
that activation of M1 receptors preferentially modulates excitability in the D2-containing 
striatopallidal MSNs (Shen et al. 2007; Oldenburg & Ding 2011). 
 
It is worth noting that muscarinic receptors express highly similar acetylcholine binding 
pockets. In particular there is a high degree of similarity in the structure of M1and M4 receptors 
(Thal et al. 2016) This has made development of highly selective compounds that act on the 
orthosteric binding sites difficult (Bradley et al. 2017). As a consequence, there is a lack of 
highly selective ligands that can act exclusively on one mAChR subtype. The lack of selective 
ligands may have led to some inconsistency in the literature, as compounds have at best, 
preference for one mAChR subtype. Therefore, a cautious approach should be adopted in 
interpreting pharmacological effects of one receptor subtype over another. mAChR allosteric 
binding sites are topographically separate from the site at which endogenous ligands bind on, 
are less evolutionarily conserved than the orthosteric binding sites (Bridges et al. 2010). 
Therefore, it may be possible to produce allosteric compounds with far greater selectivity for 
mAChR subtypes (Conn et al. 2009). Additionally, combining the use of genetic mAChR 
knock-out mice along with mice have helped researchers to understand the function of 
mAChRs (Wess et al. 2007). 
 
1.4.2 mAChRs and Dopamine function 
Converging evidence suggests that mAChRs can modulate dopamine (DA) release and 
function within the striatum. However, reports of the effects of mAChR ligands on DA release 
have been somewhat conflicting. For example, mAChR agonists have been reported to both 
potentiate and supress striatal DA release (de Belleroche & Gardiner 1982; Kudernatsch & 
Sutor 1994; Chapman et al. 1997). It is likely that differing receptor subtypes have opposing 
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roles and DA release (Threlfell et al. 2010). The conflicting results may be due to the poor 
selectivity of many classical mAChR orthosteric compounds (Conn et al. 2009). However, a 
combined approach of using more selective ligands as well as muscarinic receptor knock out 
(KO) mice, has provided evidence of the modulatory role mAChRs have on DA release.  
Pharmacological activation of M2 and M4 receptors inhibits striatal DA release, through an 
autoreceptor-mediated reduction in cholinergic tone  (Threlfell et al. 2010; Shin et al. 2015).  
The reduction in local cholinergic tone, reduces the activity of nAChRs expressed on DAergic 
axons (Threlfell et al. 2010), reducing DA release. Conversely, M5 receptor activation 
potentiates striatal DA transmission (Shin et al. 2015), likely through actions on VTA DA 
neurons. Alongside mAChR subtype differences, there are also regional influences on the 
muscarinic-dopamine relationship. For example, M2 and M4 are necessary for mAChR 
mediated control of DA release within the dorsal striatum (Threlfell et al. 2010). In contrast 
only M4, but not M2 receptors, are necessary for mAChR regulation of NAc DA (Threlfell et 
al. 2010). In a separate study, M4 KO mice were shown to display enhanced amphetamine–
induced NAc DA release relative to wild-type mice, whereas M2 KO mice did not (Tzavara et 
al. 2004); however,  no behavioural data was reported in this study. It is also worth noting, that 
the ability of mAChRs to modulate DA function is at least partially dependent on the activity 
of the DA system (Threlfell et al. 2010). This suggests, that different results may be observed 
depending on, for example, whether an animal is behaving or idle. Therefore, there is a well-
established pathway for presynaptic M4 receptors modulating DAergic function, via a decrease 
in ACh tone. M4 receptors are also able to modulate DA function independently of this 
established nAChR-mediated pathway. Pre-treatment with a nAChR antagonist does not 
entirely abolish the mAChR-mediated inhibition of DA release (Foster et al. 2016). It is likely, 
therefore, that postsynaptic M4 receptors are also involved in the modulating striatal DA 
function. This suggests that M4 receptor induced inhibition of NAc DA release, appears largely 
mediated by presynaptic autoreceptors; however, as the effect was not entirely abolished, an 
independent pathway may underlie part of the M4-DA relationship. The use of regionally 
specific KO mice has allowed this claim to be better investigated. Mice lacking M4 receptors 
solely on D1-type MSNs, show enhanced DA-release in following amphetamine challenge 
relative to WT mice (Jeon et al., 2010). This indicates a key role for these post-synaptic 
receptors in mediating the effects of ACh on DA function 
 
M1 receptors also appear to have a similar inhibitory role. M1 KO mice display enhanced DA 
release following amphetamine administration (Gerber et al. 2001). Antagonists with some 
preference for the M1 receptor, potentiate cocaine-induced DA release within the NAc (Tanda 
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et al. 2007). Given the similarity in the location of postsynaptic M1 and M4 receptors within 
the striatum (table 1.3), it is possible that there is a similar mechanism underlying the effects 
of M1 and M4 receptor ligands on DA release. However, to date, there have been no studies 
using region specific M1-KO mice needed to fully investigate this hypothesis. 
 
Alongside the physiological evidence, a number of studies have also implicated mAChRs in 
modulating DA-dependant behaviours. In particular, the antipsychotic-like effects of 
muscarinic receptor agonists have been investigated. In humans,  the  M1/M4 receptor agonist 
xanomeline, is reported to produce antipsychotic effects (Shekhar et al. 2008). One commonly 
used preclinical rodent model of psychotic-like behaviour is amphetamine-induced locomotion 
(Arnt 1995; Stanhope et al. 2001).  Amphetamine challenge is used as a model of psychotic 
like behaviour, due to its validity in predicting the efficacy of a number of antipsychotic 
treatments (Moore & Kenyon 1994), as well as being potentiated in several rodent models of 
schizophrenia (Forrest et al. 2014; Jones et al. 2011). Xanomeline treatment attenuates 
amphetamine-induced locomotor activity in rats (Stanhope et al. 2001). Furthermore, this 
attenuating effect of xanomeline is entirely abolished in M4 KO mice and significantly reduced 
in M1 KO mice (Woolley et al. 2009). Xanomeline has also been shown to attenuate 
amphetamine-induced arousal and stereotypies in nonhuman primates (Andersen et al. 2003), 
as well as reducing nonmotoric behavioural effects of amphetamine such as latent inhibition  
and pre-pulse inhibition (Barak & Weiner 2011). A preferential M1 receptor allosteric agonist 
has also been reported to reduce amphetamine induced locomotion (Jones et al. 2008). 
Although M1-specific positive allosteric modulators (PAMs) can produce antipsychotic-like 
effects in other rodent models, such as MK-801–induced pre-pulse inhibition and spatial 
memory deficits(Digby et al. 2012; Melancon et al. 2013), a number of M1 receptor PAMs 
have been reported to be ineffective at attenuating the behavioural effects of amphetamine 
(Choy et al. 2016). The antipsychotic effects of xanomeline may, therefore, be primarily 
mediated through actions on the M4 subtype.  In line with this, M4 PAMs attenuate the 
behavioural effects of methamphetamine and amphetamine (Byun et al. 2014; Wood et al. 
2017; Le et al. 2013; Chan et al. 2008; Brady et al. 2008).  
 
Conversely, mAChR antagonists have been shown to potentiate amphetamine and cocaine-
induced locomotor activity (Carlton 1961; Barrett et al. 1973; Thomsen 2014). Non-selective 
mAChR antagonism can also enhance amphetamine-induced stereotypies (Klawans et al. 
1972) and amphetamine toxicity (Mennear 1965). Preferential M1 receptor antagonists can also 
potentiate cocaine-induced locomotor activity  (Tanda et al. 2007). Together, these studies 
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suggest mAChR agonists attenuate and antagonists enhance NAc DA function, these effects 
also appear to be largely mediated through M1 and M4 receptors. There is also limited evidence 
from human studies for mAChR modulation of DA function.  mAChR antagonists can be used 
in the treatment of the hypodopaminergic disorder, PD (Brocks 1999) and the extrapyramidal 
symptoms (EPS), that follow D2 receptor antagonist treatment (Pisani et al. 2007). 
 
In rodents, mAChRs have also been implicated in a number of reward-related behaviours. 
Local administration of scopolamine into the NAc disrupts lever pressing for food reward, as 
well as free-feeding sucrose consumption (Pratt & Kelley 2004; Pratt & Kelley 2005). 
mAChRs also affect Pavlovian-instrumental transfer (PIT). PIT refers to the process of reward 
paired-cues producing excitatory (Pavlovian) effects on instrumental behaviour. Like effort-
based behaviour, PIT is highly dependent on intact NAc DA signalling (Dickinson et al. 2000; 
Wyvell & Berridge 2000; Wassum et al. 2013). Systemic administration of scopolamine 
reduces the excitatory influences of Pavlovian cues on behaviour (Ostlund et al. 2014). 
Furthermore, infusion of scopolamine into the NAc was found to supress  the  normal cue-
evoked NAc DA release observed during PIT, as well as its behavioural expression (Collins et 
al. 2016). These behavioural and neurochemical effects of scopolamine are in contrast to the 
studies that suggest mAChR antagonists facilitate NAc DAergic function. One possibility, is 
that these results are linked to the previously mentioned activity-dependent relationship 
between mAChRs and DA (Threlfell et al. 2010), although this has not been investigated.  
 
1.4.3 Muscarinic receptors as potential targets for effort related behaviour 
As previously mentioned, M1 and M4 receptor subtypes are expressed upon the striatal output 
MSNs. Both dorsal and ventral striatal MSNs express complimentary populations of excitatory 
and inhibitory G-protein coupled receptors (Girasole & Nelson 2015). Striatopallidal MSNs 
preferentially express the Gi/o-coupled dopamine D2 receptors and the Gs -coupled adenosine 
A2A receptors. Striatonigral MSNs express the inhibitory Gi/o –coupled muscarinic M4 receptors 
and the Gaolf-coupled dopamine D1 receptors. 
 
 Generally, compounds that act on these receptors have been shown to affect effort-based 
behaviour in rodents (with the current exception of M4 receptors, the effects of which are 
unknown). More specifically, compounds that would be expected to facilitate activation the 
striatopallidal pathway (such as D2 receptor antagonists and A2A receptor agonists, as reviewed 
above), have been shown to supress effort-based behaviour measured with assays such as PR 
and ERC (Cheeta et al. 1995; Mingote et al. 2008). Conversely, compounds that would be 
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expected to inhibit striatopallidal MSNs (such as adenosine A2A receptor antagonists), enhance 
effort-based behaviour in rodents (Randall et al. 2012). In support of this, chemogenetic 
suppression of striatopallidal neurons enhances PR performance (Carvalho Poyraz et al. 2016). 
Together this is in line with the supposed function of this “no-go” pathway (Albin et al. 1989), 
as decreasing activity within these neurons should facilitate motor output.  Additionally, it 
would be expected that suppression of the striatonigral pathway would impair effort-based 
behaviour. In line with this, D1 receptor antagonists impair PR performance (Bari & Pierce 
2005). It may also be expected that facilitation of this pathway could enhance effort 
expenditure. However, no study has shown an enhancement of effort expenditure with 
compounds that facilitate this pathway (e.g. D1 receptor agonists, M4 receptor antagonists).  
However, as reviewed above, despite being expressed on both MSN types, M1 receptors appear 
to preferentially excite striatopallidal neurons (Shen et al. 2007). M1 (as well as M4) receptor 
antagonism might therefore be predicted to facilitate effort-related behaviour, by reducing the 
normal actions of endogenous ACh on these neurons. In line with this prediction,  genetic 
deletion of M1 receptors in mice results in enhanced levels of locomotor activity in mice 
(Gerber et al. 2001) and increased levels of behavioural output in touchscreen systems (Bartko 
et al. 2011). 
 
1.5 Translational Approaches to measuring motivation 
 
1.5.1 RDoC Approach 
It is clear that motivational disruptions are associated with a number of heterogeneous 
disorders. In recent years, the research domain criteria (RDoC) initiative has emphasised 
understanding the neurobiology of specific symptoms that exist across disorders (Insel et al. 
2010; Cuthbert & Insel 2013). It is also necessary to understand the physiological basis of 
behaviours in healthy individuals. One element of the RDoC matrix is approach motivation, 
which includes the subconstruct effort/valuation willingness to work. Understanding the 
pharmacological substrates of such constructs, across species, may facilitate successful clinical 
outcomes.  
 
1.5.2 Touchscreen operant systems 
A recent refinement in preclinical testing has been the use of touchscreen technology to test 
cognition in rodents (Horner et al. 2013; Mar et al. 2013; Oomen et al. 2013).  Automated 
touchscreen batteries have been used for a number of years to assess cognition in humans 
(Sahakian & Owen 1992), and nonhuman primates (Weed et al. 1999). Touchscreen operant 
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system allow for a battery testing approach where a broad range of cognitive domains can be 
tested, often within the same animals. The advantages of touchscreen battery testing include 
the ability to probe domains such as attention and working memory in the same environment 
using the same reinforcers. This is advantageous as many traditional assays vary considerably 
in terms of environment. For example, many behavioural assays are aversively motivated 
(Vorhees & Williams 2006), whereas others employ appetitive food rewards as motivation 
(Carli et al. 1983; Dunnett 1985). This can make comparison problematic, as any difference in 
performance between assays, may result from an interaction between the experimental 
manipulation and task environment. The versatility of a touchscreen operant system also allows 
for assessments of complex cognitive domains that are difficult to assess within traditional 
operant systems, such as working/long-term memory, as shown in table 1.4 (Talpos et al. 2009; 
Talpos et al. 2010).  
 
Another advantage of touchscreen-based operant systems is the translational nature of the tasks 
that are possible using this method. One of the criticisms of preclinical behavioural testing is 
that many results fail to translate to humans (Garner 2014). This is especially problematic in 
the field of drug development, where large numbers of compounds that are efficacious in 
rodents fail during clinical trials (Zahs & Ashe 2010; Paul et al. 2010). One of the possible 
causes of this ‘translational gap’  is the difference in the assays used to probe the same cognitive 
process, across species (Garner 2014). Traditionally, the behavioural assays used in rodents 
vary considerably from the ones used in humans, which are often questionnaire-based. Due to 
this, there has been an effort to increase to similarity (or face validity) between human and 
rodent assays. One approach has been to back-translate some of the assays used in humans, 
such as the Cambridge Neuropsychological Test Automated Battery (CANTAB). This has 
allowed for near identical cognitive tasks to be administered in rodents and humans 
(Nithianantharajah et al. 2015; Bussey et al. 2012). Like other cognitive domains, effort-
exertion can also be probed using touchscreen systems. Touchscreen based PR was first 
developed as part of a nonhuman primate battery (Weed et al. 1999), and have recently been 
developed for mice (Heath et al. 2015) and humans as part of the EMOTICOM battery (Bland 
et al. 2016).  
 
It should be noted that face validity does not equate to predictive or construct validity.  
Attempts to establish validity of touchscreen tasks have been restricted to studies 
demonstrating similar pharmacological (MacQueen et al. 2018) and genetic (Nithianantharajah 
et al. 2015) effects across species. Whereas this may demonstrate some degree of predictive 
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validity, such evidence does not exist for the majority of touchscreen tasks. Therefore, although 
face validity is an attractive feature of cognitive assays and may increase the likelihood of 
results translating across species (Bussey et al. 2012), this does not necessarily indicate that 
assays are tapping the same cognitive processes in rodents and humans.  There are a number 
of differences between touchscreen assays in humans and those administered to rodents. 
Although performance on touchscreen tasks can be compared across species, rodents are 
required to learn a touchscreen task through appetitive reinforcement over the course of a 
number of weeks. Whereas, in human versions of the tasks, no learning of the task is required, 
and performance can be measured within a session. This, coupled with the way performance is 
reinforced between the human and rodent versions, may result in different behavioural 
processes being adopted to perform the task. Indeed, the approaches used by rodents to perform 
many traditional touchscreen assays are often ambiguous (Piantadosi et al. 2019; Phillips et al. 




Rodent Touchscreen Assay Human equivalent 
Attention 5-CSRTT 
CPT 
(Bartko et al. 2011; 
Kim et al. 2015) 
No 
Yes* 
(Beck et al. 1956) 
Memory PAL (Talpos et al. 2009) Yes (Sahakian et al. 1988) 
Working Memory TUNL/cTUNL (Talpos et al. 2010; 




ID/ED set shifting (Brigman et al. 
2005) 
Yes (Downes et al. 1989) 
Cognitive 
flexibility 
Reversal Learning (Bussey et al. 2008) Yes (Sahakian et al. 1988) 
Motivation PR 
ERC 
(Heath et al. 2015) Yes 
Yes* 
(Treadway et al. 2009; 
Bland et al. 2016) 
Table 1.4: Overview of some of the range of tasks available within rodent touchscreen system 
and human equivalents. 5-CSRTT: Five Choice Serial reaction time task; CPT – continuous 
performance task; PAL: Paired Associates Learning; c/TUNL: Continuous/Trial unique 
nonmatching to location; ID/ED: Intra dimensional/extradimensional set shifting task; PR; 
Progressive Ratio; ERC: Effort-Related Choice. *Human task is non-touchscreen based. 
 
1.5.3 In Vivo oxygen amperometry 
A complementary approach to facilitating cross-species translation of behavioural results can 
be achieved through the use of functional imaging. Neuroimaging techniques can be used to 
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demonstrate equivalent neural correlates of cognitive tasks across species (Keeler & Robbins, 
2011). In other words, that a given assay is engaging homologous neural circuitry in humans 
and rodents. Additionally, functional imaging could be used to demonstrate that drugs exert 
similar actions on neural measures across species. The most widely used imaging measure in 
humans is the Blood Oxygenation Level Dependent (BOLD) contrast measured with functional 
magnetic resonance imaging (fMRI, Ogawa, 1990). BOLD-fMRI relies on a concomitant 
increase in the level of oxygenated blood in a given brain region following neural activity 
(Logothetis 2008). In spite of  only being  a surrogate measure of neural activity, BOLD-fMRI 
has been widely used to probe the neural correlates of cognitive processes in humans as well 
as additional measures of the efficacy of pharmacological treatments (Wise & Tracey 2006; 
Poldrack 2012). 
 
A number of imaging techniques can be performed in laboratory animals that directly probe 
the neurophysiological and neurochemical correlates of behaviour. These include techniques 
such as electrophysiological recording that allow for a direct measure of neuronal activity  with 
a far higher temporal resolution than fMRI (Seamans et al. 2008). Other techniques include 
fast scan cyclic voltammetry (FSCV), which can be used to measure sub-second changes in the 
neurotransmitter dopamine (Robinson et al. 2003). Additional techniques are available that 
allow for assessment of other neurotransmitters such as acetylcholine with similar spatial and 
temporal precision (Teles-Grilo Ruivo et al. 2017). However, given the invasive nature of these 
procedures, they cannot be widely performed in humans (with some exceptions such as 
intracranial electrophysiological recordings prior to neurosurgery, Hill et al. 2012). 
Furthermore, none of the aforementioned rodent imaging techniques can provide an adequate 
proxy measure of BOLD-fMRI. fMRI can be performed in rodents; however, it requires 
animals to be restrained or anesthetised. This severely limits the ability of fMRI to probe the 
neural correlates of cognitive processes in rodents. An alternate approach would be to use 
amperometric recording to measure changes in brain tissue oxygen (O2). Crucially, this 
technique can be performed in awake animals performing complex behavioural tasks. Evoked 
and resting-state amperometric measures in rodents, closely resembles BOLD-fMRI in humans 
(Lowry et al. 2010; Francois et al. 2012). This makes it ideally suited to produce a translatable 
measure of the neural correlates of cognitive tasks or pharmacological effects. For example, 
amperometry and BOLD-FMRI produce equivalent reward prediction error signals in rats and 
humans (Francois et al. 2012; Lowry et al. 2010) as well as equivalent effects of ketamine on 
reward processing (Francois et al. 2016), . Together, these studies suggest that O2 amperometry 





Apathy, or a lack of motivation represents a widespread and severe unmet clinical need across 
a number of patient groups. In spite of differences in how motivation is assessed in humans 
and preclinical settings, there is general agreement in the actions of a number of compounds in 
facilitating effort-based behaviour in rodents and reducing symptoms of apathy in clinical 
populations (table 1.2). However, through the use of touchscreen testing of effort-based 
behaviour and O2 amperometry, it may be possible to further increase the likelihood of cross-
species translation of pharmacological effects. There is also evidence that effort-based 
behaviour may be facilitated through compounds that act on muscarinic acetylcholine 
receptors. Furthermore, this facilitation may be driven through the M1 and M4 receptor 
subtypes. Therefore, these receptors should be investigated as novel targets for 




Part 1: Facilitating cross species research into motivation through the use 
of translational assays and functional imaging 
 




Contemporary clinical trials for novel CNS medicines have been plagued by failure (Kola & 
Landis 2004; Cummings et al. 2014). The high rate of attrition in clinical trials is contrasted by 
the large number of studies demonstrating compound efficacy in rodents (Zahs & Ashe 2010; 
Geerts 2009; Garner 2014). Whereas this is almost certainly due to a combination of factors, 
one problem that has been highlighted is the markedly different ways that the cognitive 
endpoints of interest (e.g. long-term memory, psychosis) are measured across species.  
Therefore, an attempt at increasing the similarity of assays across species may help reduce this 
gap and facilitate cross-species translation. Recently, in an attempt to refine preclinical animal 
testing, rodent operant testing using touchscreen-based systems have been developed. One 
recent refinement in preclinical animal testing has been the development of touchscreen 
operant systems (Bussey et al. 2012; Hvoslef-Eide et al. 2015). These systems allow the 
assessment of a number of cognitive domains including attentional processes and long-term 
and working memory  (Oomen et al. 2013; Horner et al. 2013; Mar et al. 2013) within a single 
environment. These systems also allow for the use of assays that share a high degree of face 
validity with the automated computerised testing batteries increasingly used in clinical 
populations (Sahakian & Owen 1992; Barnett et al. 2010; Bland et al. 2016) and nonhuman 
primates (Weed et al. 1999). Although face validity does not guarantee construct validity, it 
may help facilitate cross-species translation of results. 
 
As discussed previously, it is clear that impaired motivated behaviour represents an unmet 
clinical need in a number of neuropsychiatric and neurodegenerative disorders. Therefore, the 
ability to measure motivated behaviours in rodents is of crucial importance.  Motivated 
behaviour can be divided into activational and directional components (Robbins & Everitt 
1982; Salamone 1988). Directional processes allow behaviour to be directed towards appetitive 
and away from aversive stimuli. Activational aspects of motivation allow organisms to 
overcome costs or obstacles that are associated with obtaining goals (Salamone 1988). In a 
number of disorders associated with motivational impairments, activational processes appear 
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disrupted (Barch et al. 2014; Chong et al. 2015; Salamone, Yohn, et al. 2016). Activational 
components of motivated behaviour can be probed in the laboratory through studying the 
exertion of effort. One widely used assay involves studying behaviour under a progressive ratio 
(PR) schedule of reinforcement (Hodos 1961). This task probes the ability of an organism to 
maintain instrumental responding (such as lever pressing or nose-poking) under increasing 
work demands. As the response requirement increases, an animal will eventually cease 
responding. The amount of effort an animal is willing to expend in pursuit of appetitive 
reinforcement, expressed as the maximum number of responses to obtain a single reward, is 
referred to as the breakpoint (BP, Stewart 1975). PR schedules have been used to study effort 
exertion across a number of species including rats (Hodos 1961); mice (Randt & Quartermain 
1972); pigeons (Dardano & Sauerbrunn 1964); nonhuman primates (Griffiths et al. 1975) and 
humans (Roane et al. 2001). 
 
Previous research has shown that, similar to lever and nose-poke manipulanda, rodent 
touchscreens can support the sustained repetitive response behaviour required in ratio 
schedules such as PR, at least in mice (Heath et al., 2015). The majority of the previous research 
into pharmacological enhancement of motivation in rodents has used the rat as the model 
species (reviewed in chapter 1). The development of a validated rat touchscreen PR test would 
allow the assessment of motivation in the rat using the same reinforcers, responses and test 
setting as those used in the assessment of other complex behavioural constructs in the same 
apparatus. This would allow motivated behaviour to be assessed alongside and in a comparable 
way to other cognitive processes as part of a battery approach in situations where the rat is the 
favoured species. Recently, a touchscreen based PR task was developed for use in humans 
(Bland et al. 2016). The validation of a rat touchscreen PR task would allow for measurement 
of activational processes of motivation with high face validity with humans, as well as mice 
and nonhuman primates (Weed et al. 1999; Heath et al. 2015; Kangas et al. 2016). The present 
study aimed to validate a PR task by testing the sensitivity of touchscreen PR in rats to a number 
of manipulations known to affect performance in traditional lever-based versions of PR. 
 
 In spite of being widely used as assays of motivation, there are no standard set of parameters 
used in PR. Specifically, PR tasks can vary in the nature of the schedule of reinforcement used. 
Some PR schedules increase in a linear fashion (e.g. Skjoldager et al. 1993; Aberman et al. 
1998; Bensadoun et al. 2004; Heath et al. 2015), whereas others employ exponentially 
increasing ratios (e.g. Poncelet et al. 1983; Mobini et al. 2000; Rickard et al. 2009). It is not 
known whether manipulations that affect PR performance differentially affect behaviour 
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reinforced under these different schedule types.  Therefore, performance was assessed on two 
separate reinforcement schedules: the linear PR4 and the exponential PREXP schedule.  
 
Studies using PR schedules to assay motivation often use breakpoint as the sole outcome 
variable. The use of analysis of additional measures of performance may be useful in 
establishing the psychological mechanisms underlying a change in PR performance. 
Breakpoint has been criticised as a blunt measure of motivation, ignoring within-session 
changes in responding (Olarte-Sánchez et al. 2015). A complimentary approach is to examine 
with-session changes in response rates. Through analysis of the decline in response rates 
throughout a session it is possible to extract measures of the peak and rate of decay in 
responding. The predicted peak response rate is believed to provide a measure of the maximal 
motoric output of an animal; whereas the decay rate provides a motivational measure of how 
reinforcers invigorate subsequent bouts of responding (Phillips et al. 2017). Additionally, 
changes in the structure of response bouts can be examined. Animals naturally undergo ‘break-
and-run’ type behaviour which is characterised by periods of responding, or response bouts, 
separated by pauses (Shull et al. 2001). The number of responses within a bout has been 
reported to be a measure of motoric integrity; whereas the refractory pausing between bouts 
provides a measure of an animals motivational state (Brackney et al. 2011). Analysis of these 
additional measures could potentially provide a broader view of the effects of an experimental 
manipulation than examining breakpoint alone. A summary of potential measures that can be 
taken during touchscreen PR testing is available in table 2.1. 
 
Measure Definition 




The latency from magazine exit following reward to the first 
target response in the subsequent trial 
Decay rate The exponent predicting the decline in response rates over the 
course of a PR session 
Between Bout pausing The mean length of the nonresponding period between response 
bouts 
Predicted peak response 
rate 
The predicted response rate at time point 0s, based upon the 
change over the course of a session. 
Response bout length The mean number of responses in a bout of responding 
Reward collection 
latency 
The mean latency to collect rewards following delivery 
Nontarget screen 
Responses 
The mean number of screen responses not directed at the 
stimulus per second 
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IR beam breaks The mean number of infrared beam breaks per second 
Magazine entries The mean number of magazine entries made per second 
Table 2.1: The dependant variables assessed during PR responding and the relevant constructs. 
 
In the present study, performance on two schedule types was compared in response to a number 
of manipulations. Initially, the reward outcome value was manipulated. Firstly, this was 
achieved by increasing the magnitude of reward, which was hypothesised, based on previous 
reports, to increase breakpoint (Skjoldager et al. 1993; Eagle et al. 1999; Rickard et al. 2009). 
Secondly, the reinforcer was devalued through a pre-feeding procedure, which was predicted 
to decrease breakpoints (Skjoldager et al. 1993; Eagle et al. 1999). Subsequently, performance 
was assessed following systemic administration of dopaminergic compounds. Based on 
previous reports it was predicted that administration of the D2/D3 receptor antagonist raclopride 
would disrupt PR performance (Cheeta et al. 1995; Aberman et al. 1998). Finally, it was 
predicted that PR performance would be facilitated following systemic d-amphetamine 




Twenty-four male Sprague Dawley rats (Charles River, UK) were used in the current 
experiment. Animals were group housed (4 per cage) in a light- and temperature-controlled 
environment (lights on 1900-0700). Following at least seven days habituation to the facility, 
animals were placed on a programme of controlled feeding and maintained at no less than 85% 
of their free feeding body weight at the start of food restriction. No correction was applied to 
this 85% control weight to match the animals expected growth curve.  Cages were changed 
twice weekly and drinking water was available ad libitum throughout. All testing took place 5-
7 days/week, in the animals’ dark phase. All experiments were regulated under the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations 2012 and following ethical review 
by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 
 
2.2.2 Apparatus 
All testing took place within automated rat touchscreen operant chambers (Campden 
Instruments Ltd., Loughborough, U.K.) The chambers were contained within light and sound-
attenuating boxes. The chambers consisted of black plastic walls in a trapezoidal shape (height: 
30cm, length: 33cm, width: 25cm at screen, 13cm at magazine) and a perforated stainless-steel 
floor. Each chamber was fitted with a 15-inch touch-sensitive LCD screen, with a screen 
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resolution of 1,024 x 768) IR photocells were positioned <5mm from the screen to record 
responses. Therefore, no physical force against the touchscreen was necessary for a response 
to be recorded. On the opposing side was a magazine connected to a pellet dispenser that 
delivered standard 45mg dustless pellets (TestDiet, Indiana, USA). The food tray was fitted 
with a light emitting diode and an infrared (IR) beam that registered magazine entries. Front 
and rear IR beams were fitted to monitor the rats’ activity within the chamber. Front IR beams 
were positioned 6cm from the screen and rear IR beams 5cm from the magazine. During all 
stages of testing, black plastic masks were fitted to the touchscreens that had five 9cm2 response 
apertures, at equal heights, spaced 1cm apart.  
 
2.2.3 Pretraining  
Initially, all animals were initially given a 20-minute habituation session. During this session, 
the boxes were active, but no stimuli were presented. Following this, rats underwent one day 
of screen press training. A white square stimulus was presented in the central aperture for 30s. 
A single response to this stimulus resulted in three food pellets being delivered. Stimulus offset 
and a short tone (1000ms, 3 kHz) accompanied reward delivery. Following a 5s inter-trial 
interval (ITI) the stimulus returned to the screen. If no response was made within 30s the trial 
ended, and a single food pellet was delivered, accompanied by stimulus offset and the tone. 
Each session was terminated following 100 rewards being delivered or 45 minutes having 
elapsed. 
 
2.2.4 Fixed Ratio Training 
Rats then underwent fixed ratio (FR) 1 training. During these sessions, a single response to the 
central stimulus was required for a single pellet reward delivery. Reward delivery was again 
accompanied by the tone. A 5s ITI was employed. Each session was terminated following 45 
minutes or 100 trials being completed. All animals were required to complete 100 trials within 
the 45 minutes before moving on to the next stage of training. The subsequent training stage 
consisted of FR5 responding, where five responses were required for each reward delivery. 
The first four responses in a trial were accompanied with a shorter ‘click’ tone (10ms, 3 kHz) 
and a brief (500ms) stimulus offset. The fifth response to the stimulus completed the trial and 
resulted in delivery of reward and the longer duration tone. All other parameters were identical 
to the FR1 stage of training. Each session was terminated following 100 trials (i.e. 500 target 
responses) or after 45 minutes. Each animal was required to complete 100 trials within a session 




2.2.5 Progressive ratio 
Animals were randomly assigned to either a linear (PR4) or exponential (PREXP) schedule 
(n=12 each). On both schedules, the number of target responses required increased following 
completion of each trial. On the PR4 schedule, the response requirement began at one and 
increased by four on each subsequent trial (yielding response requirements of 1, 5, 9, 13, 17 
etc.). The PREXP schedule increased according to the formula (5 * e(0.2*n)- 5), where n is the 
trial number, yielding response requirements of 1, 2, 4, 6, 9, 12 etc., to the nearest whole 
number.  If no response was made to the touchscreen within 180s, on either schedule, the 
session was terminated, otherwise sessions ended after 45 minutes elapsing. Together, a total 
of ten days of training were needed before probes were administered. Throughout this task the 
ITI was triggered following reward collection (i.e. entry and then exit from the magazine). As 
a consequence, this PR task was not self-paced. 
 
2.2.6 Outcome Manipulations 
Outcome manipulation probes were delivered in a within-subject cross-over design. Firstly, 
rats underwent a reward magnitude probe. On these days, rats received either a standard (single 
pellet) or an increased (three pellet) reward following each completed ratio.  The groups were 
counterbalanced so that on each day equal numbers of PR4 and PREXP rats were in each 
condition. A baseline day was administered between test days, where rats were tested as normal 
and received a single pellet reward for each completed trial. On the prefeeding probe days, rats 
were randomly assigned to a prefeed or no pre-feed (control) condition. Rats within the prefeed 
condition were given 1 hr of free access to homecage lab chow prior to testing. Rats within the 
no pre-feed control condition were tested as normal with chow provided after the PR session 
was completed. Equal numbers of PR4 and PREXP rats were tested on both conditions on each 
test day. Again, a baseline day was given between test days to ensure no carry-on effects of 
prefeeding were observed upon PR performance. 
 
2.2.7 Dopaminergic Manipulations 
Pharmacological challenges were delivered in a within-subject Latin square design. All drugs 
were dissolved in physiological saline and delivered via intraperitoneal injections at a volume 
of 1 ml/kg of each rat’s body-weight, 30 minutes prior to PR testing. Rats were returned to 
their home cages for the post injection period of 30 minutes. The D2/D3 receptor antagonist s(-
)raclopride(+)-tartrate salt (Sigma-Aldrich, Dorset, UK) was administered at doses of 0, 0.03 
and 0.3 mg/kg. Following a seven-day washout period,  the indirect catecholamine agonist d-
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amphetamine sulphate (Sigma-Aldrich, Dorset, UK) was administered at doses of 0, 0.1 and 1 
mg/kg. 
 
2.2.8 Behavioural Measures 
The primary measure of interest was breakpoint (BP), defined as the number of target responses 
made in the last successfully completed trial for each subject.  The mean post reinforcement 
pause (PRP) was defined as the latency between an animal removing its head from the 
magazine following reinforcement and the first touchscreen target response of the subsequent 
trial. Response rates were analysed as previously described (Phillips et al., 2017). Briefly, 
response rates per trial were calculated by dividing the number of responses made in each trial 
by the time taken to complete each trial, from the first response (therefore, excluding post 
reinforcement pauses). The first two trials in each session were excluded from the response 
rate analyses. The first trial was excluded as it only involved a single lever press, meaning it is 
not possible to calculate a response rate. The second trial was excluded as it only required two 
responses in the PREXP schedule. The low number of responses needed in this condition may 
have made comparison between groups problematic by inflating the response rate within this 
group. The following negative exponential function was then fitted to the mean response rates 
per condition: y = -a*exp(x*b); with y being the response rate and x being the trial number. 
The predicted peak response rate (a) and decay rate parameter (b) were extracted and analysed 
across conditions. Response bout analysis defined bouts as consecutive touchscreen target 
responses separated by no more than 5s. The mean number of responses in a bout was taken to 
represent a bout length. Following response bout completion, the pause until the subsequent 
target response was calculated. Only voluntarily terminated bouts were analysed and PRPs 
excluded from the bout pause analysis. Additional measures of motoric activity included the 
mean reward collection latency, the rate of IR beam breaks (beam breaks/sec), the rate of non-
stimulus (blank) touchscreen responses (blank touches/sec) and the rate of magazine entries 
(magazine entries/sec). A description of each measure is available in table 2.1 and a 





Figure 2.1: Visualisation of a PR trial including some of the measures used. Between bout 
pauses were defined as no response periods of 5s or greater. PRP: post reinforcement pause. 
 
 
2.2.9 Statistical analysis 
Analysis was conducted in SPSS Version 23 (IBM, Armonk, NY, USA) and the R software 
package (R Core Team, 2013). Graphs were produced using Prism (GraphPad, La Jolla, CA, 
USA) and the ggplot2 package in R (Wickham, 2009). To compare the effects of schedule at 
baseline, independent t-tests were used. Levene’s test for equality of variance was employed 
and corrected where appropriate. For all other tests, repeated measures ANOVAs were 
employed. The Greenhouse-Geisser correction was applied for any violations of sphericity.  




2.3.1 Effect of reinforcement schedule on baseline PR performance 
All measures were collapsed across the first five PR sessions. The mean breakpoint did not 
differ significantly according to schedule group (t(22)  = .051, p  = .96; figure 2.2A). The mean 
duration of the PRP also did not differ across reinforcement schedule groups (t(22) = 1.024, p 
= .317; figure 2.2B). Animals reinforced under the PR4 schedule did, however, make 
significantly more touchscreen responses per reward (t(22) = 2.785, p < .05; figure 2.2C).  
There were no differences between the mean number of IR beam breaks made per second (t(22) 
= 1.441, p = .164. Response rates appeared to differ between schedule groups (figure 2.2D). 
The predicted peak response rate was significantly higher in animals reinforced under the 
PREXP schedule (t(22) = 3.067, p < .01; figure 2.2E). The response rate decay was also 
significantly greater in rats tested under the PREXP schedule of reinforcement (t(22) = 3.177, 
p < .01; figure 2.2F).  Reinforcement schedule did not affect the structure of response bouts 
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(bout length:(t(17.109) = 1.367,  p  =.189); between bout pausing (t(22) = 1.336,  p  = .195)). 
Supplementary measures of motoric activity are available in Table 2.2. 
 
 Reward Collection 
Latency 




 PR4 PREXP PR4 PREXP PR4 PREXP PR4 PREXP 
Reward 
magnitude 
        
1 Pell 1.11 ± 0.06 1.36 ± 0.09# 0.07 ± 0.01# 0.05 ± 0.00# 0.02 ± 0.00 0.03 ± 0.01 5 2 
3 Pellets 0.97 ± 0.08 0.94 ± 0.12# 0.10 ± 0.01# 0.08 ± 0.01# 0.02 ± 0.00 0.03 ± 0.01 8 6 
Pre-feeding         
No Feed 1.39 ± 0.09 1.51 ± 0.13 0.06 ± 0.01* 0.05 ± 0.00* 0.02 ± 0.00 0.02 ± 0.00 3 2 
Prefeed 1.27 ± 0.05 1.56 ± 0.10 0.06 ± 0.01 0.04 ± 0.00 0.02 ± 0.00 0.03 ± 0.01 1 0 
Raclopride         
Vehicle 1.23 ± 
0.09* 
1.63 ± 0.15* 0.08 ± 0.01* 0.06 ± 0.01* 0.02 ± 0.00 0.03 ± 0.01 0 0 
0.03 mg/kg 1.28 ± 0.06 1.58 ± 0.14 0.07 ± 0.01 0.05 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 2 2 
0.3 mg/kg 1.44 ± 
0.19* 
2.65 ± 0.72* 0.05 ± 0.01† 0.04 ± 0.00 0.01 ± 0.00† 0.02 ± 0.01 1 0 
Amphetamine         
Vehicle 1.44 ± 
0.09* 
1.80 ± 0.12* 0.09 ± 0.01 0.06 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 1 0 
0.1 mg/kg 1.40 ± 
0.08* 
1.71 ± 0.16* 0.08 ± 0.01 0.06 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 1 2 
1 mg/kg 1.35 ± 0.06 1.56 ± 0.09 0.10 ± 0.01 0.09 ± 0.01† 0.05 ± 0.01 0.05 ± 0.01 6 8 
 
Table 2.2: Additional measures of motoric activity for both schedule types. Mean values ± 
SEM, of the reward collection latencies, rate of magazine entries (magazine entries per second), 
and the rate of nontarget (blank) screen responses (Nontarget responses/sec) and the number 
of rats (out of 24) failing to reach breakpoint for all experimental conditions. All behavioural 
measures were reported to two decimal places. Bold type signifies significant effects. *A 
significant group difference between schedule types, p < .05. # A significant effect of 
increasing the reward magnitude, p < .05. † A significant effect relative to the vehicle condition 





Figure 2.2: Effects of schedule of reinforcement on PR performance. A The mean breakpoint 
for both schedule groups. B The duration of the post-reinforcement pause (PRP). C The mean 
number of touchscreen responses made per reward was higher in animals reinforced with the 
PR4 schedule. D The group mean response rate for each trial, from the third trial onwards for 
both reinforcement schedule.  E Reinforcing animals under a PREXP schedule significantly 
increases the predicted peak response rate. F Reinforcing rats under a PREXP schedule 
significantly increases the rate of decay in responding. Error bars represent ±SEM. * p<.05; 
**p<.01. 
 
2.3.2 Increasing the magnitude of the reward enhances PR performance 
Increasing the magnitude of reward significantly increased breakpoint (F(1,22) = 35.183, p < 
.001; partial eta squared = .615; figure 2.3A). Breakpoints were significantly higher following 
three-pellet rewards in both schedule groups (both p < .01). Breakpoints did not significantly 
differ between schedule groups (F(1,22) = 2.13, p =.159). There was also no significant 
interaction between reward magnitude and schedule type (F(1,22) = 2.584, p = .122). 
Increasing reward magnitude did not affect PRPs (F(1,22) = .388, p =.54; figure 2.3B). The 
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duration of the PRP also did not differ between reinforcement schedule groups (F(1,22) = 
1.409, p = .248). Again, there was no significant interaction between schedule and reward 
magnitude (F(1,22) = 2.83, p = .107). The rate of IR beam breaks was not significantly affected 
by reward magnitude (F(1,22) = .311, p = .583). There was also no effect of either 
reinforcement schedule upon the rate of IR beam breaks (F(1,22) = 1.951 p = .176), or any 
interaction between schedule and reward magnitude (F(1,22) = .107 , p  = .583). Increasing 
reward magnitude did not affect any additional measure of activity (Table 2.2). 
 
Changing the magnitude of reward had did not affect response rates in either schedule group 
(figures 2.3C,D). The predicted peak response rate was not affected by increasing the 
magnitude of reward (F(1,22) = 1.630, p = .215; figure 2.3E). However, the effect of schedule 
upon the predicted peak response rate trended towards significance (F(1,22) = 4.277, p = .051). 
There was no interaction between schedule and reward magnitude (F(1,22) = 1.285, p = .269) 
upon the peak response rate. Increasing the magnitude of the reward did not significantly affect 
the rate of decay in responding (F(1,22) = 4.193, p = .053; figure 2.3F).  The rate of decay 
differed between schedule groups (F(1,22) = 9.494, p < .01; partial eta squared = .301).  The 
decay in responding was higher in the PREXP when reinforced with three-pellet rewards (p < 
.05). There was no significant schedule x reward magnitude interaction upon the response 
decay rate (F(1,22) = .687, p = .416). The length of response bouts was significantly increased 
by increasing the magnitude of rewards (F(1,22) = 6.329,  p  <.05; partial eta squared = . 223).  
The mean bout length was also significantly longer in PR4 animals (F(1,22) = 7.095,  p  < .01; 
partial eta squared = .244). However, there was no significant interaction between schedule 
and reward magnitude upon bout length (F(1,22) = 2.536,  p  = .126). The mean pause between 
response bouts was reduced by increasing the reward magnitude (F(1,22) = 24.301,  p  < .001; 
partial eta squared = .525). Pausing was not significantly affected by either schedule of 
reinforcement (F(1,22) = 1.799,  p  = .194) or by any interaction between schedule and reward 




Figure 2.3: Increasing the magnitude of reward facilitates PR performance. A Reinforcing PR 
performance with 3 pellet rewards significantly increases breakpoints in both schedule groups. 
B Changing the magnitude of reward does not alter the post reinforcement pause (PRP). C The 
PR4 group mean response rate for each trial, from the third trial onwards D The PREXP group 
mean response rate for each trial, from the third trial onwards E Increasing reward magnitude 
does not affect the predicted peak response rate. F Increasing the magnitude of reward does 
not affect the decay in responding. The PREXP group show a greater decay rate when 
reinforced with 3 pellet rewards. Error bars represent ±SEM. * p<.05; **p<.01. 
 
2.3.3 Prefeeding with chow prior to testing disrupts performance under PR schedules of 
reinforcement. 
Pre-feeding the rats with chow significantly reduced breakpoint (F(1,22) = 22,796, p < .001, 
partial eta squared = .509; figure 2.4A). Breakpoints were significantly lower following pre-
feeding in both PR4 and PREXP schedule groups (both p < .01). Breakpoint did not differ 
between schedule groups (F(1,22) = .179 p = .676). There was also no interaction between 
schedule type and pre-feeding status (F(1,22) = .041 p = .841). The duration of the mean PRP 
was not affected by pre-feeding (F(1,22) = .869, p = .361; figure 2.4B). The duration of PRPs 
was significantly affected by reinforcement schedule type (F(1,22)  = 4.494,  p < .05, partial 
eta squared = .170); however, no effect survived multiple comparison adjustments in post-hoc 
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testing. There was no interaction between pre-feeding status and schedule type upon PRPs 
(F(1,22) = .291, p = .595). Similarly, pre-feeding had no effect on the number of IR beam 
breaks made per second (F(1,22) = .964, p = .337). The rate IR of beam breaks was not 
significantly affected by either reinforcement schedule (F(1,22) = 1.187, p = .288), or by any 
interaction between schedule and pre-feeding state (F(1,22) = 1.243, p = .277). Prefeeding had 
little effect on motoric activity (Table 2.2). 
 
 
Figure 2.4: PR performance is supressed by prefeeding rats with homecage chow prior to 
testing. A Breakpoints are significantly lowered by prefeeding in both schedule groups. B 
Prefeeding with lab chow does not affect the duration of the mean post reinforcement pause 
(PRP).  C The influence of prefeeding on the PR4 group mean response rate for each trial, from 
the third trial onwards D The influence of prefeeding on the PREXP group mean response rate 
for each trial, from the third trial onwards. E Prefeeding does not affect the predicted peak 
response rate F The decay rate was significantly increased after prefeeding with chow. Error 
bars represent ± SEM. * p<.05; **p<.01. 
 
Pre-feeding appeared to affect response rates in both the PR4 (figure 2.4C) and PREXP groups 
(figure 2.4D). Prefeeding the rats with chow had no effect upon the predicted peak response 
rate (F(1,22) = 2.025, p = .166; figure 2.4E). The peak response rate also did not differ 
significantly between rats reinforced with different schedules (F(1,22) = 3.708, p = .067).  
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There was no significant prefeeding x schedule interaction upon the predicted response rate 
(F(1,22) = .548, p = .467). The rate of decline in responding was, however, significantly 
affected by pre-feeding (F(1,22) = 9.839, p < .01; figure 2.4F). Post-hoc testing revealed a 
significant increase in the rate of decay of responding in both schedule groups following pre-
feeding (both p < .05). The rate of decay was not significantly affected by reinforcement 
schedule (F(1,22) =1.749, p = .200). There was also no schedule x pre-feeding interaction 
observed upon the decay rate (F(1,22) = .011, p = .916). Response bouts were again 
significantly longer in PR4 animals (F(1,22) = 10.029,  p  <.01; partial eta squared = .313).  
However, bout length was not affected by either prefeeding (F(1,22) = .001, p = .989) or by 
any interaction between prefeeding and schedule type (F(1,22) = 2.186, p = .153). There were 
no significant effects found upon the pausing between response bouts (prefeeding state 
(F(1,22) = .187,  p  = .669); schedule type (F(1,22) = 1.907,  p  = .181); magnitude x schedule 
interaction (F(1,22) = 1.107,  p  = .304)). 
 
2.3.4 Systemic administration of the D2/D3 receptor antagonist raclopride impairs PR 
performance   
Two rats did not complete any trials following administration of the D2/D3 receptor antagonist 
0.3 mg/kg raclopride, therefore, the data from these animals were removed from all raclopride 
analyses. Administration of raclopride significantly reduced breakpoints (F(2,40) = 14.113, p 
< .001; partial eta squared = .414; figure 52.5A). Breakpoints were significantly reduced by 
administration of 0.3 mg/kg compared to vehicle in both schedule groups (p < .01).  However, 
breakpoints were not affected by reinforcement schedule type (F(1,20) = .075,  p = .788). There 
was also no interaction between raclopride administration and schedule type (F(2,40) = 234, p 
= .792). The length of PRPs was also significantly affected by raclopride administration 
(F(1.498,32.962) = 8.955, p < .01; partial eta squared = .289; figure 2.5B). Post-hoc testing 
suggested that raclopride significantly increased pausing following administration of 0.3 mg/kg 
in the PR4 group (p < .05) but not the PREXP group. There was also a significant interaction 
between the dose of raclopride and reinforcement schedule (F(1.498,32.962) = 5.042, p < .05; 
partial eta squared  = .186), suggesting that raclopride produced greater effects on pausing in 
animals reinforced under the PR4 schedule. There was also a significant effect of reinforcement 
schedule on pausing (F(1,20) = 12.523, p < .01); partial eta squared = .363). Post-hoc testing 
revealed that the mean PRP was significantly greater in the PR4 group following administration 
of both vehicle and 0.3 mg/kg raclopride. Raclopride administration significantly affected the 
rate of IR beam breaks (F(1.309,26.185) =  6.298, p < .01; partial eta squared = .239). Post-
hoc tests revealed that 0.3 mg/kg raclopride reduced the rate of beam breaks, relative to 
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administration of 0.03mg/kg raclopride, in the PREXP group only (p < .05). The rate of beam 
breaks was not affected by reinforcement schedule (F(1,22) =  .145, p = .708). There was also 
no interaction between the dose of raclopride and reinforcement schedule (F(1.309,26.185) =  
.201, p = .723). Motoric activity was largely unaffected by either dose of raclopride (Table 
2.2). 
 
Response rates following raclopride administration were analysed (figures 2.5C,D). The 
predicted peak response rate was not significantly affected by raclopride administration 
(F(2,40) = .983, p = .383; figure 2.5E). There was however, a significant effect of 
reinforcement schedule (F(1,20) = 15.662, p < .01; partial eta squared = .439). Post-hoc testing 
revealed that the PREXP group had a significantly higher predicted peak response rate 
following administration of vehicle and 0.3 mg/kg raclopride. Administration of raclopride also 
significantly affected the decay in response rate (F(1.207, 24.142) = 5.860 , p < .01; partial eta 
squared = .227; figure 2.5F). Post-hoc testing did not reveal any significant differences between 
doses. The decay rate was not significantly affected by reinforcement schedule type (F(1,20) 
= 1.448, p = .243).  There was also no interaction between the dose of raclopride and schedule 
type upon the decay rate of responding (F(1.207, 24.142) = .023, p = .977). Overall bout length 
was again longer in animals reinforced under the PR4 schedule (F(1,20) = 6.334, p <.05; partial 
eta squared = .241).The mean length of response bouts was not significantly affected by either 
raclopride administration (F(1.245,24.899) = 2.139, p = .153) or any interaction between 
schedule type and raclopride (F(1.245,24.899) = 1.440, p = .249). Raclopride administration 
did not significantly affect the length of pausing between bouts (F(1.214,24.277) = 2.231, p = 
.145). Pausing was not also not significantly affected by either schedule type (F(1,20) = .203, 






Figure 2.5: Systemic administration of the D2/D3 antagonist raclopride disrupts PR 
performance. A Raclopride administered at a dose of 0.3mg/kg significantly disrupts 
breakpoints reinforced under both PR4 and PREXP schedules. B 0.3mg/kg raclopride 
significantly increases post reinforcement pauses (PRPs) in the PR4 condition only. The 
duration of PRPs was also significantly higher in the PR4 condition. C Suppression of response 
rates by raclopride in the PR4 group for each trial, from the third trial onwards. D PREXP 
group mean response rates are suppressed following raclopride administration. E Raclopride 
administration does not significantly affect the predicted peak response rate. Rats reinforced 
with the PREXP schedule are estimated to have a significantly higher peak response rate. F 
Raclopride administration did not significantly affect the decay rate. Error bars represent ± 





2.3.5 Systemic d-amphetamine facilitates PR performance  
The indirect catecholamine agonist amphetamine significantly increased breakpoints 
(F(1.169,25.711) = 47.935, p < .001; partial eta squared  = .685; figure 2.6A). There was also 
a significant effect of reinforcement schedule (F(1,22) = 5.072, p < .05; partial eta squared  = 
.187),  as well as a significant interaction between amphetamine and schedule upon breakpoint 
(F(2,44) = 6.488, p < .01; atrial eta squared = .227). 1 mg/kg amphetamine significantly 
increased breakpoint compared to vehicle for animals on both schedules of reinforcement (both 
p<.05).  However, breakpoints were significantly higher following administration of 1mg/kg 
of amphetamine in the PREXP group. This finding indicates that amphetamine produced a 
greater effect upon breakpoints in animals tested on an exponential schedule of reinforcement 
compared to those on a linear reinforcement schedule. Amphetamine also had a significant 
effect on the mean PRP duration (F(2,44) = 13.451, p <.001; partial eta squared = .379; figure 
2.6B). Post-hoc testing revealed that 1 mg/kg amphetamine reduced the duration of PRPs 
relative to vehicle in both schedule groups. There were no significant effects of either 
reinforcement schedule (F(1,22) = .520, p = .478), or any significant  interaction between dose 
of amphetamine and schedule upon PRPs.  (F(2,44) = 2.100, p = .135). Amphetamine 
administration also significantly affected the number of IR beam breaks made per second 
(F(1.440, 31.673) = 38.390, p < .001; partial eta squared = .636). Post-hoc testing revealed that 
1m/kg amphetamine increased the rate of beam breaks in both schedule groups relative to 
vehicle (p < .01). Reinforcement schedule had no effect on the rate of IR beam breaks (F(1,22) 
= .316,  p  = .580). There was also no significant interaction between the dose of amphetamine 
and schedule type (F(1.440, 31.673) = 2.034, p = .158). Amphetamine had little effect on other 
measures of motoric activity (Table 2.2). 
 
Systemic administration of amphetamine appeared to enhance response rates (figures 6C, D). 
Amphetamine administration decreased the predicted peak response rate (F(2,44) = 6.237, p 
<.01; partial eta squared = .221; figure 2.6E). The predicted peak rate was reduced following 
1 mg/kg amphetamine relative to all other doses (p < .05) in the PREXP group only. The 
predicted peak response rate was again significantly affected by schedule type (F(1,22) = 7.44, 
p < .05; partial eta squared = .253). Post-hoc testing revealed that the peak rate was significantly 
higher in the PREXP group following administration of vehicle and 0.1mg/kg amphetamine 
(p<.05). There was no significant interaction between drug administration and reinforcement 
schedule (F(2,44) = 1.466, p = .242). The rate of decay in responding was significantly reduced 
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by amphetamine administration (F(2,44) = 25.548, p < .001; partial eta squared = .537; figure 
2.6F). Post-hoc testing revealed that 1mg/kg amphetamine reduced the rate of decay relative 
to both other doses in both schedule groups (p < .01). The rate of decay in responding did not 
differ between schedules of reinforcement (F(1,22) = 2.128, p = .159). There was no significant 
drug x schedule interaction on the rate of decay (F(2,44) = .506, p = 606). As with previous 
conditions, the mean length of response bouts was significantly greater in PR4 rats (F(1,22) = 
9.767 p < .01; partial eta squared = .307) Bout length was not significantly affected by either 
administration of amphetamine (F(2,44) = 2.112,  p  = .133) or by any interaction between the 
dose of amphetamine and schedule type (F(2,44) = 1.467,  p = .242). In contrast, amphetamine 
significantly reduced the length of the mean pause between response bout (F(2,44) = 10.409, 
p < .001; partial eta squared = .321). Pausing did not differ between schedule groups (F(1,22) 
= 1.105 p = .305). There was however a significant interaction between amphetamine and 
schedule on the length of the pause ((F(2,44) = 8.281, p < .01; partial eta squared = .271). Post 
hoc testing revealed that 1mg/kg of amphetamine reduced the length of between bout pausing 




Figure 2.6: Facilitation of PR performance following systemic administration of d-
amphetamine. A Administration of 1mg/kg d-amphetamine significantly increase breakpoints 
in both schedule groups. Breakpoints are significantly higher in the PREXP group relative to 
rats reinforced under the PR4 schedule following administration of 1mg/kg amphetamine. B 
The duration of the mean post reinforcement pause (PRP) is significantly reduced by 1mg/kg 
amphetamine, in both reinforcement schedule conditions. C Enhancement of response rates 
following administration of amphetamine in rats reinforced with the PR4 schedule. D Response 
rates are enhanced following administration of amphetamine in rats reinforced with the PREXP 
schedule E. Amphetamine significantly reduces the predicted peak response rate in animals 
reinforced under the PREXP schedule only.  The decay rate of responding is significantly 





2.4.1 Progressive ratio as an assay of motivation 
PR schedules are widely used across species, to probe motivated behaviour. Touchscreen 
versions of PR have been developed to assess motivation in mice (Heath et al., 2015), humans 
(Bland et al., 2016) and nonhuman primates (Weed et al., 1999). Maintaining high face validity 
between species may increase the likelihood of successful translation of findings (Bussey et 
al., 2012). Additionally, development of a rat touchscreen variant of progressive ratio will 
allow for assessment of motivation in this species within the same environment and using the 
same reinforcers earned in the assessment of more complex behaviours (Horner et al., 2013; 
Mar et al., 2013; Oomen et al., 2013).  In the present study, a novel rat touchscreen PR task 
was assessed and found to be sufficiently sensitive for detecting changes in performance 
following outcome manipulations and systemic administration of dopaminergic drugs 
previously found to be efficacious in non-touchscreen versions of the schedule. The similarity 
in results across these different procedures further strengthens the use of measurement of 
responding under PR schedules of reinforcement to assay motivation.  Together, this represents 
the successful validation of the task for use in the rat touchscreen operant system.  
 
2.4.2 Effect of reinforcement schedule on PR performance. 
Both linear and exponential schedules of reinforcement are widely used in PR tasks. The 
reinforcement schedule determines the frequency that rewards are delivered with respect to 
operant responding. Relative to the linear PR4 schedule, the PREXP schedule has an initially 
high frequency of reinforcement that then declines rapidly. In the absence of any additional 
manipulations, breakpoints were remarkably similar between the two schedules (figure 2.2A). 
This is in spite of the difference in the total number of screen responses needed to achieve these 
breakpoints (figure 2.2C). This finding indicates that prior history of reinforcement within a 
session has little influence upon breakpoint. Likewise, the duration of PRPs did not differ 
between the two schedule types. The duration of PRPs are strongly affected by work or effort 
requirements (Powell, 1968; Baron et al., 1992; Alling & Poling, 1995), suggesting a 
motivational component to the length of the pause, which may explain the lack of a difference 
in PRPs between schedule types. Additionally, there were no group differences in between bout 
pausing, in line with the interpretation of this variable as a measure of motivation to work for 




We also observed stark differences in the pattern of response rates between schedules. The 
initial predicted peak response rate was significantly higher in the PREXP schedule. The group 
differences observed are likely a reflection of the lower work requirements in the first few 
analysed trials in the PREXP condition (i.e. 4,6,9 vs 9,13,17 stimulus touches required in the 
linear PR4 schedule). The lower ratio requirement may allow the rats to respond at an initial 
faster rate. Furthermore, rats reinforced under the PREXP schedule also displayed a 
significantly greater rate of decay in responding. This may be a reflection of a more rapid 
progression in response requirements in the exponential schedule. This rapid increase may 
result in the faster decay in responding due to a process such as instrumental extinction. The 
two schedules differ in response requirements, particularly at later schedules. It would be useful 
to test whether animals trained on the different schedule types show different rates of extinction 
in the absence of reinforcement (as measured by total number of screen touches and response 
rates). This could allow for the investigation of whether PR4 and PREXP show different rates 
of instrumental extinction. 
  
2.4.3 Outcome manipulations 
Increasing the magnitude of rewards resulted in a significant increase in breakpoints, in line 
with previous reports (Skjoldager et al. 1993; Eagle et al. 1999; Rickard et al. 2009).  Larger 
magnitude rewards increase the vigour of operant responding (Skjoldager et al. 1993). 
Breakpoints may represent the outcome of a cost/benefit decision making process (Salamone, 
Correa, et al. 2009). If an action or series of actions lead to a greater benefit (e.g., a larger food 
reward), then an organism should be more willing to overcome greater costs to obtain the goal. 
The rat touchscreen PR task was also sensitive to the effects of outcome devaluation through 
prefeeding. This is also in line with previous reports showing that both specific (Skjoldager et 
al. 1993) and nonspecific satiety (Eagle et al. 1999) results in a reduction in breakpoints. 
Prefeeding with chow would be expected to devalue the reinforcer and reduce the effort an 
organism is willing to expend to receive the reward.  
 
The length of PRPs was not significantly affected either by changing reward magnitudes or 
prefeeding. PRPs have been shown to increase with the ratio requirements (Powell 1969; Baron 
et al. 1992).  Increasing reward magnitudes, increases trial completion and therefore the 
average ratio requirement within a session. This would be expected to increase the length of 
the average PRP. This result may explain why larger magnitude rewards did not decrease 
pausing. PRPs were also unaffected by prefeeding rats with homecage chow. This matches 
previous findings (Skjoldager et al. 1993; Eagle et al. 1999) of prefeeding on pausing under 
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PR schedules. This is in contrast to the effects observed under FR schedules, where prefeeding 
animals has been reported to increase the duration of PRPs (Sidman & Stebbins 1954). Again, 
this may be as a result of prefeeding decreasing the total number of trials completed, and 
therefore decreasing the mean ratio requirement in these sessions. Together, this highlights a 
potential confound in evaluating performance based upon mean PRP across a PR session, 
without controlling for the total number of trials completed. 
 
Neither increasing the reward magnitude nor prefeeding significantly altered the peak response 
rate. This is in agreement with the view that this variable reflects some measure of maximal 
motoric output (Phillips et al. 2017). Increasing the magnitude of reward also did not 
significantly affect the rate of decay in touchscreen responding. Previous reports suggest the 
efficacy of different food reinforcers in supporting PR performance does not appear to affect 
response rate decay (Kim et al. 2017). Therefore, it is not surprising that larger magnitude 
rewards do not affect the rate of decay, in spite of larger rewards supporting higher breakpoints. 
In contrast, reward devaluation through prefeeding significantly increased the rate of decay of 
responding. It is likely, therefore, that each food reward earned has a reduced ability to activate 
and support subsequent effortful behaviour resulting in an accelerated decay in response rates.  
 
2.4.4 Dopaminergic manipulations 
Effort-based responding is highly sensitive to dopaminergic manipulations (Salamone & 
Correa, 2012). Presently, systemic administration of raclopride and amphetamine decreased 
and increased breakpoints respectively. This is in line with previous reports in lever-based 
versions of PR (Poncelet et al., 1983; Cheeta et al., 1995; Aberman et al., 1998), as well as in 
the mouse touchscreen version (Heath et al., 2015).  Amphetamine was able to produce a 
greater effect on breakpoints in animals reinforced under the PREXP schedule of 
reinforcement.  This suggests that this schedule may have higher sensitivity for detecting the 
effects of manipulations that facilitate PR performance. Exponential PR schedules are 
commonly used in drug self-administration studies (Richardson & Roberts, 1996). The rapidly 
increasing response requirement in later trials reduces the risk of ceiling effects in time-limited 
sessions (Roberts et al., 1989). In a similar vein, exponential schedules allow higher 
breakpoints to be reached with fewer responses and fewer rewards earned. This may reduce 
the influence of motor fatigue and/or satiety affecting the enhancement of breakpoints.  
 
Both raclopride and amphetamine affected the duration of the PRPs. Amphetamine has 
previously been reported to decrease the length of PRPs (Evenden & Robbins 1983), whereas 
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D2 receptor antagonists increase pausing (Salamone 1986). The effects of dopaminergic 
compounds on PRP were in contrast to the lack of effects observed following the outcome 
modulations. The magnitude of the effects produced by the higher doses of raclopride and 
amphetamine appeared far larger than those produced by prefeeding and increasing reward 
magnitude. It may be the case that PRP as a measure is not as sensitive to changes in motivated 
behaviour as breakpoint, and larger effects are needed to detect significant changes in this 
measure. One notable effect is that raclopride appeared to produce a greater effect on pausing 
under the PR4 schedule of reinforcement (figure 2.5B). Breakpoints were roughly equal 
between groups following the high dose of raclopride (figure 2B). To achieve this breakpoint 
under a PR4 schedule, the mean response requirement is greater than that under the PREXP 
schedule, which begins small and undergoes larger increases in later trials. The length of PRPs 
is determined in part by the upcoming response requirement (Schlinger et al., 2008). Therefore, 
the larger response requirements in the PR4 group likely exacerbate the effects of raclopride 
on pausing, resulting in longer PRPs.  
 
Another notable result was the effect of amphetamine on the pattern of response rates. The high 
dose of amphetamine reduced both the peak response rate and the rate of decay in responding. 
The reduced initial peak rate may be a reflection of the anxiogenic and/or appetite supressing 
effects of amphetamine (MacPhail & Gollub 1974; Lapin 1993).  The reduction in the rate of 
decay may have been a result of amphetamine altering the rats’ response to extinction. The low 
frequency of reinforcement relative to responding may result in extinction in later PR trials 
(Killeen et al. 2009). A slower decay in response rates may have reflected an increased 
resistance to extinction. However, if this were the case, it may have been expected that a greater 
effect upon the rate of decay would be observed in the PREXP group. The sharper increase in 
ratio requirements observed in the exponential schedule suggests a greater likelihood of 
extinction occurring relative to the linear schedule used in the PR4 group. As amphetamine 
reduced the rate of decay similarly in both groups, an increase in resistance to extinction is 
unlikely to be the sole explanation for a reduction in the rate of decay. A previous study, 
investigating within session changes in response rates reported that a similar dose of 
amphetamine (0.8mg/kg), increased the activating or motivational effects of reinforcers upon 
behaviour (Mobini et al. 2000).The reduced rate of decay observed presently may reflect an 
increase in the behavioural activation following each reinforcer. As a consequence, each 
reinforcer is able to support behaviour for longer, which may also underlie, at least in part, the 




2.4.5 Comparisons to other PR tasks  
It is worth noting that, in the absence of any additional manipulations, breakpoints are lower 
in touchscreen PR than those observed in lever-press PR tasks. For example, across both linear 
and exponential schedule types, breakpoints in excess of 100 are typically observed in lever-
responding rats (Skjoldager et al. 1993; Olarte-Sánchez et al. 2015; Bezzina et al. 2015). 
Therefore, the present findings of rats returning breakpoints in the region of ~45-55, is 
considerably lower than those seem with levers. The rate of operant responding is highly 
sensitive to physical characteristics such as the height of the lever (Skjoldager et al. 1993) and 
the required response force (Alling & Poling 1995). The touchscreen used in the present study 
use IR photocells to record screen touches (in fact, the rat is not strictly speaking required to 
‘touch’ the screen). Therefore, touchscreen responding would be expected to require less 
physical effort than responding on a lever. The differences in breakpoint, therefore, cannot be 
explained in terms of force-requirements. One possibility is that the biophysical feedback from 
touchscreen responding is considerably less than that obtained by pressing a lever. In turn, 
there may be less salient cues to associate with reward. Pavlovian cues associated with reward 
are able to strongly influence instrumental behaviour (Rescorla & Solomon 1967). The reduced 
salience of cues associated with touchscreen responding relative to lever-pressing, may 
therefore reduce their invigorating effects upon responding (e.g. Saunders & Robinson 2011). 
 
A separate possibility is the delay between response and reward. Increasing the delay from a 
response to a reward will shift behaviour to obtaining an immediately available, but less 
preferred reward (Thiébot et al. 1985). In the current touchscreen PR task, it is only possible 
to make a response every 0.5s. This is due to a brief stimulus-offset, added to provide visual 
feedback that a response has been made (see Methods). As a consequence, the rate of 
responding would be expected to be lower than a lever-based version of PR where rats are able 
to make multiple lever responses every second (e.g. Olarte-Sánchez et al. 2015).  The longer 
time taken to complete each ratio may increase the costs associated with obtaining reward and 
result in animals ceasing responding earlier. Taken together this suggests that in spite of less 
physical effort being required to respond compared to levers, the touchscreen may be more 
‘cognitively effortful’.  The reduced breakpoints and response rates in touchscreen PR may 
confer certain advantages: the avoidance of ceiling effects that may obscure potential 
faciliatory effects of interventions, particularly when using time-limited schedules, and a lower 
number of responses which may reduce the potentially confounding influences of satiation and 
motor fatigue upon performance.  It should be noted that although the majority of animals 
reached a breakpoint (had a three-minute period without touching the screen within a 45-
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minute session, table 2.2), a number of animals failed to do so. This was especially apparent 
following administration of amphetamine, where 14/24 rats failed to reach breakpoint. This 
represent a potential confound, since an animals breakpoint should represent the maximum 
number of responses emitted for a given reward, The inclusion of a time constraint suggests 
that the breakpoints reported in this study may not have been a true reflection of motivation. 
This further supports to concurrent analysis of response rate data to measure motivated 
behaviour, which may have been less affected by the time constraint. 
 
2.4.6 Conclusions 
Taken together, this study demonstrates the successful adaption and validation of PR for the 
rat operant touchscreen system. Like the mouse touchscreen- and traditional lever-based 
versions, the rat touchscreen PR variant is sufficiently sensitive to detect bidirectional changes 
in motivated behaviour following outcome manipulations and dopaminergic drugs. 
Furthermore, this study demonstrates that the use of exponential schedules of reinforcement 
may provide a greater sensitivity to detecting the effects of compounds that enhance PR 
performance. Additionally, this study demonstrates the utility of the complementary approach 
of studying within-session changes in behaviour in addition to cumulative parameters, such as 
breakpoint. Finally, effort-based motivated behaviour can now be assayed, with high face 





Chapter 3. Validation of a test battery to probe effort-related decision-making in rats 
 
3.1 Introduction 
In spite of being widely used as assays of motivated behaviour, there are several confounds 
associated with the use of PR schedules. For example, manipulations that affect appetite or 
hedonic processes could also influence breakpoint (Pratt & Kelley 2004; Higgs et al. 2005; 
Maccioni et al. 2008). Therefore, it may not be clear whether a manipulation that disrupts PR 
performance is affecting effort exertion or the primary motivation for the food reinforcer. An 
alternative or complementary approach is to examine effort-related decision making processes 
(Salamone et al. 1991).  In effort-related decision making tasks, rodents are given the choice 
between making an effortful response for a valued reward or making a lower effort action for 
a less preferred reward (Salamone et al. 1991; Salamone et al. 1994). These effort-related 
choice (ERC) tasks allow for better dissection of changes in motivated behaviour  (Salamone, 
Correa, et al. 2009). A widely studied operant version of the ERC task involves a choice 
between lever-pressing under a fixed ratio (FR) schedule for sucrose pellets or consuming 
freely available chow (Salamone et al. 1991).  Under low/moderate ratio requirements, rodents 
will typically choose to lever press for pellets. However, as the effort requirement for the 
preferred reward increases, animals will shift from lever pressing to consuming the freely 
available chow. Crucially, ERC can differentiate between perturbations that affect effort 
exertion and those that affect hedonic or appetitive processes. For example, a drug that 
specifically affects effort-exertion processes will reduce lever pressing and cause a shift in 
behaviour to the less preferred reward (Salamone et al. 1991). In contrast, a manipulation that 
disrupts hedonic processes would supress both lever pressing and chow consumption 
(Salamone et al. 2007). 
 
In operant boxes, effort is typically manipulated by increasing the number of responses 
required for reward. However, by increasing the response requirement there is a concomitant 
increase in the delay from trial onset to reward delivery.   Such delays represent a separate cost 
from effort which also affects behaviour. For example, increasing the time taken for a valued 
reward to be delivered will shift animals behaviour towards a less preferred but immediately 
available option (Thiébot et al. 1985; Evenden & Ryan 1996). As a consequence, any 
manipulation that affects PR or operant ERC performance, particularly at high ratios, could be 
affecting tolerance of delays rather than effort exertion. The effort discounting (EFD) task 
offers a way to account for the separate costs of delay and effort (Floresco et al. 2008).  During 
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EFD, a given response results in a large food reward and a separate response yields a smaller 
reward. Throughout a session the response requirement for the large reward increases, whereas 
the response requirement for the low reward remains constantly low. Importantly, a delay can 
be added to the low reward, that matches the time taken to complete the equivalent large reward 
trial (figure 3.1C). As the delays are matched, only the effort requirements vary between the 
small and large rewards. Using this task, it has been shown that animals will shift behaviour, 
within a session, from the large reward to the small reward as the effort requirement increases. 
Furthermore, through the use of EFD it can be shown that certain pharmacological 
manipulations can affect effort independently of delay (Floresco et al. 2008).  
 
A separate approach to control for potential delay confounds would be to manipulate effort 
requirements without changing the response requirements. Maze-based versions of ERC 
(Salamone et al. 1994; Pardo et al. 2012) and EFD (Bardgett et al. 2009) use a barrier obstacle, 
which an animal has to scale to obtain the large reward, whereas the small reward is available 
without the need to scale any barrier. The height of the barrier allows for the effort to be 
increased without substantially increasing the delay to reward; however, these tasks lack the 
advantages of automated operant testing. The use of a touchscreen stimulus as a manipulandum 
could allow for stimulus height to be increased within a session. Therefore, an effort 
discounting task could be developed that replaces an increasing ratio for the large reward with 
an ascending stimulus. As the height increases, rats would be expected to shift behaviour 
towards the small reward stimulus which remains at floor level (figure 3.1B). This approach 
would also remove the need for an animal to learn that a given number of responses is required 
for reward delivery. Therefore, a task using an ascending stimulus may provide a measure of 
effort-related choice in the absence of potential cognitive confounds.  
 
The present chapter aimed to validate a battery of tasks to assess effort-based behaviour in rats. 
The validation of an effort-based battery of touchscreen tasks may aid discovery of novel 
treatments by helping facilitate the translation of results from rats to clinical populations (see 
chapter 1). Furthermore, the use of a touchscreen allows each task to be compared to the many 
other tests in the same context using the same food rewards. The present chapter describes an 
attempt to adapt and validate a battery of effort-based decision-making assays for use in rats as 
well as validate a novel rearing effort discounting (RED) task  
 




A total of 34 male Sprague Dawley rats (Charles River, UK) were used in the current 
experiment.   The twenty-four rats were tested on the ERC and EFD tasks, had previously been 
tested on the PR task (chapter 2). A separate cohort of ten naive rats were tested on the Rearing 
Effort Discounting (RED) task. All housing and husbandry procedures were identical to those 
described previously (chapter 2). 
 
3.2.2 Apparatus 
All testing took place within automated Bussey-Saksida touchscreen chambers as described in 
detail in chapter 2. Masks and stimulus sizes are outlined in figure 3.1A. 
 
3.2.3 Effort-Related Choice  
Initially, animals underwent  FR5 testing identical to previous procedures (chapter 2), with no 
trial limit imposed. Sessions were terminated following 30 minutes. Once stable performance 
was reached, approximately 20g of homecage chow was scattered on the floor of the chambers 
and FR5 ran otherwise as normal. Following each session, the remaining chow was weighed 
to calculate the amount consumed.  Rats were initially habituated to this FR5-Chow procedure 
for ten days. In total, ERC training took 14 days. Following this period, data were analysed 
from three consecutive FR5 sessions. Subsequently, rats were given three consecutive days 
each of FR10, FR20 and finally FR40. This escalating FR procedure was used to avoid 
potential extinction effects. 
 
The primary measures of interest were the number of stimulus responses made and the amount 
of chow consumed. The post-reinforcement pause (PRP), the inter-response interval (IRI) and 
the latency to the first response were analysed as measures of task engagement.  In order to 
assess general activity levels, the mean reward collection latency; the rate of IR beam breaks 
(beam breaks per second) and the rate of nontarget screen touches (blank touches per second) 
were recoded. 
 
3.2.4 Effort discounting 
During EFD, responding to either a left or right stimulus (balanced across subjects) resulted in 
delivery of the large reward (LR, 3 pellets). A response to the opposite stimulus resulted in 
delivery of the small reward (SR, 1 pellet). All reward delivery cues (tone and magazine light) 




Initially animals undertook discrimination training which consisted in presenting rats with forty 
free-choice trials where both the LR and SR stimuli were presented simultaneously. A single 
response to either stimulus resulted in reward delivery. If no response was made to either 
stimuli within 30s an omission was recorded and the next trial commenced. Sessions were 
terminated after completion of 40 trials or following 45 minutes elapsing. Rats were required 
to make 30 LR choices (i.e. 75%) within a session before moving onto the next stage of 
training. All animals reached this criterion within seven days. 
 
Animals then underwent five days of EFD training.  Throughout testing, sessions were split 
into four bins of ten trials. The number of responses needed for the LR delivery increased 
following each bin.  The response requirement for the LR in each of the four bins was: FR1, 
FR6, FR12, FR18.  Prior to the start of each bin, two forced-choice trials were randomly 
presented (one each for the SR and LR stimuli), that helped inform the rats of the upcoming 
response requirements. During forced-choice only one stimulus was presented, and animals 
had to complete both forced-trials before being presented with the ten free-choice trials. Once 
a response was made to the LR stimulus in a free choice trial, the SR stimulus was removed 
from the screen until the start of the subsequent trial. Sessions were terminated following 40 
free-choice trials or 45 minutes.  
  
In order to add an equivalent delay to the SR (figure 3.1C), the mean response times for LR 
trials during bins 2, 3 and 4 were calculated from the previous stage of testing.  During the 
subsequent EFD sessions, reward delivery following SR choices was delayed according to the 
mean LR response times: bin 2- 6.64s: bin 3: 14.80s; bin 4: 25.50s. All other parameters were 
maintained from the previous sessions. Rats were tested on this delayed-EFD for five 
consecutive days. The primary measures of interest were the percentage of free-choice trials in 





Figure 3.1: A Details of the mask dimensions and stimuli locations in the tasks used in the 
present study. B Visualisation of the rearing effort discounting task. C Overview of trials within 
the effort discounting task and the effort discounting with equivalent delays variant. Blue bars 
represent a touchscreen response to either the SR or LR stimuli. SR: small reward; LR: large 
reward; 1 Pell: a single pellet reward; 3 Pells: Three pellets given as a reward. 
 
3.2.5 Rearing effort discounting  
Rearing effort discounting (RED) is an adapted EFD task in which the repeated response 
requirement is replaced by a requirement for the animal to rear up to respond to the LR 
stimulus, which increases in height at the start of each bin. This allows for the effort to be 
increased without substantially increasing the time taken to complete a LR trial. This also 
reduces possible cognitive confounds as the effort required in any given trial is apparent to the 
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rat, unlike in the traditional EFD task during RED two white rectangular stimuli (see figures 
3.1A,B) were presented, 4.5 cm apart. A response to one stimulus resulted in a single pellet 
delivery, whereas a single response to the other resulted in three pellets being delivered. The 
location of the small (SR, 1 pellet) and large (LR, 3 pellets) rewarded stimuli was 
counterbalanced across subjects, and remained constant for the duration of the study.  
 
An overview of the training procedure is available in figure 3.2A. Following screen touch 
training (chapter 2), rats were trained to discriminate between the large and small rewards. 
Discrimination sessions consisted of 20 forced choice trials, followed by 20 free choice trials. 
At the start of each trial, the magazine light flashed (250ms on/off) until the rat entered the 
magazine (therefore, unlike all other tasks, this task was self-paced). Following magazine entry 
either the SR or LR stimulus was presented on the screen and remained presented until touched. 
Reward delivery(SR: 1 pellet, LR: 3 pellets) was accompanied by stimulus offset, magazine 
illumination and tone (as described in chapter 2). Ten SR and ten LR trials were presented in a 
random order, with no type presented more than two times in a row. Following these forced 
choice trials, each rat undertook twenty free-choice trials. Here, both LR and SR stimuli were 
both presented on the screen, a single response to either the LR or SR stimuli resulted respective 
reward delivery and trial completion. All other trial parameters were identical to the forced 
choice trials. Rats were required to select the LR stimulus on at least 15 out of 20 free-choice 
trials to complete the reward magnitude discrimination. 
 
Rats were subsequently trained to respond to an ascending LR stimulus. During these sessions 
only the LR stimulus was presented. As before, the centre of the stimulus was 2.5 cm from the 
floor of the chamber, and a response resulted in delivery of three food pellets. Every two trials, 
the stimulus was raised by 2.5cm (but remained the same shape and size). This continued for a 
maximum of 20 trials when the centre of the stimulus was 25cm from the floor of the chamber. 
If no response was made to the stimulus within 300s the session ended, otherwise sessions were 
terminated after completion of the 20 trials. Four consecutive daily sessions of height training 
with these parameters were given. Subsequently, three additional sessions were administered 
with the response period reduced to 180s, 60s and 40s respectively. 
 
 Finally, animals underwent free choice discrimination training, to examine any influence of 
satiety on choice, in the absence of any escalating effort requirements. During free choice 
discrimination, forty free choice trials were presented. If no response was made to either stimuli 
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within 40s an omission was recorded and the next trial was initiated.  All rats were given three 
consecutive daily sessions of this discrimination testing before undergoing the RED task. 
 
Subsequently, rats were tested on the RED task. As before, this consisted of 40 trials separated 
into four bins of ten free-choice trials. During bin 1, both the SR and LR stimuli were located 
level with the floor of the chamber (stimulus centre 2.5cm from floor). However, during 
subsequent bins, the LR stimulus was elevated, whereas the SR stimulus remained fixed in the 
lower position. The centre of the LR stimulus was located at the following heights: bin 2- 
7.5cm, bin 3 – 12.5cm, bin 4 – 17.5cm. Again, a single response to either stimuli was needed 
for reward delivery of their respective magnitudes. All other session parameters remained 
constant. Analysis was conducted by bin to examine the effects of increasing the response 
stimulus height on the discounting of large rewards. Following stable performance, rats were 
tested on several validation probes, which can be seen in figure 3.2B. As with the EFD analysis, 
the primary variables of interest were the percentage of trials within each bin that a subject 






Figure 3.2: Experimental timeline of the rearing effort discounting task. A An overview of the 
training for Rearing effort discounting. LR: Large reward. B Outline of the validation 
procedures used during the Rearing effort discounting testing. 
 
Reward magnitude probe.  
During this probe, the heights of stimuli in bins 2 and 3 were increased (due to the lack of a 
difference in LR choices between bins 1 and 2 and bins 3 and 4 at baseline, see results). The 
height of the LR stimulus was as follows: bin 2 – 10cm, bin 3 - 15 cm (bin 4 remained at 17.5 
cm). A response to the LR stimulus resulted in 6 food pellets being delivered; all other 






















the rate of discounting. Rats received three consecutive days of increased magnitude training. 
Behavioural results were collapsed across the three days 
 
Increased height probe 
An increasing height probe was carried out in order to examine whether increasing the heights 
of the LR stimulus increased the rate of discounting. As with the standard RED, the LR and 
SR stimuli were located adjacent to each other during bin 1. The height of the LR stimulus 
during the remainder of the task was as follows: bin 2 – 12.5cm; bin 3 – 20cm; bin 4 – 25cm. 
Therefore, relative to the standard RED task the LR stimuli were located at equal during bin 1, 
2.5 cm higher during bin 2, 5cm higher during bin 3 and 7.5 cm higher during bin 4. Rats 
received three consecutive days of increased height training. Behavioural results were 
collapsed across the three days 
 
3.2.6 Drugs 
S(−)-Raclopride(+)-tartrate salt (Bio-techne, Abington, UK) was administered via 
intraperitoneal injection at a dose of 0.1 mg/kg  of each rat’s body weight (volume: 1 mg/ml), 
30-minutes prior to testing.  This dose was chosen to avoid the potential motoric effects 
observed previously (chapter 2). Raclopride was dissolved within physiological saline and 
administered prior to EFD with equivalent delays condition and RED testing 
 
3.2.7 Statistical analyses 
 All statistical analyses were conducted using SPSS (Version 23.0, IBM Corp, Armonk, NY, 
US). Graphs were produced using Prism (GraphPad, La Jolla, CA, USA). Repeated measures 
ANOVAs were used to analyse all results. When needed, a Greenhouse-Geisser correction was 
applied to adjust for violations in sphericity. All post hoc testing was corrected using 




3.3.1 Increasing the work requirement shifts behaviour during Touchscreen ERC testing 
Figure 3.3A shows how increasing the ratio requirement significantly reduced the number of 
screen responses made (F(3,69) = 53.246,  p  < .001; partial eta squared = .698). The number 
of target responses made under the FR5 schedule was significantly greater than all other 
conditions (p < .001); whereas the number of responses made under the FR40 schedule was 
significantly smaller than all other conditions (p < .001). There was no difference between the 
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FR10 and FR20 schedules (p > .05). Figure 3.3B suggests that increasing the work requirement 
significantly increased chow consumption (F(3,69) = 34.907,  p <.001; partial eta squared = 
.603; figure 3.3B). The amount of chow consumed was significantly lower on the FR5 schedule 
compared to all other schedules (p < .001). Chow consumption on the FR40 schedule was 
significantly greater than the FR10 (p < .01). No other comparisons were significant. Increasing 
the ratio requirement significantly affected task engagement. Increasing the ratio also increased 
the mean inter-response interval (IRI; F(1.13,25.996) = 11.165, p < .01; partial eta squared = 
.327; figure 3.3C). The mean IRI was significantly shorter on the FR5 schedule compared to 
all other schedules (p < .05). The IRI of rats reinforced on a FR40 schedule was also 
significantly longer than the FR10 (p < .01). There were no other differences in the mean IRI.  
Increasing the ratio requirement did not significantly affect the latency to the first response 
within a session (F(2.272, 52.259) = 1.386 ,  p = .254).  
 
 
Figure 3.3: Increasing the ratio requirement affects ERC performance. A Increasing the 
number of responses for pellet delivery reduces target touches and B increases chow 
consumption. C The mean inter response interval is increased at the highest ratio. Symbols 
note a significant(p<.05) post-hoc comparison * Significantly different from FR5; # 
significantly different from FR10; † significantly different from FR20; $ significantly different 
from FR40. Error bars display the SEM. 
 
Changing the ratio requirement also appeared to reduce the activity levels of rats within the 
chambers. As shown in figure 3.4A, increasing the work requirement decreased the rate of IR 
beam breaks (F(3,69) = 11.675,  p < .001; partial eta squared = .337). Beam breaks were 
significantly greater in the FR5 condition compared to the FR20 (p < .01) and FR40 conditions 
(p < .001). There were no significant differences between any other condition (all p > .05). The 
rate of nontarget screen touches was also significantly affected by the ratio requirement, as 
shown in figure 3.4B (F(2.058, 47.326) = 10.378 , p < .001; partial eta squared = .311). The 
number of blank touches made per second was significantly higher in the FR10 schedule 
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relative to all other conditions (all p < .05). The majority of rats (17/24) failed to complete a 
trial in the FR40 condition. Therefore, PRP and reward collection latency were only analysed 
for the FR5, FR10 and FR20 schedules. The ratio requirement did not significantly affect either 
the duration of the PRP (F(1.470, 20.864)  = 2.490,  p  = .113)  or the reward collection latency 
(F(2,42) = .128 , p  = .881; figure 3.4C).  
 
Figure 3.4: Effects of increasing the ratio requirement on measures of motoric performance A 
Increasing the ratio requirement decreases the rate of IR beam breaks. B The rate of blank 
(nontarget) screen responses is highest in the FR10/Chow condition. C Changing the response 
requirement did not affect the latency to collect rewards. Symbols note a significant post hoc 
comparison (p<.05). * Significantly different from FR5; # significantly different from FR10; † 
significantly different from FR20; $ significantly different from FR40. Error bars display the 
SEM. 
 
These data indicate that increasing the ratio during the ERC task decreases operant responding 
and shifts behaviour towards the less preferred, freely available chow. This is in line with 
previous reports using levers in rats and the touchscreen in mice (Salamone et al. 1997; Heath 
et al. 2015). A reduction in the total target screen responses and mean IRIs suggest at higher 
ratios rats spend less time engaged in operant responding.  
 
3.3.2 Effort discounting without programmed delays 
Given the high rates of chow consumption in the ERC, it may be necessary to develop a 
touchscreen-based assay of effort-related decision making that does not include a freely 
available chow option. Therefore, rats were tested on a touchscreen effort discounting (EFD) 
task.  Figure 3.5A suggests that increasing the large reward (LR) response requirement, reduced 
the percentage of LR choices (F(3,69) = 66.922,  p < .001, partial eta squared = .744). The 
percentage of LR choices under each ratio differed significantly from all others (all p < .05). 
Concurrently, as seen in figure 3.5B, increasing the ratio requirement of the LR also resulted 
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increased the percentage of small reward (SR) choices (F(3,69) = 55.960,  p  < .001; partial eta 
squared = .709). The percentage of SR choices made within each bin differed between each 
other condition (all p < .05).  However, as seen in figure 3.5C, increasing the work requirement 
for the LR did not affect the rate of omissions (F(2.278, 52.386) = 1.804 ,  p  = .170; figure 
3B). Together, these results suggest that increasing the work requirement for the large reward 
option resulted in rats shifting their preference towards the small reward across the course of  
the session.  
 
3.3.3 Effort discounting with equivalent delays 
In this condition, a delay was added to the small reward to match the average time taken to 
complete a LR trial in each bin. This allowed for the effects of effort-requirements to be 
separated from the effects of escalating delays. Figure 3.5D shows how, in the presence of 
equivalent SR delays, increasing the effort needed to obtain the large reward again significantly 
decreased the percentage of LR choices made (F(1.764, 40.574) = 56.873,  p  < .001; partial 
eta squared = .712). The percentage of LR choices made in under each ratio differed 
significantly from each other ratio (all p < .01).  Figure 3.5E shows there was also a significant 
effect on the percentage of SR choices made (F(3,69) = 9.334,  p  < .001; partial eta squatted 
= .289). Post hoc comparisons revealed that there was a significant increase in SR choices from 
bin 1 to bins 2 (p < .001), bin 3 (p < .01). However, there were no other significant differences 
between the percentage of SR choices between any other bins (all p >.05). This suggests, 
despite an initial increase in the small reward choices made, there were no increases following 
bin 2.  
 
In contrast to the effects observed in the absence of delays, there was a significant increase in 
omissions over the course of a session, as seen in figure 3.5F (F(1.662, 38.231) = 49.249, p < 
.001; partial eta squared = .682; figure 3F). The percentage of choices that ended in omissions 
in bin 1 did not differ from bin 2 (p = .135).  There was however a significant increase in 
omissions from bin 2 to bins 3 and 4 (both p < .001). The percentage of omissions also 
increased from bins 3 to 4 (p < .001) Together these results suggests, that in the presence of a 
delayed SR, increasing the ratio requirement for the LR decreases the preference for that reward 
option; however, instead of shifting behaviour towards SR choices, there was an increase in 





Figure 3.5: Touchscreen effort discounting performance in rats (A-C) Effort discounting 
without any reward delays and (D-F) effort discounting with an equivalent delay added to the 
small reward (to match the average time taken to complete a LR trial in each bin). A Increasing 
the response requirement for the large reward decreases large reward choices and B increases 
small reward choices. C In the absence of any delay, increasing the work requirements for the 
large reward did not affect omissions. With equivalent delays D increasing the work 
requirement decreased the choice of large rewards. E However, only an initial small increase 
in small reward choices was observed. F In the presence of delays, increasing the work 
requirement causes an increase in omissions. Symbols above data points note a significant post 
hoc comparison (p<.05). * Significantly different from FR1; # significantly different from FR6; 
† significantly different from FR12; $ significantly different from FR18 Error bars display the 
SEM. 
 
3.3.4 Raclopride increases the rate of omissions during effort discounting 
To test the effects of a dopaminergic challenge, 0.1mg/kg of raclopride was administered prior 
to the EFD with equivalent SR delays. Figure 3.6A shows how LR choices were significantly 
reduced both by increasing the response requirement (F(3,69) = 51.014,  p < .001; partial eta 
squared = .689) and by raclopride administration (F(1,23) = 32.487,  p < .001; partial eta 
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squared = .585). There was also a significant interaction between ratio and drug (F(3,69) = 
6.476, p < .01; partial eta squared = .220). Under both vehicle and raclopride conditions there 
was a significant decrease in LR choices across the session (i.e. between FR1 and FR18 
conditions). Furthermore, whereas raclopride did not affect LR choices under FR1 (p = .90); 
raclopride reduced the percentage of LR choices compared to vehicle at all other ratio 
requirements (all p < .001).  Together, this suggests that raclopride administration increased 
the rate of effort discounting. 
 
As seen in figure 3.6B, the percentage of SR choices was also significantly affected by the LR 
ratio (F(3,69) = 3.654 ,  p < .05; partial eta squared = .137). However, raclopride did not affect 
the percentage of trials ending in SR choices (F(1,23) = 2.499, p = .128).  There was however, 
a significant interaction between LR ratio and raclopride on SR choices (F(3,69) = 3.548, p 
<.05; partial eta squared = .134; figure 3.6B). In the vehicle condition, SR choices were greater 
in bin 3 compared to bin 1 (p <.05). Following raclopride administration, there were no 
significant differences in SR choices between any bin (all p > .05). When comparing between 
drug conditions,  SR choices were higher following administration of raclopride in bin 2 (p < 
.01) only (all other comparisons p > .05). Together, these data suggest that raclopride produced 
an initial increase in SR choices; however, this did not increase with escalating LR effort costs. 
  
Figure 3.6C shows how the percentage of trials ending in omission was significantly affected 
by both LR response requirement (F(1.894,43.567) = 48.362,  p  < .001; partial eta squared = 
.678) and raclopride administration (F(1,23) = 26.905, p < .001; partial eta squared = .539). 
There was also a significant interaction between response requirement and drug on omissions 
(F(3,69) = 11.616, p < .001; partial eta squared = .336). In the vehicle condition, there was no 
difference in omission rates between bins 1 and 2 (p =.807); however, omission rates differed 
significantly between all other bins (p < .05). In the raclopride condition, omissions differed 
significantly between each bin (all p < .05). When comparing between drug conditions, 
raclopride significantly increased the percentage of omissions made in bins 2-4 (p < .01) but 
not bin 1 (p <.05). This result mirrors the effects of raclopride on LR choices (figure 3.6A) and 
suggests that raclopride increases the rate of omissions, but only under effortful conditions. 
Together, this highlights how, in the presence of delays, decreases the choice of high effort 






Figure 3.6: Effect of raclopride on effort discounting performance with a delayed small 
reward. A Raclopride and higher work requirements decrease large reward choices. B 
Raclopride produces only a small effect on small reward choices. C Raclopride increases the 
effects of ratio on omissions. Rac: Raclopride 0.1mg.kg, Veh: Saline vehicle. Symbols above 
data points note a significant (p<.05) post hoc comparison.* A significant difference between 
drug conditions. Error bars display the SEM. 
 
3.3.5 Rearing Effort Discounting 
The previous results demonstrate that the addition of a delay to the low-effort option, results in 
an increase in the rate of response omissions. We therefore sought to develop a task that allows 
effort to be manipulated in the absence of any substantial increase in the delay-to-reward. 
Maze-based ERC tasks use the height of a barrier to increase the effort needed to obtain a 
reward (Salamone et al. 1994). In the rearing effort discounting (RED) test, the height of the 
LR stimulus increased across a session, rather than the ratio requirement. During height 
training, all animals were able to successfully respond the maximum LR stimulus height 
(25cm), in the absence of a SR response option.  
 
For the baseline RED procedure, the following LR stimulus heights were used: bin 1-2.5cm 
(floor level) bin 2- 7.5cm, bin 3 – 12.5cm, bin 4 – 17.5cm.  Figure 3.7A shows that increasing 
the height of the LR stimulus, significantly decreases LR choices (F(3,27) = 24.547,  p  < .001; 
partial eta squared = .723). The percentage of the LR choices did not differ between bins 1 and 
2 or bins 3 and 4 (p > .05); however, all other comparisons were significant (all p < .01).  
During baseline RED training, no omissions were made, meaning every non-LR choice was a 
SR choice. Therefore, increasing the height of the stimulus had an equal but opposite effect on 
the percentage of SR choices (F(3,27) = 24.547,  p  < .001; partial eta squared = .723; figure 
3.7B).  Together, these data demonstrate that increasing the height of the LR stimulus results 




3.3.6 Effect of increasing the large reward magnitude on RED performance 
 Figure 3.7C shows how LR choices were significantly affected by both bin (F(1.524, 13.720) 
= 11.963, p< .01; partial eta squared = .571) and reward magnitude (F(1,9) = 11.963,  p  < .01; 
partial eta squared = .596). There was no significant interaction between reward magnitude and 
bin (F(3,27) = .757,  p = .528; partial eta squared = .078). Overall, LR choices were greater 
when reinforced with 6 pellets compared to the standard 3 pellet rewards (p < .01). This 
suggests that increasing the magnitude of the reward facilitates selection of the high effort, LR 
option independently of the height of the stimulus.  As seen in figure 3.7D, increasing the 
magnitude of the large reward option also significantly affected the percentage of SR choices 
(F(1,10) = 15.240 ,  p  < .01; partial eta squared = .629). There was also a significant main 
effect of bin on SR choices (F(1.543, 13.890) = 11.007, p < .01; partial eta squared = .550). 
Again, there was no interaction between bin and the large reward magnitude on SR choices 
(F(1.565, 14.081) = .971,  p  = .382; ). Overall, having a larger LR significantly decreased 
small reward choices (3 pellets: 39.67 ± 5.97, 6 pellets: 27.42 ± 5.06; p < .01). The percentage 
of omissions was not affected by either reward magnitude (F(1,9) = 2.250,  p = .168), bin  
(F(3,27) = 2.096, p = .124) or by any bin x magnitude interaction (F(3,27) = 2.020,  p  = .135).  
 
 
Figure 3.7: (A-B) Rearing effort discounting performance and (C-D) effects of increasing the 
magnitude of the large reward on rearing effort discounting. A Increasing the height of the 
large rewarded stimulus decreases responses and B increases choices of the small rewarded 
stimulus. C Increasing the magnitude of the large reward increases large reward and D 
decreases small reward choices. Symbols above data points note a significant post hoc 
comparison (p<.05). *Significantly different from bin 1; #significantly different from bin 2; 
†significantly different from bin 3; $ significantly different from bin 4. Error bars display the 
SEM. 
 
3.3.7 The effects of increasing the height of the large rewarded stimulus on RED performance 
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Increasing the height of the LR stimuli decreased the percentage of LR choices, as can be seen 
in figure 3.8A (F(1,9) = 31.14, p < .001; partial eta squared = .776). There was also a significant 
effect of bin (F(3,27) = 30.737,  p < .001; partial eta squared = .774) and a significant bin x 
height interaction (F(3,27) =  23.978,  p < .001; partial eta squared = .727) on LR choices. The 
percentage of LR choices decreased from bin 1 to 4 in both height conditions (standard p < .05; 
increased height: p < .001). The percentage of LR choices differed between height schedules 
in bin 4 only (p < .001). As shown in figure 3.8B, increasing the height of the LR stimulus also 
affected the SR choices (F(1,9) = 24.214, p < .01; partial eta squared = .729). There were also 
significant effects of bin (F(2,27) = 25.890, p < .001; partial eta squared = .742) and a bin x 
height schedule interaction (F(3,27) = 18.360, p < .001; partial eta squared =.671). SR choices 
increased significantly from bin 1 to 4 in both height conditions (standard: p < .05; increased 
height: p < .001). Between height conditions, there was a significant difference in the 
percentage of SR choices in bin 4 only (p <.001). The percentage of trials ending in omissions 
was also affected by both height (F(1,9) = 6.036, p < .05; partial eta squared = .402) and bin 
(F(1,966, 17.694) = 6.152, p < .05; partial eta squared = .406). The bin x schedule interaction 
on omissions was also trending towards significance (F(1.922,17.30) = 3.368, p = .06; figure 
3.8C). Overall the percentage of omissions was significantly increased by increasing the target 
height (p < .05).  
 
 
Figure 3.8: Effects of stimulus height on rearing effort discounting. A Increasing the stimulus 
height only decreases large reward choices at the final height. B Increasing the large reward 
stimulus height causes a shift in responding to the small reward stimulus in the final bin only. 
C Increasing the large stimulus results in a small increase in omissions in the final bin. Symbols 
above data points note a significant (p<.05) post hoc comparison. * Significantly different from 
bin 1; $ significantly different from bin 4; ‡ Significant difference between drug conditions. Error 
bars display the SEM 
 
3.3.8 Effect of raclopride administration on RED performance 
 
72 
Subsequently, the effects of 0.1mg/kg of raclopride on rearing effort discounting was tested.  
As seen in figure 3.9A, the percentage of LR choices was significantly reduced by both bin 
(F(3,27) = 5.323,  p  < .01; partial eta squared = .507) and raclopride administration (F(1,9) = 
9.240, p < .05; partial eta squared = .372). However, there was no interaction between 
raclopride and bin (F(3,27) = 1.187, p = .333; figure 7A). Concurrently, as seen in figure 3.9B, 
SR choices were significantly increased by both raclopride administration (F(1,9) = 9.333, p < 
.05; partial eta squared = .507) and bin (F(3,27)  = 4.321, p < .05; partial eta squared = .324). 
However, there was no drug x bin interaction (F(3,27) = .401,  p  = .753; figure 7B). The 
percentage of omissions, which can be seen in figure 3.9C, were not significantly affected by 
either raclopride (F(1,9) = 4.355,  p = .067) or bin (F(1.119,10.069) = 2.591,  p  = .137). There 
was also no significant interaction between raclopride and bin (F(1.231, 11.082) = 2.771,  p  = 
.121). 
 
Figure 3.9: Effect of systemic raclopride on rearing effort discounting. A Raclopride has only 
a small effect on large reward choices B Raclopride does not affect small reward choices. C 
Raclopride produces a small increase in omissions. Veh: saline vehicle; Rac: Raclopride 
0.1mg/kg. Error bars display the SEM 
 
3.4 Discussion 
The ability to accurately measure effort-based decision-making in rodents can help provide a 
translational means of measuring motivation. The use of choice tasks can offer a 
complimentary approach to progressive ratio assays, particularly when testing the effects of 
novel pharmacological interventions. Choice assays allow for dissociation of activational and 
directional components of motivation (Salamone & Correa 2012). Furthermore, a number of 
choice tasks may avoid the confounds of progressively increasing reward delays observed in 
PR (Wanat et al. 2010), that may confound interpretation of results. Finally, effort-based 
decision-making tasks have been developed for use in clinical populations (Treadway et al. 
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2009; Chong et al. 2015). The present chapter explored the potential of three effort-based 
decision-making tasks for use within the rat touchscreen operant system.   
 
3.4.1 Effort related choice  
Operant ERC tasks have been widely used to understand the neural and pharmacological 
substrates of effort-based behaviour (Salamone, Correa, et al. 2016; Bailey, Simpson, et al. 
2016). In the present study, increasing the response requirement for food pellets resulted in a 
significant decrease in touchscreen responding for food pellets. This decrease in touchscreen 
responding was accompanied with a significant increase in the consumption of freely available 
chow. This behavioural shift is in line with the previous lever-based versions and the mouse 
touchscreen ERC task (Salamone et al. 1997; Cagniard et al. 2006; Heath et al. 2015). 
Additionally, increasing the response requirement increased the mean inter-response interval 
(IRI) and decreased the rate of IR beam breaks. This suggests that the rats disengaged from 
touchscreen responding as the response requirement increased. This behavioural shift is 
believed to be an outcome of a cost-benefit decision process (Salamone, Correa, et al. 2009). 
Increasing the response requirement increases the cost associated with the preferred reward, as 
the costs begins to outweigh the benefit of the preferred reward a shift occurs to the less 
preferred food reward. The point at which animals shift is sensitive to both pharmacological 
manipulations and individual differences in neurochemical correlates (Randall et al. 2012).  
  
One issue of note was the baseline performance of rats during ERC responding, when tested 
under low effort requirements (i.e. FR5). In traditional versions of ERC, in the absence of any 
other manipulations, rats consume very little chow on a FR5 schedule (Salamone et al. 1991; 
Cousins & Salamone 1994). This is in contrast to the present study where rats consumed, on 
average, almost 7.5g of chow in 30 minutes of testing at this ratio. The number of touchscreen 
responses observed (~180) was also substantially lower than the number of lever presses 
typically seen in a 30-minute ERC session, which is typically above 1000 (Salamone et al. 
1991; Cousins and Salamone 1994). Therefore, under low-effort conditions, rats already spend 
considerable periods of time consuming the freely available chow rather than engaging in 
operant responding. This is likely due to the nature of the touchscreen manipulandum (see 
chapter 2). Importantly however, the present results suggest that the rat touchscreen ERC is 
still sensitive to the behavioural shift that occurs when increasing the effort requirement; the 





3.4.2 Effort discounting 
The EFD task, like the ERC task, allows for the dissociation of effort-based processes and 
hedonic/motoric confounds on effort-related decision-making. However, the EFD task is 
advantageous as it can also control for the effects of delays conferred by escalating response 
requirements (Floresco et al. 2008). In the absence of any delay attached to the small reward, 
rats displayed the expected shift in behaviour from the large rewarded (LR, 3 pellets) response, 
to the small reward (SR, 1 pellet), as the number of responses needed for the LR increased 
(figures 3.5A,B).  
 
Subsequently, a delay was added to the SR in each bin that matched the time taken to obtain 
the LR. Initially, there was a small shift from the LR to the SR as the response requirement 
increased from one to six. However, as the requirement increased, an increase in response 
omissions, rather than an increase in the number of SR choices was observed (figures 3.5D-F). 
This effect was exacerbated by administration of raclopride, which further increased the effects 
of response requirement on omissions. In previous versions of EFD, administration of 
dopamine receptor antagonists increases the rate of effort discounting and facilitates the shift 
from LR to SR choices (Floresco et al. 2008). However, we presently observed an increase in 
the shift from LR choices to omissions with no effect on the rate of SR choices.  
 
A likely explanation for this result is the duration of the SR delays imposed. These delays are 
determined from the time taken to obtain the LR in any given bin. The delay between making 
a response and receiving an appetitive reward represent a separate cost to the total number of 
responses made (Bailey et al., 2016). The delays imposed in the present study (FR6- 6.64s, 
FR12 - 14.80s, FR18 - 25.50s) were substantially longer than those reported in lever-based 
EFD paradigms (e.g. FR5 – 1.7s, FR10 – 2.8s, FR20 – 6.5s; (Floresco et al. 2008). As discussed 
previously (chapter 2), the response rates observed on touchscreen responding appear lower 
than those observed with levers. The delays imposed to the SR were calculated based on the 
time taken to complete the corresponding LR trial within the same bin. As responding is slower 
within a touchscreen system the costs associated with the delayed SR are higher than would be 
expected within an otherwise identical lever-based task. Therefore, rats do not have a low-cost 
option to shift behaviour towards, as, the costs associated with either the LR (effort costs) or 
SR options (delay costs) both increase across bins. This would explain the sharp increase in 
omissions observed, particularly in later bins. In the original lever-based version (Floresco et 
al., 2008), the shorter delays imposed on the SR mean in later trials rats are still presented with 




It should also be noted that dopamine receptor antagonists can increase the rate of delay- as 
well as effort-discounting (Wade et al. 2000; Floresco et al. 2008). Therefore, it is likely that 
the effect of raclopride was to reduce the rats’ tolerance to perform either option, which resulted 
in the increase in omission rates. Therefore, it appears that EFD with equivalent delays, as 
currently tested, may require an alteration of the parameters used or an extended training 
schedule, for use within the touchscreen operant system. An alternative approach would be to 
utilise the condition without delays. Several studies do not include a condition using equivalent 
delays when using lever-based EFD tasks  (Hosking et al. 2015; Robles & Johnson 2017). 
However, it may also be necessary to subsequently test any drug effects on a delay-discounting 
procedure to control for any delay-based mediating effects, which may unnecessarily inflate 
the number of animals needed for an experiment. 
 
3.4.3 Rearing effort discounting 
A separate approach to the study of effort related processes is to manipulate effort in the 
absence of altering the delay to reinforcement. In human and nonhuman primate studies this 
can be examined through increasing the force needed for a reward (Chong et al. 2015; Nougaret 
& Ravel 2015). In rodents, this has previously been achieved by imposing a physical barrier 
that must be scaled between the animal and a reward (Salamone et al. 1994; Pardo et al. 2012). 
This approach may also be advantageous as it reduces the cognitive demands placed on the 
decision making; as the degree of effort needed to obtain the reward is readily apparent, the 
animal is not required to learn at any given stage of a session how many responses are required 
for reward delivery. 
 
The present study used a vertically ascending response stimulus to assess effort discounting in 
rats. Increasing the height of a stimulus associated with a large reward reduced the rats’ 
preference for this reward and increased the responding for a lower smaller reward. In contrast 
to the delayed EFD task, increasing the effort needed for the large reward did not significantly 
increase the rate of omissions. Furthermore, the RED task is sensitive to manipulations that 
affect cost/benefit valuations. Increasing the benefits of performing the effortful actions made 
rats more resilient to the high effort costs.  Conversely, increasing the costs associated with a 
goal decreased rats’ preference for this action. This is in spite of the fact that all rats readily 




However, there appeared to be a strong effect of repeated training on RED performance. Rats’ 
preference for the LR in later bins, increased throughout the study. Within early stages of 
training, a strong discounting effect was observed (figures 3.7A,C); however, by the final 
stages, there was little discounting (figures 3.8B; 3.9A). This confound was especially apparent 
following the application of raclopride. In spite of an overall reduction in number of large 
reward choices and concomitant increase in small reward choices, raclopride did not appear to 
preferentially affect the high effort trials. The likely explanation is that due to repeated training 
effects, the stimulus heights employed were not sufficiently effortful. Following vehicle 
administration, the rats still selected the large reward option in over 80% of trials in the final 
bin (with a stimulus height of 17.5cm). Dopamine receptor antagonists, at moderate doses, 
produce little effect on low-effort operant responding (Salamone et al. 1997). Increasing the 
height of the large reward stimuli in the later bins may be necessary to demonstrate an 
interaction between dopamine receptor antagonism and effort.  The practice effect on 
performance may limit the utility of the task for long-term studies of effort-based processes, or 
those examining chronic treatment effects. It may be possible to reduce the ceiling effects 
observed by decreasing the differences in the reward magnitudes between the low effort and 
high effort options (e.g. 1 vs 2 pellets) or by altering some other task parameter. 
 
3.4.4 Conclusions 
The present chapter describes the adaptation of two existing and one novel effort-based 
decision-making tasks for use in the rat touchscreen system. Each task had limitations. For 
example, rats performing on EFD with equivalent delays showed high rates of omission. This 
would make it difficult dissociate motivational effects from hedonic/motoric changes. When 
tested on the RED task rats demonstrated a strong practice effect, which limits its suitability to 
for repeated/longitudinal testing. ERC, in spite of low levels of baseline may represent the best 
task for assaying effort-related decision-making behaviours using the touchscreen in rats. In 
spite of a low number of trials completed at FR5, it is still possible to reduce this number by 
increasing the ratio requirement, suggesting the absence of any significant floor effects.  
Currently therefore, the ERC assay may be best suited to studying the effects of effort-related 





Chapter 4. Oxygen responses within the nucleus accumbens are associated with 
individual differences in effort exertion in rats 
 
4.1 Introduction 
Recently, the RDoC initiative (Insel et al. 2010; Cuthbert & Insel 2013) has put forward the 
idea that transdiagnostic biological domains such as motivation may afford a greater 
opportunity for therapeutic modulation than do existing psychiatric symptom clusters. Thus, 
an imperative is to gain a more foundational understanding of the neural substrates underlying 
motivated behaviours in healthy individuals, patient populations and animal models, using 
methodology that optimises translation between species. As previously discussed, activational 
components of motivation are disrupted across a number of disorders (Chapter 1). Within the 
RDoC matrix, approach motivation has been highlighted as a cluster of symptoms that are 
relevant to a number of neuropsychiatric disorders. One subconstruct of approach motivation 
is the “effort valuation/willingness to work”, which could be assessed in rodents using a PR 
schedule of reinforcement. Through the use of PR, the neural substrates of effort-based 
behaviour have been widely explored (Bailey, Simpson, et al. 2016). Dopaminergic and 
excitotoxic lesions of the nucleus accumbens (NAc) core can profoundly alter PR performance 
(Aberman et al. 1998; Bowman & Brown 1998; Hamill et al. 1999), and has been linked with 
a apathy in a number of disorders (reviewed in chapter 1).  
  
Concomitantly to measuring direct behavioural changes in effort motivation, neuroimaging and 
electrophysiological techniques can be used to assess its underlying neurophysiological 
correlates.  Such an approach can help establish the so called ‘neuro-cognitive’ validity of tasks 
cross-species. That is that assays probe the same cognitive processes and are supported by 
equivalent neural structures (Bussey et al. 2012; Hvoslef-Eide et al. 2016). There are a number 
of functional imaging measures that can be used in rodent research to accurately measure direct 
neural (e.g. electrophysiology) or neurochemical (e.g. micro-dialysis/voltammetry) parameters 
during behaviour. However, in humans, the vast majority of functional imaging research is 
performed using the blood oxygen level dependant (BOLD) contrast measured by functional 
magnetic resonance imaging (fMRI, Ogawa et al. 1990). BOLD-fMRI is only a surrogate 
measure of neural activity, relying on a process of neurovascular coupling to infer neural 
processes from changes in oxygenated blood that are correlated with changes in neural activity 
(Logothetis et al. 2001; Logothetis & Wandell 2004). However, fMRI is a non-invasive 
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measure with high spatial resolution. Coupled with the wide availability of facilities, this makes 
fMRI a valuable tool in exploring the neural correlates of behaviour.  BOLD-fMRI can be 
performed in rodents; however it typically requires rodents to be restrained and/or anesthetised 
(Li et al. 2016). Constant potential in vivo oxygen (O2) amperometry can also be used to assess 
changes in regional brain O2 levels in response to changes in neural activity (Lowry et al. 2010). 
Crucially, in vivo O2 amperometry allows for recording of neurophysiological changes in 
animals performing complex behavioural tasks (e.g. McHugh et al. 2011; 2014; Li et al. 2015). 
Furthermore, unlike other preclinical imaging techniques, O2 amperometry can provide an 
adequate (in terms of both validity and viability) proxy measure of the BOLD response in 
awake rodents (Lowry et al. 2010; Howe et al. 2013; Francois et al. 2016). 
 
A series of studies have been performed to validate O2 amperometry as a surrogate measure of 
neuronal activity. These studies broadly belong to two categories. Firstly, several experiments 
have demonstrated a tight correlation with electrochemically measured oxygen and direct 
electrophysiological recording (Li et al. 2011) and proxy hemodynamic measures of neuronal 
function including regional cerebral blood flow (Lowry et al. 1997) and fMRI-BOLD (Lowry 
et al. 2010). The second class of studies have focused on demonstrating the ability to detect 
well-established neural correlates of behaviour, such as reward prediction errors (Francois et 
al. 2012) across species (Francois et al. 2016). Taken together, this suggests that O2 
amperometry can be used to compare the neurophysiological correlates of behaviour to be 
across species 
 
As reviewed above, the NAc has been widely implicated in effort-based behaviour.  The 
orbitofrontal cortex (OFC) may also be a particularly relevant regional substrate that is not only 
implicated in a number of neuropsychiatric disorders associated with apathy (Menzies et al. 
2008; Kanahara et al. 2013) but also mediates aspects of instrumental behaviour required for 
PR schedule performance  (Cetin et al. 2004; Gourley et al. 2010; Münster & Hauber 2017). 
However, the effects of lesions to the mOFC and NAc produce different effects on effort-
exertion (Bailey et al., 2016). The inclusion of a secondary region of interest, would also allow 
to the demonstration that any effects detected are at least partially regionally-specific, and not 
due to a confound caused by some global change in O2 across the brain. 
 
The aim of the present study was to assess the relative contribution of the NAc and OFC regions 
to rodent performance under a PR schedule of reinforcement, using O2 amperometry. The 
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influence of effort requirements on NAc and OFC O2 responses were assessed, as well as the 
association between individual differences in motivated behaviour and O2 responses. Finally, 
O2 responses to rewards delivered independently of behaviour were examined. It is 
hypothesised that O2 responses, as a measure of neural activity would be greater in later, higher 
effort trials. Moreover, given the established role of the NAc in effort based-behaviour it is 
hypothesised that this association between trial effort and  O2 responses  would be found in the 
NAc, but not the OFC. 
 
4.2 Materials and Methods 
 
4.2.1 Animals 
Male Wistar rats (Charles River, UK) were the subjects used in this study. A total of twenty-
one rats underwent behavioural testing. Two were subsequently excluded due to poor signal 
quality resulting in all trials containing multiple artefacts (see 4.2.4 below). Four rats were 
excluded due to all electrodes being either mis-located NAc electrodes or having unidentifiable 
co-ordinates (see 4.3.1). Resulting in fifteen rats being included in the main (NAc) analysis. A 
further five rats were excluded from the OFC analysis due to incorrectly located or 
unidentifiable OFC electrodes. All animals were group housed (3-4 per cage) throughout the 
study, in a temperature (20-22°c) and light controlled (lights on 0700-1900) environment. All 
testing took place during the light phase. Animals were given at least seven days of acclimation 
in the facility prior to surgical implantation of oxygen recording electrodes. Following a two-
week surgical recovery period, animals were placed on a schedule of controlled feeding and 
maintained at no less than 85% of their free feeding body weight measured post-surgery. No 
correction was applied to this 85% control weight to match the animals expected growth curve 
(weight at training: 585g ± 10.38; weight at testing: 612g ± 16.45). Water was freely available 
throughout the study. All experimental procedures were conducted at Eli Lilly and Company 
Limited in accordance with the Animals (Scientific Procedures) Act 1986 and following 
approval from the local Animal Welfare and Ethical Review Board (AWERB). 
 
4.2.2 Carbon paste electrode construction and in vitro calibration   
Carbon paste electrodes (CPEs) were constructed and calibrated in vitro as previously 
described (McHugh et al. 2011; Francois et al. 2012; 2014) from 8T (200 μm bare diameter; 
270 μm coated diameter) Teflon®-coated silver wire (Advent Research Materials, Suffolk, 
UK). Probes had a surface area of 0.05mm2. The Teflon insulation was slid along the wire to 
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create a ~ 2mm deep cavity, which was filled with carbon paste. Carbon paste was prepared by 
mixing 7.1 g of carbon graphite powder and 2.5 ml of silicone oil (both Sigma-Aldrich, O’Neill 
et al. 1982). All electrodes were soldered to gold connectors. Reference and auxiliary 
electrodes were also prepared from 8T Teflon®-coated silver wire by removing the Teflon® 
tip.  
 
In vitro calibration took place within a three-electrode glass electrochemical cell (C3 cell stand, 
BASi), with an Ag/AgCl reference electrode and a BASi platinum auxiliary electrode. 
Calibrations were performed in a 15-ml phosphate buffered saline (PBS) solution with a pH of 
7.4, saturated with gaseous nitrogen (N2), atmospheric air (from a RENA air pump), or pure 
O2.  This provided a 3-point calibration of known concentrations of 0 μM (N2 saturated), 240 
μM (air saturated), and 1260 μM (O2 saturated) oxygen. CPEs were chosen for implantation if 
their calibration curves were linear and the measured O2 values from the saturated solutions 
were not greatly different from those expected (least square linear regression, R2 ≥ 0.98). 
 
4.2.3 Surgical implantation and in vivo validation of carbon paste electrodes 
Rats were anaesthetised with 4% isoflurane (1 L/min O2) and then maintained on 2% isoflurane 
(1L/min O2) throughout the surgical procedure. CPEs were implanted into the following 
regions: bilaterally into the NAc [from bregma: anteroposterior (AP), +1.4mm, mediolateral 
(ML), ±1.4 mm and from dura: dorsoventral (DV): -6.1 mm]; and unilaterally into the medial 
orbitofrontal (mOFC, from bregma : AP, +4.4mm; ML, +0.6mm and from dura: DV, -4.0mm) 
and the lateral orbitofrontal cortices (lOFC, from bregma: AP, +3.8mm; ML, +2.6mm and from 
dura: DV, -4.4mm). The reference electrode was implanted, posterior to bregma, into the left 
posterior cortex (from dura: DV, -1mm). The auxiliary electrode was secured to a screw 
positioned, posterior to bregma, above the right posterior cortex. All electrodes were secured 
with dental cement and the gold connectors inserted into a six-pin socket (Plastics One), which 
in turn was cemented into place. Animals received analgesics pre- and post-surgery (carprofen, 
5 mg/kg, subcutaneous; Pfizer) as well as antibiotic (Convenia, 5mg/kg, subcutaneous; Pfizer) 
administration post-surgery to aid recovery. Following surgery, animals were placed in 
thermostatically controlled cages and allowed to regain consciousness.  
 
In vivo electrode validation of the electrodes took place following a two-week post-surgery 
recovery period by inducing mild hyperoxia and hypoxia through administration of gaseous O2 
(BOC medical) and nitrogen (BOC gases) respectively. Gases were administered to the animal 
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via a polyurethane tube held ~2cm from rats’ snouts for 30s. Three O2 and three nitrogen 
challenges were administered (in alternating order). Validation was considered successful if a 
positive signal was observed after all O2 challenges, but none of the nitrogen challenges.  
 
4.2.4 Constant potential in vivo oxygen amperometry recording technique 
Constant potential amperometry (CPA) was used to measure local event-related in vivo changes 
in tissue O2, as previously described in detail (Lowry et al. 1996; Francois et al. 2012; 2014). 
Briefly, a constant negative potential (-650 mV) was applied to CPEs to allow for the 
electrochemical reduction of dissolved O2 to occur at the electrode tip. Changes in the measured 
current are directly proportional to changes in tissue O2 (Hitchman 1978). During each of the 
recording sessions, rats were tethered to a four channel potentiostat (Biostat, ACM 
Instruments) via a six-pin socket and a flexible six-core cable (both Plastics One). A PowerLab 
8/30 Data Acquisition System was used for analogue/digital conversion, and data were 
collected using Chart v.5 software (AD Instruments) at a sample rate of 200 Hz. Changes in 
current at each CPE were recorded and analysed separately. The negative potential was applied 
for at least 5 minutes prior to the start of any behavioural testing.  
 
Following each behavioural session, raw recordings from each electrode were visually 
inspected. Although no distinct criteria were applied, any trials displaying apparent artefacts 
(by visual inspection) were excluded from all analyses. No further attempt was made to 
improve the signal quality of these artefact trials. Event related changes in current were 
analysed according to previous reports (Francois et al. 2012; 2014).  Linear interpolation was 
used to replace occasional missing data points and a biquad Butterworth filter (high pass 0.1 
Hz) was used for artefact suppression. Time 0s was taken as the time of reward delivery on 
completion of each ratio from which changes in O2 current were measured. To compensate for 
different baseline between channels, data were normalised to the mean current in the 1s period 
preceding reward delivery. A boxcar-averaging algorithm was used to down sample the data, 
keeping a single average from multiple 0.5s non-overlapping windows. In the case of the NAc, 
the signals from the bilateral electrodes were averaged, to create a single NAc response for 
each animal. As there were no differences in reward O2 responses between medial and lateral 
OFC responses, and to increase the power of the analyses, data from these electrodes were 
averaged into a single curve for each animal. The area under the curve (AUC) and the peak 




4.2.5 Behavioural Apparatus 
Behavioural testing took place within standard rat operant chambers (Med-Associates, 
Vermont, USA). Chambers were housed within sound and light attenuating boxes. Each 
chamber consisted of a house light and two retractable levers either side of food magazine. 
Standard food pellets (45mg, BioServ) were delivered to the magazine via an automated 
dispenser. Experimental sessions were governed by programmes written with Med-PC 
software. 
 
4.2.6 Progressive Ratio Testing  
All behavioural testing took place following surgical recovery, 5 days per week. Rats were 
randomly assigned to either a right or left active lever; this would be the only lever presented 
throughout the experiment. Training began with one day of magazine training. Over a period 
of 30 minutes, food pellets were delivered independently of any behaviour with a variable 
interval of 60s (range 15-105s). Following magazine training, animals began fixed ratio (FR1) 
training. Each session began with a 30s of pre-session blackout, after which the house light 
was turned on and the lever presented.  A single lever press was required for a food pellet to 
be delivered, and the lever retracted. Following reward delivery, the lever remained retracted 
for a 15s intertrial interval (ITI). The session was terminated after either 45 minutes or 
following 50 completed trials.  All animals were required to complete all 50 rewarded lever-
presses within a session before moving onto the next stage of training. During the next stage 
of training, five lever presses were required for reward delivery (FR5). As before animals were 
required to complete 50 trials (250 lever-presses) before moving onto the final stage of training. 
All other parameters remained identical to FR1 training.  Finally, animals were placed on a 
progressive ratio (PR) schedule of reinforcement. Session parameters were identical to the FR1 
and FR5 stages, apart from the ITI, which was increased to 30s. The response requirement on 
each trial was determined by the following formula: (5 * e(0.2*n)-5); where n is the trial number, 
resulting in response requirements of: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40 etc.  As with the 
touchscreen PR task (chapter 2), this task was not self-paced as reward collection initiated the 
subsequent trial. All animals were initially trained for five days without any O2 recordings, to 
ensure a stable behavioural performance. Then rats underwent five days of habituation to the 
tethering and recording procedures to ensure no adverse effects of the tethering procedure. 
During these sessions, PR and CPA recordings were performed as normal, however the data 
were not analysed. Following this period, animals received ten sessions of PR (1 session per 
day), from which O2 responses were analysed. The primary behavioural measure of interest 
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was breakpoint, defined as the number of lever presses completed in the last successfully 
completed trial. Additional measures of behaviour included the rate of lever presses and the 
delay-to-reward (the mean latency from trial start to completion). 
 
4.2.7 Whole Session O2 amperometry analysis 
As slow drifts in baseline over the course of a session may confound event-related analyses, 
global changes in O2 levels following session start were assessed. Following the first lever 
presentation, the change in current was divided into 120s non-overlapping bins. As animals are 
typically only actively engaging in the task for a portion of the 45-minute PR session (i.e. the 
period prior to breakpoint being reached), the change in global O2 levels was examined for the 
rats’ mean active period. The mean active period across all session (latency to last completed 
ratio) for the rats included in the NAc analysis was 1041 ± 127.97s. The mean active period 
for the rats included in the OFC analysis was 1207 ± 170.33s. 
 
4.2.8 Progressive Ratio O2 amperometry Analysis 
During the PR task, changes in the recorded current was assessed for a period of 30s following 
reward delivery (at the successful completion of every ratio).  O2 responses were averaged, 
within regions, and across PR sessions, to create a single reward response per region per 
subject. The influence of effort requirements on O2 responses was assessed by dividing each 
PR session in half based on the number of trials completed. The first half of trials were deemed 
‘low effort’ and the latter half deemed ‘high effort’ trials, regardless of the total number of 
trials completed (e.g. Wanat et al. 2010; Covey et al. 2016). O2 reward responses following 
low and high effort trials were averaged across the ten sessions to give a single low and single 
high effort  O2 response per region per subject. Individual differences in motivated behaviour 
were obtained by dividing the animals into high and low performing rats based upon a median 
split of the mean breakpoint across the ten PR sessions. O2 reward responses were then 
compared between these two groups of low and high performing rats. To account for 
differences in the number of trials completed between these two groups, a separate group 
comparison was conducted on the minimum number of trials completed by all subjects across 
all sessions. Behavioural stratification also took place based upon median splits the mean delay 
to reward and the mean response rate across the ten PR sessions.  
 
4.2.9 Non-contingent reward delivery testing 
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It is possible that the vigorous, repetitive lever pressing that occurs during PR performance 
may confound the O2 signal analysis. Therefore, following completion of PR testing, animals 
were exposed to a single session, where food pellets were delivered independently of any 
behaviour. Small (1 pellet) or large (3 pellets) rewards were delivered pseudo-randomly 
without any cue, according to a 120s variable interval schedule (range 90-150s).  
 
4.2.10 Non-contingent reward O2 amperometry analysis 
For the NAc, O2 were again examined for 30s following reward from a 1s pre-reward baseline. 
O2 signals from OFC electrodes were analysed for 45s following reward, as O2 levels remained 
elevated 30s post reward. O2 signals in response to small and large rewards were analysed 
separately. Additionally, O2 changes following small and large rewards were examined in the 
previously identified high and low performing groups. Finally, O2 responses to single pellet 
rewards were compared in the first half and second half of trials. This was in order to examine, 
whether in the absence of any behaviour, there was any temporal-dependent change in the 
magnitude of OFC and NAc O2 responses. 
 
4.2.11 Histology 
In order to confirm CPE placement, rats were euthanized and brains were rapidly removed and 
placed in 10% buffered paraformaldehyde solution prior to histological analysis (Covance, 
US). Brain sections (200 µm) were viewed microscopically to view location of electrode tips; 
any animal with improper electrode locations was excluded from the analysis. 
 
4.2.12 Experimental design and Statistical analysis 
Statistical analyses was based upon previous amperometry studies (Francois et al., 2012; 2014). 
In cases where O2 data were excluded (due to excessive noise), the behavioural data were also 
excluded. Therefore, the stability in breakpoints across the ten PR sessions was assessed using 
a mixed model design, which allows for missing cases with a Sidak correction for multiple 
comparisons was applied during post hoc testing. All O2 analyses were completed separately 
for the NAc and OFC regions. The temporal stability of the O2 signal was assessed by averaging 
each subjects’ global O2 signal across sessions, to give a single global signal per subject. 
Repeated measures ANOVA was used to test for any significant within-session change in O2 
signals. When appropriate, a Greenhouse-Geisser correction was applied to correct for 
violations in sphericity. Examining the influences of work-requirement upon O2 responses to 
reward was achieved by dividing each subjects’ trials into early (low effort) and late (high 
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effort) trials based upon the number of trials each subject completed in a session. Each subject’s 
O2 reward responses were averaged across trial type and session to give a single O2 reward 
responses per subject for both early and late trial types. The time course of these O2 reward 
responses were analysed using a repeated measures ANOVA, with a Fishers correction applied 
to post hoc comparisons. The parameters of each subjects’ O2 response (AUC and peak value) 
for early and late trials were then compared via within-subject paired t-tests.  
The effects of individual differences in PR performance and O2 responses were tested by 
arbitrarily splitting animals into high and low performers based upon a median split of the mean 
breakpoints from across the ten PR sessions. The time courses were again analysed using a 
mixed model ANOVA, with a Fisher’s post hoc test. The parameters of each subjects mean O2 
reward response from all trials was then compared by high and low responding groups via 
independent t-tests. The same between-subject approach was taken when assessing subjects’ 
O2 responses based upon their mean response rate and mean delay-to reward for each session, 
where parameters of the O2 reward response were compared between groups created by median 
splits of the mean delay-to-reward and response rate.  Behavioural measures were compared 
between high and low responders and between early and late trials and analysed via repeated 
measures ANOVAs. In the case of the non-contingent reward delivery testing, O2 reward 
responses to one and three-pellet rewards were compared within and between high and low 
performing groups. Repeated measures ANOVAs were used to test for significance, with a 
Sidak correction applied to any post hoc test. For all statistical tests a significance criterion of 
p < .05 was adopted. All statistics were conducted using SPSS version 23.0 (IBM Corp) and 





Figure 4.1 shows the locations of the 15 NAC (figure 4.1A) and 10 OFC (figure 4.1B) carbon 
paste electrodes (CPEs).  
 
Figure 4.1: Reconstructions of CPE placements within: A the NAc and B the OFC.  The 
location of CPE tips are marked by the black circles.  Coronal slices are adapted from (Paxinos 
& Watson 2009) 
 
4.3.2 Behavioural analysis 
For analysis purposes, O2 responses following reward delivery were collapsed across 10 PR 
sessions. Therefore, the stability in behavioural performance across these ten sessions was 
examined. As seen in figure 4.2A, there was a significant effect of session upon breakpoint 
(F(1,9) = 2.248, p < .05); however, post-hoc testing revealed no significant differences in 
breakpoint between sessions (all comparisons  p >.05). Additionally, there was only a small 
degree of variance within-subjects; the mean range of trials completed (maximum trials 
completed within a session -  minimum number completed) was 3.93 (SEM ± 0.45). Together, 
these analyses suggest that collapsing behaviour (and therefore O2 responses) across the 10 PR 
sessions is a suitable approach.  
 
To assess the relationships between effort and O2 reward responses, O2 signals were compared 
between early and late trials as well as low and high responding rats (figure 4.2B). Therefore, 
behavioural differences between these groups were examined. The mean number of completed 
lever presses between early and late trials were examined (figure 4.2C). There were significant 
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effects of trial type (F(1,13) = 44.946, p < .001; partial eta squared = .776) and group (F(1,13) 
= 11.873,  p < .01; partial eta squared = .477). There was also a significant trial type x group 
interaction (F(1,13) = 10.623,  p < .01; partial eta squared = .450). High responding animals 
made a significantly greater number of lever presses between early and late trials (p < .01), as 
did low responding rats (p< .05). High responding rats also made significantly more lever 
presses than low performing rats in both early (p <01) and late trials (p <01). Figure 4.2D shows 
the mean delay to reward in early and late trials for low and high responding groups. Delay to 
reward increased between early and late trials (F(1,13) = 56.788, p <.001; partial eta squared 
=.814), however there was no effect of response group (F(1,13) = .065, p = .803), nor any 
group x trial interaction (F(1,13 = . 078, p = .780). The mean rate of responding of high and 
low responding groups in early and late trials was also examined (figure 4.2E). The response 
rate decreased significantly between early and late trials (F(1,13) = 217.578, p <.001; partial 
eta squared =.944), however there was no effect of response group (F(1,13) = 1.610, p = .227), 
nor any group x trial interaction (F(1,13 = 2.898, p = 0.113)).  
 
Figure 4.2: Overview of behavioural performance (A-B) and stratification of behavioural 
measures by trial type and response groups (C-E). A The group level mean breakpoint across 
the ten PR sessions. B Division of high and low responders based upon a split of subjects’ 
mean breakpoint. C The mean number of lever presses made were greater in late trials, and in 
high responding rats. D The mean delay to reward was significantly greater in late trials, but 
did not differ between groups. E The mean rate of lever pressing was reduced in late trials, but 




4.3.3 Within session O2 signal stability  
NAc O2 recordings from a total of 143 PR sessions (15 rats, 5-10 sessions per subject) were 
analysed. There was no significant change in the NAc O2 current during the mean period of 
activity (F(1.2,16.9) = 2.033, p = 0.171). For the OFC, O2 recordings from a total of 83 sessions 
(10 rats, 5-10 session per subject) were analysed. There was no significant change in current 
over the mean active period (F(1.4,12.7) = 1.465, p = .260). This highlights the stability of the 
basal signal over time and suggesting that any event-related observations were unlikely to be 
confounded by slow drifts in baseline signal. 
 
4.3.4 Early versus late trial stratification 
NAc O2 responses appeared greater in the late, higher effort trials (figure 4.3A). O2 responses 
were significantly affected by both time post reward (F(1,14) = 5.463, p < .001; partial eta 
squared = .281) and trial type (F(1,59) = 34.917,  p < .001; partial eta squared = .714). There 
was also a significant interaction between time and trial type (F(59,826) = 39.408,  p < .001; 
partial eta squared = .738).  In early trials, there was an initial increase in O2 levels, the 
measured current was significantly greater than baseline for the first 4s post reward (all 
comparisons p < .05, figure 4.3A). There was subsequently a significant decrease in O2 levels, 
which were significantly lower than baseline from 18s to the end of the 30s trial (all 
comparisons p < .05, figure 4.3A). In late trials, there was a significant positive response that 
was sustained for the duration of the 30s; all-time points were significantly greater than 
baseline (all comparisons p < .05). The magnitude of the O2 signals was significantly greater 
in late trials compared to early trials from 6s post reward for the remainder of the 30s duration 
(all p < .05). For each subject, the peak value and the AUC of the mean NAc O2 response was 
extracted. The peak O2 value during late trials had a significantly greater peak response value 
(t(14) = 4.870, p < .01; figure 4.3B) and AUC (t(14) = 5.863, p < .001; figure 4.3C), relative 
to early trials. This suggests that completion of higher effort trials was associated with greater 
O2 responses to reward.  
 
 As with the NAc, O2 responses to rewards within the OFC appeared greater in later trials 
(figure 4.3D). O2 levels were significantly affected by time post reward (F(59,331) = 22.750,  
p  < .001; partial eta squared = .717). However, there was no effect of trial type (i.e. early vs 
late; F(1,9) = 2.923,  p = .12). There was also no significant interaction between trial type and 
time post reward upon the change in OFC O2 levels (F(59,531) = 1.152,  p  = .213). The peak 
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OFC O2 response was significantly elevated in late trials (t(9) = 3.636, p <.01; figure 4.3E); 
although the difference in the AUC was not significant (t(9)  = 1.760, p = .112, figure 4.3F).  
 
Figure 4.3: Tissue O2 responses within the NAc (A-C) and OFC (D-F) during PR performance. 
A. Mean O2 reward responses within the NAc following the first half (“early”) and second half 
(“late”) of PR trials across all subjects. The solid grey line represents a significant increase in 
O2 levels in early trials, compared to 0s. The dashed grey line shows all time points that are 
significantly lower than 0s, in early trials. The solid black line shows all time points within late 
trials with significantly higher O2 levels compared to the 0s timepoint. B The peak NAc O2 
reward response was significantly greater in late relative to early trials. C The area under the 
curve (AUC) of the NAc response was significantly elevated in late trials  relative to the early 
PR trials. D The mean OFC O2 reward response following the early and late PR trials across 
all subjects.  E The peak value of the OFC response was significantly greater in late relative to 
early trials F The AUC of the OFC reward response did not differ between early and late trials. 
* p <.05; ** p < .01; *** p <.001. Error bars represent the SEM. 
 
4.3.5 Low versus high responder stratification 
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To examine the relationships between the magnitude of O2 responses and behavioural 
performance, correlations were conducted between the mean breakpoint and NAc O2 signal 
parameters for each rat. Significant positive correlations were observed between mean 
breakpoint and the peak O2 value (r = .606, p < .05; figure 4.4A) and between breakpoint and 
the AUC (r = .672, p <.01; figure 4.4B) of the NAc O2 response, suggesting an association 
between individual differences in behaviour and NAc O2 responses. This relationship was 
further examined by grouping subjects according to average breakpoint (n=7 low responders, 
n=8 high responders; figure 4.2A). There was no significant difference in the mean bodyweight 
of these groups (t(14) = 1.669, p = .119; high responders = 583 ± 29.89g; low responders = 
640 ± 12.82g). The high responding group displayed significantly greater O2 responses relative 
to the low performing group (figure 4.4C). The recorded current was significantly affected as 
a function of time (F(59,767) = 6.112, p < .001; partial eta squared = .320) as well as response 
group (F(1,13) = 18.396, p < .001; partial eta squared = .586). There was also a significant 
interaction between time and response group (F(59,767) = 2.908, p < .001; partial eta squared 
= .183). In low responding rats, there was a significant decrease in O2 levels compared to 
baseline from 24s post reward to the end of the 30s (p < .05). In high responding rats, there 
was an initial positive O2 response, before returning to baseline. The mean time course for high 
responders displayed a significant positive change in the measured current from 0.5s post 
reward until 18.5s post reward (all p < .05, figure 4.4C). Between subjects, high responding 
rats displayed a significantly greater O2 signals, compared to low responders from 3.5s post 
reward for the remainder of the 30s analysed (all p < .05). Other O2 signal parameters were 
also significantly different between groups.  Both the peak O2 response (t(13) = 4.288, p <. 05; 
figure 4.4D and the AUC (t(14) = 4.298, p < .01; figure 4.4E) were significantly greater in high 
performing rats.  
 
However, this association may be confounded by differences in the number of trials completed 
between groups. Therefore, an additional between-subjects’ analysis of the high and low 
response groups was limited to the first five trials of each session, the minimum number of 
trials completed by all animals across all sessions. The high response group still displayed a 
greater O2 response, during these trials, compared to the low response group (figure 4.4F). The 
measured current in the first five trials was significantly affected by both time post reward 
(F(59, 767) = 5.562, p < .001; partial eta squared = .300) and response group (F(1,13) = 6.210, 
p <.05; partial eta squared = .323). There was also a significant interaction between time post 
reward and response group upon the measured current (F(59, 767) = 1.543, p <.01; partial eta 
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squared = .106). In low responding rats, no significant positive or negative change from 
baseline was observed. In high responding rats, there was an early significant increase in O2 
responses. The measured current was significantly greater than baseline for the first 15s 
analysed (all p < .05, figure 4.4F). No other time points differed significantly from baseline. 
High responding rats displayed significantly greater O2 responses, compared to low responders 
from 5.5s to 16s post reward (all p <.05). Again, both peak O2 response (t(13) = 3.911, p < .01; 





Figure 4.4: Associations between behavioural performance and NAc O2 responses during PR 
performance. A The significant positive correlation between each rats’ breakpoint and peak 
value of their respective O2 response. B The significant positive correlation between breakpoint 
and the AUC of the NAc O2 response. C The mean NAc O2 reward responses in low and high 
performing rats. The dashed grey line shows all time points that had significantly lower O2 
levels relative to 0s, in low responding rats. The solid black line shows all time points with 
significantly higher O2 levels compared to the 0s time point, within the high responding group. 
D The peak NAc O2 response was significantly greater in high performing rats. E The AUC of 
the O2 response was significantly greater in high performers F The mean O2 response for high 
and low performing rats from the first five trials of each session. The solid black line shows all 
time points with significantly higher O2 levels compared to the 0s time point, within the high 
responding group only. G High performing rats had a significantly higher peak NAc O2 
response in the first five trials. H The AUC of the O2 response to reward in high performing 
rats was also significantly greater in the first five trials. * p <.05; error bars represent the SEM. 
 
The time courses for the mean OFC responses following reward were also analysed. The 
measured current was significantly affected by time post-reward (F(59,472) = 21.024,  p <.001; 
partial eta squared = .724), but not by response group (F(1,8) = .143, p = .715). There was, 
however, a significant interaction between response group and time (F(29,472) = 1.469,  p  
<.05; partial eta squared = .281). There was no significant difference between groups at any 
time point (all comparisons p > .05). For the OFC analysis, subjects were again split into groups 
based on breakpoint.   As shown in table 4.1, there were no significant differences in the OFC 
O2 responses between high and low performing groups [AUC: (t(8) = .813, p = .440); peak 








Breakpoint, r (p-value) 
Peak Response 2.60 ± .40 2.92 ± .53 .431 (.214) 
AUC 44.72 ± 10.05 53.00 ± 8.97 .435 (.209) 
 
Table 4.1: The association between behavioural performance and parameters of the OFC O2 
reward response. There were no significant differences between low and high responding 
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groups (Values are means ± SEM) nor any significant correlation between breakpoint and 
either O2 reward response parameter. 
 
4.3.6 Delay and response stratification 
Alongside increasing response requirements, the delay to reward concomitantly increases 
throughout a PR session (e.g. figure 4.2B), which may explain the differences in O2 responses. 
To examine the relationship between delay and O2 responses, rats were divided into groups, 
based on a median split of the mean delay to reward, creating  longer (n = 8) and shorter delay 
(n = 7) groups. NAc O2 responses did not significantly differ between these two groups (Peak 
response: t(8.85) = .205, p = .842; AUC: t(9.77) = .305, p = .756). Although this cannot exclude 
the influence of reward delay upon the magnitude of O2 reward responses, it suggests the 
association between individual differences and O2 reward responses was not fully mediated by 
differences in delay-to rewards. NAc O2 signals were also analysed based upon the average 
rate of responding. There were no significant differences in NAc O2 responses between rats 
with low (n = 7) and high (n = 8) response rates [peak O2 response: t(7.91) = .610 p = .559; 
AUC: t(13)  = 1.578, p = .139)].  
 
The association between OFC O2 responses and delay-to-reward and rates of responding were 
also examined. As with the NAc, there were also no significant group differences when rats 
were grouped by delay-to-reward [AUC:(t(8) = 1.532, p = .164); peak response:(t(8) = 1.629, 
p = .142)]; nor response rate [AUC:(t(8) = 1.282, p = .236); peak response:(t(8) = 1.657, p = 
.136)] . Table 4.2 summarises the lack of an association between the parameters of the O2 
response and the delay and response rate groups. Differences in the AUC and peak values of 
the O2 responses between NAc and cortical regions are in line with previous reports (Francois 
et al., 2014). 
 






1.22 ± .15 1.31 ± .41 1.12 ± .44 1.40 ± 18 
AUC 13.40 ± 5.74 9.01 ± 12.47 -.01 ± 12.35 20.81 ± 6.16 
 





3.23 ± .41 2.21 ± .45 2.20 ± .44 3.24 ± .04 
AUC 58.15 ± 9.31 37.42 ± 8.2 38.66 ± 8.80 56.91 ± 9.41 
 
Table 4.2: The association between groups based upon median splits of delays-to-reward and 
rate of responding for both the parameters of the Nucleus accumbens (NAc) and orbitofrontal 
cortex (OFC) O2 reward responses. There were no significant differences in the parameters of 
the O2 reward response between these groups. Values are means ± SEM. 
 
4.3.7 Non-contingent reward delivery 
To control for nonspecific effects of arousal or that may have existed between response groups, 
O2 responses to rewards delivered independently of behaviour were examined. Delivery of 
small (1 pellet) and large (3 pellets) rewards elicited strong positive NAc O2 responses (figure 
4.5A). O2 responses to small and large rewards were examined based on the previously 
identified low and high PR response groups. There were significant main effects of both reward 
magnitude (F(1,13) = 7.112, p < .05; partial eta squared = .354) and group (F(1,13) = 5.344, p 
<.05; partial eta squared = .291) for the peak O2 response, but no significant interaction between 
the two (F(1,13) = 2.116, p = .138, Figure 4.5B). There were, however, no significant effects 
of reward magnitude (F(1,13) = 3.463, p = .086); group (F(1,13) = 161, p = .165) nor any 
interaction (F(1,13) = 2.258, p = .157), for the AUC. Trials were then divided into first half 
and later half of the trials. NAc O2 responses to single pellet rewards did not appear to change 
between early and late trials (figure 4.5C). Neither the peak NAc response (t(14) = .570, p = 
.578) nor the AUC (t(14) = 1.605, p = .131) significantly differed between early and late trials. 
Suggested that the previous differences between early and late trials were not as a consequence 
of the passage of time or the accumulation of rewards. 
 
OFC O2 responses to small and large reward delivery were also analysed as described above. 
Delivery of small and large rewards resulted in a O2 response, lasting longer than previously 
analysed 30s period post reward delivery.  O2 responses following delivery of non-contingent 
food rewards was therefore analysed over a longer period of time (45s) (figure 4.5D). The peak 
OFC response was not significantly affected by reward magnitude (F(1,8) = 2.492,  p  = .153), 
nor by response group  (F(1,8)= .168, p =  .692). There was  also no significant magnitude x 
group interaction effect on the peak OFC response (F(1,8) = 1.915 ,  p = .204). There was, 
however, a significant main effect of reward magnitude (F(1,8) = 15.910, p < .01; partial eta 
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squared = .665), on the AUC of the OFC O2 response (Figure 4.5E).  However, the AUC was 
not affected by response group (F(1,8) = .18,  p = .682), nor any significant magnitude x group 
interaction (F(1,8) = .006, p = 942).  OFC O2 responses to small rewards in early and late trials 
were also examined (figure 4.5F). As with the NAc, there were no significant differences 
between trial types in the magnitude of the OFC O2 responses [peak response: (t(9) = 1.281, p 
= .232); AUC:(t(9) = .412, p = .690)]. Since there were no differences in the delay to reward 
between early and late trials in this condition, this highlights that the previous observed effects 




Figure 4.5: Tissue O2 changes following uncued rewards within the NAc and OFC. A The 
mean O2 responses to 1 (“small”) and 3 pellet (“large”) rewards within the NAC.  B The peak  
NAc O2 response of the responses to single and three pellet rewards for both low and high 
responding animals. C NAc O2 responses to early and late single pellet reward trials. D The 
mean OFC O2 responses to 1 and 3 pellet rewards. E The AUC of the OFC O2 response to small 
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and large rewards for both low and high responding rats. F OFC O2 responses to early and late 
single pellet reward trials.  Error bars represent the SEM 
 
4.4 Discussion 
Using a highly translatable proxy measure of neural activity, as well as a translational 
behavioural assay of motivation, it was found that O2 responses to reward within the NAc were 
predictive of individual differences in motivated behaviour. To our knowledge, no previous 
study has investigated the association between a functional imaging measure such as this and 
individual differences in effort-based behaviour.  Furthermore, the assessment of changes in 
tissue O2 allows for direct comparison of results with human BOLD-fMRI. Functional 
neuroimaging can be used to help establish equivalence of cognitive processes across species. 
Whereas there are several rodent imaging techniques that can directly measure 
electrophysiological and neurochemical correlates of behaviour, it is not typically possible to 
perform such techniques in humans. Given the widespread use of fMRI in humans, techniques 
such as O2 amperometry, may better help bridge the translational divide, and facilitate basic 
research into clinical benefit.  
 
In the present study, O2 responses to rewards within both the NAc and OFC increased in 
magnitude as the effort exerted to obtain the rewards grew. These increases in O2 responses 
were not observed in the absence of any work requirements, suggesting that neither 
accumulation of rewards nor the progression of time was sufficient for an increase in O2 
responses. Moreover, the magnitude of the O2 responses within the NAc was associated with 
behavioural performance. Rats exerting greater amounts of effort displayed greater NAc O2 
responses to rewards. This association remained when controlling for the total number of trials 
completed, highlighting how subjects that show greater NAc activity in early, low effort trials, 
subsequently continue to overcome greater effort costs, and achieve higher breakpoints. 
Furthermore, these high performing rats also showed greater NAc O2 responses to rewards 
delivered independently of any behaviour. This observation suggests that the previous results 
were not a confound resulting from differences in activity levels between groups. In contrast, 
O2 responses within the OFC did not predict PR performance. Consequently, the pattern of 
activity observed within the NAc displayed at least some degree of regional specificity.  Taken 
together, this suggests that PR performance is directly related to the neural responses to reward 




4.4.1 Physiological basis of the measured O2 signals 
The physiological origin of the O2 signal measured within the NAc has been previously 
discussed in detail (Lowry et al. 2010; Francois et al. 2012; 2014). The measured signal reflects 
changes in extracellular tissue concentrations of O2 (Lowry et al. 1997). Increases in 
hemodynamic measures such as tissue O2 concentrations or the BOLD contrast, occur in 
response to neuronal activation and/or changes in cerebral blood flow. This allows for the use 
of techniques such as CPA and BOLD-fMRI as proxy measures of neural activity. Tissue O2 
concentrations are highly correlated with induced changes in regional cerebral blood flow 
(Lowry et al. 1997), as is the BOLD signal measured with fMRI (Logothetis & Wandell 2004). 
Changes in cerebral blood flow appear primarily related to local synaptic activity (Mathiesen 
et al. 2000). Similarly, BOLD-fMRI is believed to reflect afferent inputs to an area rather than 
spiking outputs (Logothetis et al. 2001). Together, this raises the possibility that the present 
changes in O2 levels, within the NAc, are driven by afferent inputs to this region. A major input 
to the NAc, are dopaminergic neurons projecting from the ventral tegmental area. This input 
pathway has been widely linked with, among other processes, effort exertion. Lesions to this 
pathway severely disrupt PR performance (Aberman et al. 1998; Sokolowski & Salamone 
1998; Hamill et al. 1999). Furthermore, manipulation of this pathway either via optogenetic or 
pharmacogenetic tools can bidirectionally affect breakpoints (Fischbach-Weiss et al. 2018; 
Boekhoudt et al. 2018). As with the current O2 results, the magnitude of phasic DA reward 
responses, measured with fast scan cyclic voltammetry (FSCV) are greater in later, higher 
effort PR trials (Wanat et al. 2010; Covey et al. 2016) whereas, DA responses to rewards 
following low-effort trials are negligible (Wanat et al. 2010).  Together, this raises the 
possibility that the current O2 results may reflect changes in DAergic neuron activity within the 
NAc, However, more appropriate methods (e.g. FSCV) should be used to confirm this.  
 
In the present study, negative O2 responses were observed on several occasions, as have been 
observed in previous studies (McHugh et al., 2014; Francois et al., 2014). O2 changes in 
response to rewards were calculated as a relative change, compared to a 1s pre-reward baseline 
period. During the pre-reward period, it is likely that the animals would have been actively 
engaged in lever pressing. A degree of NAc activity, and therefore extracellular O2, would be 
expected during this baseline period. The negative changes observed in the present study, may 
therefore represent a return to normal levels. In support of this, in the absence of any pre-reward 




4.4.2 O2  reward responses and individual differences in behaviour 
It is noteworthy that high responders still show significant positive NAc O2 changes in response 
to rewards in spite of the likely pre-reward neural activity. A greater neural response to reward 
may motivate future behaviour, enabling subjects to remain on task for longer and overcome 
greater effort requirements. Appetitive rewards, such as food, produce activational effects, that 
can increase the vigour and frequency of behaviour (Skjoldager et al. 1993) Likewise, 
enhanced NAc DA release has an activational effect on behaviour (Robbins & Everitt 1992; 
2007).  The increased NAc O2 responses in high performing rats may, therefore, reflect a 
greater level of behavioural activation in response to food rewards.  
 
In operant testing, effort is typically modulated by increasing the number of lever responses 
needed for reward. As a consequence, the delay from trial onset to reward delivery also 
increases. Reward-based DA responses have been shown to increase in response to escalating 
delays (Wanat et al., 2010). DA responses within the NAc have also been shown to signal 
reward prediction errors (RPE, Schultz et al., 1997). The increasing response requirements 
during PR may result in rewards becoming more unpredictable as a session progresses. The 
present findings could also be a reflection of greater RPEs in high effort trials. It is not clear, 
however, how either of these could account for the differences in NAc O2 signals between low 
and high performing animals, since there was no difference in the mean delay to reward 
between these two groups.  Although we sought to further examine the effects of longer delays 
as well as changes in RPEs, these should be fully investigated in future and separate studies. A 
control group with rewards yoked to delivery of rewards on a PR task (e.g. Wanat et al., 2010) 
would allow us to investigate the role of increasing delays on O2 reward responses in the 
absence of any effort component. The contribution of NAc during expectancy of upcoming 
rewards has already been investigated using O2 amperometry. (Francois et al., 2012, 2014). 
Interestingly, alterations in  reward anticipation have previously been linked to motivational 
deficits in some clinical populations (Wolf et al., 2014; Barch et al., 2016), and therefore 
assessing changes in O2 signals pre-reward delivery could also be of interest as a potential 
correlate of motivated behaviour. 
 
Alongside regulating effort exertion, a number of studies have also investigated the role of 
NAc DA in Pavlovian-instrumental transfer (PIT). During PIT, cues associated with rewards 
are able to exert strong influences on behaviour, enhancing instrumental responding in their 
presence. Dopaminergic receptor blockade within the NAc disrupts PIT (Dickinson et al., 
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2000), whereas intra-accumbens infusions of d-amphetamine enhances the Pavlovian 
influences on instrumental responding (Wyvell & Berridge, 2000).  FSCV has been used to 
extend these findings, showing that a reward-paired cue that generates PIT is accompanied by 
a phasic DA response (Wassum et al., 2013). Moreover, the magnitude of the PIT effect was 
correlated with the magnitude of the phasic DA response (Wassum et al., 2013). When 
examining the effects of noncontingent reward delivery in NAc O2 responses, it appears that 
only the high responding rats show an increased magnitude O2 response following the three-
pellet reward delivery (figure 4.5B). It is worth noting that high responders appeared to only 
show a greater magnitude reward response following three pellet rewards. Since, this probe 
was conducted after PR training, animals had only been exposed to single pellet rewards. The 
enhanced increase to these unexpectedly large rewards, may be a larger positive prediction 
error, which may reflect individual differences within the plasticity of the mesolimbic DA 
system. Furthermore, during this probe, rewards were delivered independently of any 
instrumental contingency, suggesting the O2 responses may reflect Pavlovian influences upon 
reward. The present association between NAc O2 responses and individual differences in PR 
performance may, therefore, be a reflection of individual differences in Pavlovian influences 
on behaviour or incentive motivation. In other words, the greater incentive motivation enabled 
the high performing rats to overcome greater effort costs to obtain more rewards under the PR 
schedule of reinforcement. 
 
4.4.3 The role of the OFC in effort-related behaviour 
The use of a control region is important to demonstrate that any results are not caused by some 
global change in tissue O2 levels that may confound the results. This may be especially 
important when using a behavioural assay such as PR, which involves a large amount of 
vigorous, repetitive responding. In the present study, we used the OFC primarily as a control 
region. There was no association between behavioural performance and OFC O2 reward 
responses, suggesting that the effects observed within the NAc display some degree of regional 
specificity. Previous reports have demonstrated that the medial and lateral regions of the OFC 
are functionally distinct (Noonan et al. 2012, for a review). Within the lateral OFC, excitotoxic 
lesions do not affect breakpoints in either rats (Kheramin et al. 2005) or mice (Gourley et al. 
2010). In contrast, excitotoxic lesions to the medial OFC result in an increase in breakpoints in 
rats (Münster & Hauber 2017) and mice (Gourley et al. 2008), resembling the effects of 
excitotoxic lesions to the NAc (Bowman & Brown 1998). The medial OFC has strong 
projections to the NAc core (Hoover & Vertes 2011). In contrast, the lateral OFC projects 
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mainly to dorsolateral regions of the striatum (Schilman et al. 2008), an area that is not involved 
in supporting PR performance (Eagle et al. 1999). Together, these studies suggest the medial, 
but not the lateral, OFC regulates effortful instrumental responding. Presently, the majority of 
the CPEs were located within the lateral OFC (figure 5.1B), which may explain the lack of 
association between OFC O2 recordings and behavioural performance.  
 
OFC O2 responses did, however, increase between early and late PR trials. It is unlikely that 
this effect represents RPE signals as OFC activity is not well correlated with RPEs  (Hare et 
al. 2008).  The lateral OFC has been widely implicated in modulating delay-based responding 
(Winstanley et al. 2006; Zeeb et al. 2010). Lesions to the lateral OFC reduce an animal’s ability 
to tolerate delays for larger rewards (Mar et al. 2011) and levels of the DA metabolite DOPAC, 
increase within the lateral OFC, during a delay-discounting task (Winstanley et al. 2006). The 
increased O2 reward responses in late trials may, therefore, have been a reflection of the greater 
delay-to-reward experienced in those trials. OFC O2 signals were also modulated by reward 
outcome. Lateral regions of the OFC encode information regarding reward magnitude during 
reward receipt (van Duuren et al. 2007; 2008) suggesting, CPA can accurately capture OFC 
activity during processing of reward.  The lack of a difference in the magnitude of OFC O2 
signals between the non-delayed early and late trials in the non-contingent reward delivery 
probe alongside the lack of an association with PR performance, further suggests that the 
differences in OFC O2 signals between early and late trials is a reflection of the role of the OFC 
in delay-based behaviour.  
 
4.4.4 Use in  drug discovery 
Drug discovery can be aided through the use of functional imaging to provide additional 
measures of compound efficacy beyond behavioural effects (Wise & Tracey 2006; Li et al. 
2016). In the present study, through the use of a translatable imaging technique, it is possible 
to detect a neural correlate of PR performance.  PR schedules as assays of motivation are useful 
for testing novel compounds due to ease of application and relatively high throughput. 
However, the unspecific nature of measures such as breakpoint may inflate the likelihood of 
false positives. If a compound that increased breakpoint also enhanced the NAc reward 
response, it would provide a stronger argument for a change in motivation than a behavioural 
change alone. Such approaches have been used in the cases of analgesic drug discovery (Duff 
et al. 2015; Wanigasekera et al. 2018). The examination of a drug effect upon neural activity 
could be used early in clinical trials (i.e. Phase II), to reduce the expensive Phase III failures. 
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However, it would be first necessary to test whether humans display the same association 
between NAc activity and effort-exertion, measured with fMRI. If this could be established, it 
would also strengthen the argument that the cognitive process of interest (i.e. effort 
expenditure) translates across species (Keeler & Robbins 2011) 
 
4.4.5 Conclusions 
Amperometric measurement of tissue O2 changes, a highly translatable and valid proxy 
measure of BOLD-fMRI in behaving rodents, provided a novel insight into the role of the NAc 
function and individual differences in effort-related behaviour. The O2 response to reward 
within the NAc is related to effort exerted under a PR schedule of reinforcement. This 
highlights the dynamic role neural signals within the NAc play in maintaining motivated 
behaviour. Furthermore, this study demonstrates in vivo O2 amperometry can be used to probe 
the neural correlates of behaviour in rodents. Furthermore, through the use of such techniques, 
hypotheses can be derived that can subsequently be tested in humans, therefore facilitating 
cross-species research. 
 
Within the RDoC framework (Cuthbert and Insel 2013) aberrant approach motivation has been 
identified as a transdiagnostic symptom of psychiatric disorders. One subconstruct of 
motivation within this framework is effort valuation/willingness to work, The use of PR 
schedules can be used, across species, to probe these subconstructs of motivated behaviour 
(Young & Markou 2015). The approach taken by the RDoC initiative emphasises the need to 
bypass diagnostic categories and first understand the neural substrates of behavioural 
constructs in both healthy and nonhealthy subjects. Therefore, the present study is in line with 
this approach. Through identifying a translatable imaging correlate of PR performance, future 
studies could use fMRI to determine whether there is an equivalent association between the 
BOLD response and PR performance in humans and whether this association is disrupted in 




Part 2: Muscarinic antagonists as a novel target for symptoms of 
amotivation 
 
Chapter 5. Effects of muscarinic receptor antagonism on effort-related behaviour  
 
5.1 Introduction 
Based upon a previous review of the literature, a number of compounds that enhance motivated 
behaviour in rodents also appear to have efficacy in reducing apathy in clinical samples 
(chapter 1).  A number of these compounds, either directly or indirectly modulate dopaminergic 
activity. There is also a wealth of studies demonstrating that muscarinic acetylcholine receptor 
(mAChR) antagonists can facilitate dopaminergic activity. Based upon this, compounds that 
act as mAChR antagonists may facilitate motivated behaviour in rodents and could be a novel 
target for the treatment of apathy.  
 
In rodents, motivated behaviour can be readily assessed by probing expenditure of effort for 
food rewards (Salamone & Correa 2012). However, few previous studies have investigated a 
role of mAChRs in effort-related behaviour. Systemic administration of the nonselective 
mAChR antagonist scopolamine has been reported to facilitate progressive ratio (PR) 
performance in an ‘inverted-u’ pattern (Stewart et al. 1974). However, this claim was based on 
visual inspection of behavioural data from six rats only, two of which did not show any increase 
in PR breakpoints. Moreover, a lack of control tests raises the possibility that this enhancement 
in breakpoint was driven by a confounding behavioural change. A separate study examined the 
role of mAChRs within the nucleus accumbens (NAc) on effort-related choice (ERC) 
behaviour (Nunes et al., 2013). Intra-NAc infusion of a nonselective mAChR agonist shifted 
behaviour from lever-pressing for a palatable reward to consumption of a less preferred, but 
freely available reward (Nunes et al., 2013).  Co-administration of scopolamine subsequently 
reversed this motivational deficit. Together, these studies suggest that mAChR antagonists may 
facilitate effort-based behaviour. It should be noted that in spite of the evidence linking 
muscarinic antagonism to facilitation of motivated behaviour, these effects are contrary to what 
would be expected in Alzheimer’s disease (AD). Apathy is one of the most prevalent 
psychological symptoms of AD (Landes et al. 2001).  However, AD is also associated with a 
reduction in cholinergic tone (Coyle et al. 1983), with the most effective symptomatic 
treatments upregulating the cholinergic system (Seltzer et al. 2004). Additionally, muscarinic 
receptor agonists have been widely investigated as therapeutic options for AD (Langmead et 
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al. 2008). Together, this suggests that a separate approach to treating apathy may be needed in 
AD. 
 
Another consideration is the potential role of mAChR subtypes. In line with the effects of M1 
and M4 receptors upon dopaminergic function and behaviour reviewed earlier (chapter 1),  it 
would be expected that antagonism of these receptors would facilitate motivated behaviour. 
Only one study has investigated the effect of preferential M1 receptor antagonism on PR 
performance (Klinkenberg & Blokland 2011). Systemic administration of the preferential M1 
receptor antagonist biperiden did not affect breakpoint. However, PR sessions were limited to 
1050 lever presses (Klinkenberg 2012). This could have created ceiling effects and may explain 
why biperiden did not increase breakpoints.  No study has investigated a role of M4 receptor 
ligands in effort-based behaviour.  
 
The present chapter aimed to test the effects of mAChRs antagonists on motivated behaviour. 
Initially, the effects of systemic administration of several muscarinic receptor  antagonists were 
tested on touchscreen PR performance in mice (Heath et al. 2015; Heath et al. 2016). Firstly, 
the effects of the non-specific mAChR antagonist scopolamine were examined. Then to 
investigate the role of the M1 receptor subtype the centrally acting antagonist biperiden was 
tested. However, biperiden also produces some peripheral effects when administered 
systemically (Guthrie et al. 2000). Therefore, telenzepine, a M1 antagonist that does not 
effectively cross the blood-brain barrier (Ichikawa et al. 2002; Pediani et al. 2016), was used 
to examine potential peripherally-mediated  M1 receptor effects on PR performance. Finally, 
the contribution of the M4 receptor was tested through examining the effects of the preferential 
antagonist tropicamide. 
 
Subsequently, the effects of the preferential M1 receptor antagonist biperiden and the 
nonselective mAChR antagonist scopolamine were tested on a number of control tasks the 
examine the behavioural mechanisms underlying the changes in PR performance. To control 
for potential effects on satiety and motor output the drugs were tested prior to FR5 
performance. Potential changes in appetite were examined by testing the effects of the 
compounds upon free milkshake consumption. To test whether the effects were sensitive to 
changes in outcome value, the compounds were tested following reinforcer devaluation 
through prefeeding prior to PR testing. Additionally, to control for any increases in 
perseverative-like responding, biperiden was tested under extinction conditions. Subsequently, 
both biperiden and scopolamine were tested upon a touchscreen ERC task to assess for any 
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changes in effort-related decision making (Heath et al. 2015). Finally, to examine the effects 
of biperiden upon dopaminergic function, biperiden and the indirect catecholamine agonist 
amphetamine were applied alone and in combination prior to PR performance. 
 
5.2 Materials and Methods 
5.2.1 Animals 
Sixty-four male C57BL/6 mice (Charles River Laboratories, Margate, UK) were involved in 
this study and divided into four cohorts (n = 16 each, see table 5.1). Mice were 6-8 weeks old 
at the start of the study and group housed (4 per cage) in a temperature and light controlled 
facility (lights on 1900-0700). Following arrival at the facility, animals were given seven days 
to acclimatise with handling limited to routine husbandry. The mice were then placed on a 
schedule of controlled feeding and maintained at approximately 85% (and no less than 80%) 
of their free-feeding body weight. No correction was applied to this 85% control weight to 
match the growth curve (weigh at start of testing: 25.3g ± 0.4). Cages were changed once 
weekly and drinking water was available ad libitum throughout. All behavioural testing took 
place 5-7 days per week during the animals’ dark phase. Two mice failed to complete the 
pretraining procedure and was removed from the study. Another mouse was culled due to ill-
health part way through the study. All experiments were conducted in accordance with the 
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 and following ethical 
review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 
 
5.2.2 Apparatus  
All testing took place in standard mouse Bussey-Saksida touchscreen chambers (Campden 
Instruments Ltd, Loughborough, UK), The behavioural arenas were housed within light and 
sound attenuating chambers, which were fitted with a fan for ventilation and to reduce 
background noise. Each behavioural arena consisted of a stainless-steel floor and trapezoidal 
black plastic walls opening out to a 12.1-inch touch sensitive screen (resolution 800x x 600) at 
one end and a reward delivery magazine at the other. Entries into the magazine were monitored 
via an infrared (IR) beam. Magazines were also fitted with a light-emitting diode, that 
illuminated upon delivery of the liquid reward (Yazoo® strawberry milkshake; Friesland 
Campina UK, Horsham, UK) used in the study. IR beams were also fitted across the floor 6 
cm in front of the touchscreen and 3cm from the magazine to monitor activity levels during 
testing. Black plastic masks consisting of five 4x4cm response apertures, spaced 1 cm apart 
were placed in front of each screen. During the current study, stimuli were only presented in 




5.2.3 Behavioural training 
Prior to behavioural testing, mice were exposed to the milkshake reinforcer in their home cages, 
to reduce any effects of neophobia. Subsequently, mice were habituated to the testing 
chambers. This consisted of a 20-minute exposure session, where the touchscreens were active, 
but no stimuli were displayed and there were no programmed consequences of behavioural 
output. 200μl of milkshake was placed in each magazine prior to the habituation session. Initial 
operant testing began with a single screen touch training session. During this session, a white 
square stimulus was presented in the central response aperture for 30s. Upon stimulus offset a 
reward tone (1000ms, 3kHz) was issued, the magazine was illuminated and 20μL of milkshake 
was delivered.  Following reward delivery, entry into the magazine initiated a 5s inter trial 
interval (ITI) and extinguished the magazine light. Following the ITI the next trial began. If 
the mouse touched the stimulus during the 30s presentation period, the stimulus was 
immediately turned off and the tone, triple the usual reward (60μL of milkshake) was delivered 
and the ITI was immediately triggered. Each session was terminated following 30 trials 
 
Animals then undertook fixed-ratio (FR) training. Each trial commenced with the presentation 
of the response stimulus in the central aperture. A single response to the stimulus resulted in 
stimulus offset, the reward tone and 20μL of milkshake being delivered to the magazine. Entry 
and subsequent exit from the magazine began the ITI, which was shortened to 4.5s, following 
which the next trial began immediately. Sessions were terminated following 30 rewards being 
delivered or 60 minutes elapsing. All animals were required to complete 30 trials within the 
60-minute session before moving on to the next stage of training. The subsequent stage 
consisted of responding on a FR2 schedule. During this stage, two touches to the white square 
stimulus were needed for trial completion. Following the first response in each trial, the 
stimulus was briefly removed (500ms) and a short ‘click’ sound (10ms, 3kHz) was played. 
This brief offset and sound accompanied all subsequent stimulus responses. A session was 
again terminated following 30 trials (i.e. 60 stimulus responses) or 60 minutes elapsing. Once 
30 trials were completed within a 60-minute session, animals moved onto FR3 training. During 
FR3 training, three stimulus responses were needed for reward delivery. All other session 
parameters remained the same as the FR2 training. FR3 training was followed by FR5 training, 
where five stimulus responses were required for reward delivery. Aside from changes in 
response requirements, all session parameters remained the same. Animals were required to 
complete 30 trials (150 stimulus responses) within 60 minutes for two consecutive FR5 




5.2.4 Progressive ratio (PR) Procedure 
The parameters of the PR schedule (Heath et al., 2015) were identical to the FR schedule except 
that the response requirement for reward delivery increased by a linear +4 step following each 
trial, yielding response requirements of 1,5,9,13,17 etc. No trial limit was imposed. If no 
response was made to the touchscreen within 300s, sessions were terminated, otherwise 
sessions ended after 60 minutes.  As with the rat touchscreen PR task (chapter 2), this task was 
not self-paced. 
 
5.2.5 Uncapped Fixed Ratio Procedure 
Uncapped Fixed Ratio-5 (FR5) testing was used to test for any changes in satiety/motor output 
changes. During FR5 testing, five responses were required for each reward delivery. No trial 
limit was imposed. Sessions were terminated following 60-minutes. 
 
5.2.6 Food Consumption Procedure 
The milkshake consumption test took place within the touchscreen chambers. Mice were given 
60-minutes of free access to milkshake which was placed within a small bowl that was fixed 
to the floor of the chamber. The bowls were weighed before and after the session to determine  
milkshake consumption. 
 
5.2.7 Prefeeding procedure 
The prefeeding procedure involved giving mice 60-minute free access to either a bowl 
milkshake reinforcer (prefeed) or water (control), within the homecages, prior to PR testing. 
Subsequently, the bowls were removed and the drug administered (see Drugs section for 
details). Animals had no further access to the bowls prior to PR testing. All mice received both 
vehicle and drug following prefeeding with both water and milkshake (resulting in four 
experimental conditions per compound).  
 
5.2.8 Extinction Procedure 
In this paradigm, the white target screen stimulus was presented; however, responding did not 
yield reward delivery nor the presentation of reward associated cues such as the stimulus offset 
tone or the sound of the milkshake pump. However, the usual brief stimulus offset and ‘click’ 
tone accompanied stimulus responses. Sessions were terminated after 60-minutes or following 




5.2.9 Effort Related choice Procedure 
During effort related choice testing (Heath et al. 2015) two pellets of standard lab chow 
(approximately 5g) were weighed and scattered on the floor of each touchscreen chamber. 
Animals were then tested on the FR5 schedule for 60-minutes. Following testing, the remaining 
chow (including spillage) was weighed to calculate consumption. 
 
5.2.10 Behavioural Measures  
During all PR tests, including the prefeeding tests and amphetamine tests, behavioural 
measures were calculated as described in the rat touchscreen PR4 and ERC programs (Chapters 
2 and 3).  During FR5 responding, response rates were calculated by fitting the parabolic 
function:  y = -b(x)2+a to calculate the predicted peak response rate (a) and decay rate parameter 
(b, Phillips et al., 2017). Unlike the PR calculations it was not necessary to exclude the first 
trial from the response rate analysis. Otherwise all behavioural measures were taken as in the 
PR analysis. During extinction testing it was not possible to calculate any measure related to 
reward delivery (post reinforcement pause, reward collect latency). In the absence of discrete 
trials in the extinction procedure, the response rate analysis was calculated by taking the time 
to complete blocks of five responses. 
 
5.2.11 Drugs 
All compounds were dissolved in physiological saline and administered via intraperitoneal 
injections at a volume of 10ml/kg of body-weight, 30 minutes prior to testing.   The following 
doses were tested: Scopolamine hydrobromide (Bio-techne, Abingdon, UK): 0.1 and 
0.3mg/kg; biperiden hydrochloride (Sigma-Aldrich, Dorset, UK): 1 and 3mg/kg; telenzepine 
dihydrochloride (Bio-techne, Abingdon, UK): 3 and 10mg/kg; and tropicamide (Bio-techne, 
Abingdon, UK): 2.5, 10, 20mg/kg. Amphetamine (Sigma-Aldrich, Dorset, UK), 0.1, 1mg/kg. 
When applied in combination, amphetamine and biperiden were co-administered in the same 
syringe to reduce the number of injections needed. Drug routes, doses and vehicles were 
selected based upon previous behavioural effects in mice: scopolamine (Shannon et al. 1999; 
Podkowa et al. 2016; Witkin et al. 2014); biperiden (Witkin et al. 2014; Popelíková et al. 2018); 
telenzepine (Yano et al. 2009; Ztaou et al. 2016); tropicamide (Veeraragavan et al. 2011; Ztaou 
et al. 2016) and amphetamine (Heath et al. 2015). 
 
5.2.12 Experimental design and statistical analysis 
Table 5.1 outlines the experimental procedures undertaken by each cohort. During PR testing, 
all compounds were administered in a within-subject, Latin square design. Tropicamide was 
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also subsequently administered at a higher dose in a counterbalanced within-subject crossover 
design. At least one day of drug free baseline testing was given between drug administration 
days within the Latin square and cross-over experiments. A drug free washout period of at least 
five days was given between each Latin square experiment. Statistical analyses were conducted 
with SPSS version 23.0 (IBM Corp, Armonk, NY, US) and the R software package (R Core 
Team, 2013). Graphs were produced using Prism (GraphPad, La Jolla, CA, USA) and the 
ggplot2 package in R (Wickham, 2009).  Repeated measures ANOVAs were used to analyse 
the results of all Latin square designs. When violations of sphericity were detected, the 
Greenhouse-Geisser correction was applied. Effect sizes were calculated as partial eta squared 
values. All reported post hoc testing was Bonferroni corrected to account for multiple 
comparisons. Cross-over designs were analysed with paired t-tests.  
 
Cohort 1 2 3 4 
Number of 
mice at testing 
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5.3.1 Nonselective antagonism of mAChRs with scopolamine facilitates PR performance and 
increases nonspecific locomotor activity at higher doses  
To initially investigate the role of mAChRs in motivated behaviour, scopolamine was 
administered prior to PR performance. Figure 5.1A shows how systemic administration of 
scopolamine significantly increased breakpoint (F(1.37,20.56) = 9.957, p < .001; partial eta 
squared = .399). Scopolamine at doses of 0.1 mg/kg (p < .05) and 0.3 mg/kg (p < .01) increased 
breakpoint relative to vehicle. In contrast, scopolamine had no significant effect upon PRPs, 
figure 5.1B (F(1.40,21.06) = 1.331, p = .279). Scopolamine, as seen in figures 5.1C,D, 
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appeared to significantly increase activity levels. The rate of IR beam breaks was significantly 
increased following scopolamine administration (F(2,30) = 5.562, p < .01; partial eta squared 
= .284; Figure 5.1C).  Scopolamine at 0.3mg/kg increased the rate of IR beam breaks relative 
to both other doses (both p < .05). Scopolamine administration also increased the rate of non-
target screen touches (F(2,30) = 10.12, p < .001; partial eta squared = .403; Figure 5.1D). The 
rate of non-target responses was significantly elevated following 0.3mg/kg of scopolamine 
relative to vehicle and 0.1 mg/kg (both p < .01).  
 
Analysis of response rates (Figure 5.1E) revealed that scopolamine did not significantly affect 
either the predicted peak response (F(1.33,19.89) = 1.71, p = .209) or the decay rate (F(2,30) 
= 2.671, p = .086; Figure 5.1F). Administration of scopolamine did also not significantly affect 
the mean length of response bouts (F(2,30) = .229 , p = .796). There was however, a significant 
effect upon the duration of pausing between bouts (F(2,30) = 4.775, p < .05; partial eta squared 
= .241; Figure 1G). The mean pause duration was significantly shorter following 0.3mg/kg of 
scopolamine compared to the 0.1mg/kg condition (p < .01). Additional measures of activity 
are available in table 5.2. These data indicate that scopolamine can increase effort expenditure, 
but that it also appears to increase nonspecific locomotor activity levels at high doses.  
 
Figure 5.1: The effects of scopolamine on PR performance. A Systemic administration of 
scopolamine enhances breakpoint. B Scopolamine does not affect post-reinforcement pausing. 
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Scopolamine increases measures of general activity including the C rate of IR beam breaks and 
D blank screen touches. E Effect of scopolamine upon response rates. F Scopolamine did not 
affect the rate of decay in responding. G Administration of the high dose of scopolamine 
reduces the mean pause between response bouts. Error bars represent SEM. * p < .05; **p<.01. 
 
5.3.2 Systemic administration of the M1 receptor antagonist biperiden enhances PR 
performance without affecting general activity levels. 
It is possible that the effect of scopolamine upon PR performance was driven by actions at the 
M1 receptor subtype. To investigate this, the preferential antagonist biperiden was tested.  
Figure 5.2A shows that breakpoints were significantly increased following systemic 
administration of biperiden (F(2,30) = 18.168, p < .001; partial eta squared = .548). Biperiden 
at 3 mg/kg significantly increased breakpoint compared to both vehicle and 1 mg/kg (both p < 
.01).   As shown in figure 5.2B, biperiden also significantly decreased the duration of the mean 
PRP (F(2,30) = 8.366, p < .01; partial eta squared = .358). PRPs were significantly shorter 
following 3mg/kg relative to both vehicle (p < .01) and 1 mg/kg of biperiden (p < .05). 
Biperiden (figures 5.2C and 5.2D) did not significantly increase measures of nonspecific 
activity. Neither the rate of IR beam breaks (F(2,30) = .927, p = .407; Figure 5.2C), nor the 
rate of nontarget screen touches (F(1.23, 18.48) = 1.266, p = .286; Figure 5.2D) were 




Figure 5.2: Enhancement of PR performance following administration of biperiden. A 
Breakpoint is dose-dependently increased by biperiden. B Biperiden reduces the length of the 
post reinforcement pause (PRP).  Administration of biperiden does not affect measures of 
general activity, including C the rate of IR beam breaks and D the rate of blank screen touches 
. E Biperiden affects response rates during PR performance. F The highest dose of biperiden 
significantly reduces the decay rate of responding. G Administration of biperiden does not 
increase the mean length of a response bout. H Biperiden significantly reduces the length of 
pauses between response bouts. Error bars represent SEM. * p < .05; **p<.01;  ***p<.001. 
 
Biperiden also affected the pattern of response rates (Figure 5.2E). The predicted peak response 
rate was not significantly affected by biperiden administration (F(1.35, 20.23) = 2.05, p = 
.1.46). However, as shown in figure 5.2F, biperiden significantly reduced the response decay 
rate (F(2,30) = 9.576, p <.01, partial eta squared = .390; Figure 52F). 0.3mg/kg of biperiden 
significantly reduced decay rate relative to the vehicle (p <.01). Biperiden did not significantly 
affect the mean length of response bouts (F(1.480,22.203) =.515, p = .551; Figure 5.2G). 
However, there was a significantly effect of biperiden upon pausing between bouts, figure 5.2H 
(F(1.295,19.423) = 9.682, p <.01; partial eta squared = .392; Figure 5.2H). 3 mg/kg of biperiden 
significantly reduced the duration of pausing between bouts relative to vehicle (p <.01). 
Supplementary measures of activity are available in table 5.2. 
 
Scopolamine Veh 0.1mg/kg 0.3mg/kg 
Reward Collection Latency 1.32 ± .04 1.33 ± .05 1.42 ± .13 
Magazine entries per second 0.02 ± .00 0.02 ± .00 0.03 ± .00* 
Biperiden Veh 1mg/kg 3mg/kg 
Reward Collection Latency 1.43 ± .06 1.48 ± .05 1.56 ± .09 
Magazine entries per second 0.01 ± .00 0.01 ± .00 0.02 ± .00 
Telenzepine Veh 3mg/kg 10mg/kg 
Reward Collection Latency 1.46 ± .07 2.26 ± .56 1.49 ± .06 
Magazine entries per second 0.01 ± .00 0.02 ± .00 0.02 ± .00 
Tropicamide Veh 20mg/kg  
Reward Collection Latency 1.35 ± .03 1.31 ± .03  




Table 5.2: Effects of muscarinic antagonists upon supplementary measures of activity. Mean 
values ± SEM of reward collection latencies and rate of magazine entries during PR 
performance following systemic administration of Scopolamine, biperiden, telenzepine and 
tropicamide. * Significantly different to 0.01mg/kg of scopolamine (p < .05). 
 
Together, these results suggest that biperiden facilitates PR performance without significantly 
affecting measures of general activity. These data also suggest that the previous effects of 
scopolamine upon motivation may have been driven by the M1 receptor, whereas the effects 
on locomotor activity may have been driven by a different receptor subtype. 
 
5.2.3 Systemic administration of telenzepine does not affect PR performance 
As a control for potential peripheral effects, the M1 receptor antagonist telenzepine, believed 
to have relatively poor brain penetrance (Ichikawa et al. 2002; Pediani et al. 2016), was 
administered prior to PR performance. Figure 5.3A shows how telenzepine did not significantly 
affect PR breakpoint (F(2,30) = 2.772, p = .079). The duration of the mean PRP was also not 
affected by administration of telenzepine (F(2,30) = .624, p = .543; Figure 5.3B). Neither the 
rate of IR beam breaks (F(2,30) = 1.617, p = .215), nor the rate of blank touches was affected 
by any dose of telenzepine administered (F(2,30) = .503, p = .610). Response rates were also 
unaffected following telenzepine administration (Figure 3.5C). Telenzepine had no significant 
effect on the predicted peak response rate (F(2,30) = .172, p = .884). The decay in response 
rates was also not affected by telenzepine (F(1.28,19.17) = .595, p = .558). Systemic 
administration of telenzepine produced no significant effect upon the mean length of a response 
bout (F(2,30) = .432, p = .654). Telenzepine also did not affect the duration of pausing between 
response bouts (F(1.452,20.328) = .328, p = .655). Taken together, these data indicate that 
telenzepine had no effect on effort-related behaviour. Therefore, the effects of biperiden are 




Figure 5.3: PR performance is unaffected by systemic administration of telenzepine. A 
Breakpoint is not affected by either dose of telenzepine. B The post reinforcement pause (PRP) 
is unaffected by telenzepine.  C Telenzepine does not affect the decay in response rates.  Error 
bars represent SEM. 
 
5.2.4 Blockade of M4 receptors with tropicamide facilitates PR performance and at high 
doses increases some measures of activity. 
To test for a potential contribution of the M4-receptor subtype in facilitating motivated 
behaviour, tropicamide was administered at doses of 2.5 and 10 mg/kg. Neither dose 
significantly affected PR breakpoint, figure 5.4A (F(2,30) = 2.007, p = .152). There was 
however, a trend towards an effect on PRP (F(2,30) = 3.268, p = .052; Figure 4B). There were 
also no  significant effects upon the rate of IR beam breaks (F(2,30) = 1.950, p = .162) or the 
rate of nontarget screen touches (F(2,30) = 1.708, p = .198). Tropicamide also failed to affect 
response rates (predicted peak rate: (F(2,30) = .722, p = .494); decay rate: (F(2,30) = .814, p = 
.452). There was however, a significant drug effect upon the mean number of responses within 
a bout (F(2,30) = 3.582, p <.05; partial eta squared = .193). However, post hoc testing did not 
reveal any significant comparisons. Tropicamide also affected pausing between response bouts 
(F(2,30) = 3.335, p <.05; partial eta squared = .182). Again, no post hoc comparisons were 
significant (all p > .05) 
 
Given the strong trend towards an effect of tropicamide on several measures of PR 
performance, animals were subsequently administered the higher dose of 20 mg/kg.  At this 
dose, figure 5.4C tropicamide significantly increased PR breakpoint (t(15) = 2.218, p < .05). 
Tropicamide failed to affect PRPs (t(15) = 1.01, p = .328; Figure 5.4D) or IR beam breaks 
(t(15) = .567, p = .579). There was however, a significant increase in nontarget touches, 
following tropicamide administration, figure 5.4E (t(15) = 3.153, p < .01). Tropicamide at 
20mg/kg did not affect response rates (Figure 5.4F). Neither the predicted peak response rate 
(t(15) = .507, p = .619), nor the rate of decay in responding (t(15) =1.393, p = .184) were 
significantly affected. 20mg/kg of tropicamide also failed to significantly affect the length of 
response bouts (t(15) = 1.856, p = .083). There was also no effect of drug administration upon 
pausing between bouts (t(15) =.228, p = .823). Supplementary measures of behaviour are 
available in table 5.2. These results suggest that antagonism of M4 receptors may facilitate PR 
performance through an enhancement in nonspecific activity levels. The enhanced activity 
levels observed following scopolamine administration may have been driven through its 




Figure 5.4: Tropicamide at high doses increases breakpoint but also nonspecific activity. 
Neither A breakpoint nor B the duration of the post reinforcement pause (PRP), were affected 
by either 2.5 or 10mg/kg of tropicamide. C The high dose of tropicamide increases breakpoint 
but D fails to affect PRP. E The rate of nontarget blank screen touches is significantly increased 
by tropicamide. F Tropicamide has no effect upon the decay in responding during PR 
performance. Error bars represent SEM. * p < .05; **p<.01.   
 
5.2.5 Scopolamine and biperiden do not affect performance on a FR5 schedule of 
reinforcement or alter free-feeding behaviour 
The previous results demonstrate that PR performance can be enhanced through systemic 
administration of both scopolamine and biperiden. However, an increase in breakpoint could 
be driven by a number of behavioural mechanisms other than a change in motivation. 
Therefore, scopolamine and biperiden were tested on an uncapped FR5 schedule to investigate 
the potential drug effects on satiety and/or motor fatigue.  Figure 5.5A shows how drug 
administration, under these low effort conditions, did not affect the number of trials completed 
(F(2,28) = 2.180, p = .132). There was however, a significant effect of drug administration on 
the duration of the mean PRP, as can be seen in figure 5.5B (F(2,28) = 4.678, p < .05; partial 
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eta squared = .250). PRPs were shortened following biperiden administration compared to 
scopolamine (p < .01). The mean reward collection latency was also affected by drug 
administration (F(1.316, 18.42) = 8.461,  p < .01; partial eta squared  = .377; Figure 5.5C). 
Biperiden administration significantly increased the mean reward collection latency relative to 
vehicle (p <.05). Figure 5.5D shows that there was also an effect of drug on the rate of IR beam 
breaks (F(2,28) = 3.920,  p < .05; partial eta squared = .219). Scopolamine, but not biperiden, 
significantly increased the rate of IR beam breaks compared to vehicle (p < .05). Drug 
administration did not significantly affect the rate of nontarget (blank) screen responses 
(F(2,28) = .009,  p = .991). There was also no significant effect of drug upon the rate of 
magazine entries (F(2,28) = 2.689,  p = .085). Crucially, response rates, which can be used to 
index the onset of satiety (Phillips et al., 2017)  also appeared unaffected (figure 5.5E). Neither 
the predicted peak response rate (F(2,28) = .180,  p = .836), nor the decay in response rate 
(F(2,28) = .958,  p = .396; Figure 5.5F) were affected by drug administration. 
 
 To further control for any nonspecific drug effects on appetite, the effect of scopolamine and 
biperiden administration on free strawberry milkshake consumption was tested. Drug 
administration, which can be seen in figure 5.5G, produced no effect on 60-minute milkshake 
consumption (F(2,28) = 1.388, p = .266). Together, these data indicate that the previously 
observed effects of scopolamine and biperiden on PR were unlikely to be driven by changes in 
satiety, motor fatigue or appetite. 
 
Figure 5.5: The effects of scopolamine and biperiden upon FR5 performance (A-F) and free 






























































































trials completed in a 60-minute session. B Neither scopolamine nor biperiden reduce the 
duration of post reinforcement pauses (PRPs) relative to vehicle, however, there is a significant 
difference between scopolamine and biperiden.  C The latency to collect rewards is increased 
by biperiden administration.  D The rate of IR beam breaks is significantly increased following 
administration of scopolamine but not biperiden. E. Neither biperiden nor scopolamine affect 
response rates reinforced under a FR5 schedule F The decay rate in FR5 responding is 
unaffected by systemic scopolamine and biperiden. G Neither scopolamine nor biperiden 
significantly affect milkshake consumption during a 60-minute free-feeding test. Error bars 
display represent SEM. Veh: Vehicle (saline); Scop: Scopolamine 0.3 mg/kg; Bip: Biperiden 
3 mg/kg;*  p < .05; **p<.01.   
 
5.2.6 The effects of scopolamine and biperiden on PR are reduced in partially satiated mice. 
In order to assess whether the effects of scopolamine and biperiden were sensitive to changes 
in outcome value, the effects of drugs were tested following prefeeding with milkshake.  
Initially, the interaction between scopolamine and prefeeding was assessed. Figure 5.6A shows 
how breakpoint was significantly reduced by prefeeding (F(1,15) = 49.903,  p < .001; partial 
eta squared = .769) and increased by administration of scopolamine (F(1,15) = 108.182, p < 
.001; partial eta squared = .878). There was also a significant drug x prefeeding interaction 
upon breakpoint (F(1,15) = 16.529, p < .01; partial eta squared = .524). Scopolamine increased 
breakpoint following prefeeding with water (p < .001) and milkshake (p < .05). Breakpoints 
were also lower following prefeeding with milkshake in both drug conditions (p < .001; figure 
5.6A).  PRPs were not affected by prefeeding (F(1,15) = .136, p = .718; partial eta squared = 
.009), but were reduced by scopolamine (F(1,15) = 5.753, p<.05; partial eta squared = .277). 
The interaction between scopolamine and prefeeding was not significant (F(1,15) = .812, p= 
.382).  
 
Figure 5.6B shows how the rate of IR beam breaks was significantly decreased by prefeeding 
(F(1,15) = 5.544,  p = .050; partial eta squared = .232) but not affected by scopolamine (F(1,15) 
= 3.662,  p = .075). There was however, a significant interaction between the drug and 
prefeeding (F(1,15) = 10.106,  p < .01; partial eta squared = .403). Scopolamine significantly 
increased the rate of IR beam breaks following prefeeding with water (p < .01) but not 
milkshake (p = .899). Prefeeding with milkshake significantly reduced the rate of IR beam 
breaks in the scopolamine (p < .01), but not the vehicle condition (p = .762). Figure 5.6C shows 
how the rate of nontarget screen responses was also significantly reduced by prefeeding 
(F(1,15) = 8.726,  p < .01; partial eta squared = .368) and increased by scopolamine (F(1,15) 
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= 14.186,  p < .01; partial eta squared = .486). There was also a significant interaction between 
prefeeding status and scopolamine on the rate of nontarget screen touches (F(1,15) = 6.043,  p 
< .05; partial eta squared = .287). Scopolamine increased nontarget responses following 
prefeeding with water (p < .01) but not following prefeeding with milkshake (p = .124). 
Prefeeding with milkshake reduced the rate of nontarget touches in the scopolamine (p < .05), 
but not vehicle condition (p = .072).  
 
The decay in response rates was also examined. The decay rate was significantly increased by 
prefeeding (F(1,15) = 8.538,  p < .05; partial eta squared = .363) and reduced by scopolamine 
administration (F(1,15) = 9.095,  p <.01; partial eta squared = .377). There was also a 
significant interaction between drug administration and prefeeding state (F(1,15) = 5.139,  p 
<.05; partial eta squared = .255). Scopolamine significantly reduced the decay rate in both 
prefeeding conditions (p < .05). The rate of decay was significantly higher following 
prefeeding with milkshake in both drug conditions (p <.05). Supplementary measures are 
available in table 5.3. Together, these results suggest that, the majority of the effects of 
scopolamine are abolished following prefeeding with milkshake. However, scopolamine was 















































































































Figure 5.6: Interaction effects of prefeeding with water and milkshake and biperiden and 
scopolamine administration upon PR performance.  A Prefeeding with milkshake attenuates 
the effect of scopolamine upon breakpoint. B The scopolamine induced increase in IR beam 
breaks and C blank screen touches are abolished by prefeeding the mice with milkshake D. 
The effects of biperiden upon breakpoint are abolished in mice prefed with milkshake. E 
Neither biperiden administration nor prefeeding affects the rate of beam breaks or F blank 
touches. Error bars display represent SEM. Veh: Vehicle (saline); Scop: Scopolamine 0.3 
mg/kg; Bip: Biperiden 3 mg/kg; *p < .05; **p<.01.   
 
The interaction between biperiden and behaviour was also examined through prefeeding. 
Figure 5.6D shows how prefeeding with milkshake had a significantly reduced breakpoint 
(F(1,13) = 48.481,  p <.001; partial eta squared = .789). There was also a significant effect of 
biperiden administration (F(1,13) = 10.161,  p <.01; partial eta squared = .439), as well as drug 
x prefeeding interaction (F(1,13) = 4.875,  p <.05; partial eta squared = .273). Biperiden 
significantly increased breakpoint following prefeeding with water (p < .01), but not following 
milkshake (p = .211). Mice prefed with milkshake exhibited lower breakpoints in both drug 
conditions (both p < .001). Prefeeding also increased the mean PRP (F(1,13) = 6.896,  p <.05; 
partial eta squared = .347). Biperiden administration, however, did not affect PRPs (F(1,13) = 
.155,  p = .700). In addition, there was no interaction between biperiden and prefeeding 
observed upon PRP (F(1,13) = .283  p = .604).  
 
As seen in figure 5.6E, the rate of IR beam breaks was not significantly affected by either 
prefeeding (F(1,13) = 3.027,  p =.107), biperiden (F(1,13) = 2.470,  p =.142; Figure 6E) or by 
any prefeeding x drug interaction (F(1,13) = 1.579,  p = .233). Prefeeding did, however reduce 
the rate of nontarget screen touches (F(1,13) = 12.396  p <.01; partial eta squared = .488). 
There was also a significant effect of drug on the rate of nontarget responses, which can be 
seen in figure 5.6F (F(1,13) = 7.367  p <.05; partial eta squared = .362). There was no 
interaction between biperiden and prefeeding state (F(1,13) = .013,  p =.910). 
 
 Finally, the effects of biperiden and prefeeding on response rates were examined. Prefeeding 
had no significant effect on the rate of decay (F(1,13) = 1.197,  p =.294). There was also no 
effect of systemic administration of biperiden (F(1,13) = .033,  p =.859). There was, however, 
a significant interaction between drug and prefeeding state (F(1,13) = 11.093,  p <.05; partial 
eta squared = .331). Biperiden reduced the rate of decay in responding following prefeeding 
with milkshake only (p<.01). Supplementary measures are available in table 5.3. Together, 
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these effects suggest the behavioural effects of biperiden are abolished in partially satiated 
mice.  
 
Table 5.3: Effects of muscarinic antagonists upon supplementary measures of activity 
following prefeeding with either water or milkshake. Mean values ± SEM of PR performance 
following prefeeding with either water or milkshake and administration of scopolamine or 
biperiden. Comparisons only reported in cases of a significant drug x prefeed interaction 
*Significantly different from vehicle (Milkshake condition only, p < .05). 
 
5.2.7 Scopolamine and biperiden do not significantly affect effort related choice behaviour 
in intact mice 
When examining the effects of scopolamine and biperiden on effort-related choice behaviour, 
drug administration produced no significant effects on chow consumption (F(1.092,15.439) = 
1.552, p = .323; Figure 5.7A). There was however, a significant effect of drug administration 
on the number of FR5 trials completed (F(2,30) = 4.320, p < .05; partial eta squared = .224; 
Figure 5.7B). Neither compound significantly affected the number of trials completed relative 
to vehicle administration (both p > .05); however, mice treated with biperiden completed more 
trials compared to scopolamine (p < .05).  PRPs were not affected by drug administration 
(F(1.516,17.337) = .956, p = .396). Drug administration also had no effect on either the rate of 
IR beam breaks (F(2,30) = .251 p = .780)  or the rate of nontarget screen touches (F(2,30) = 
.706, p = .502). Together, this suggests that neither biperiden nor scopolamine affect effort-





Veh 0.3 mg/kg Veh 3mg/kg 
Water 1.59 ± .20 1.50 ± .08 1.31 ± .07 1.30 ± .06 
Milkshake 
 
1.35 ± .04 1.69 ± .10 1.41 ± .08 1.96 ± .40 
Magazine entries per 
sec 
Scopolamine Biperiden 
Veh 0.3 mg/kg Veh 3mg/kg 
Water 0.01 ± .00 0.03 ± .00 0.01 ± .00 0.01 ± .00 




Figure 5.7: The effects of scopolamine and biperiden of effort related choice (ERC) behaviour. 
ERC performance is unaffected by drug administration. Nether scopolamine nor biperiden 
affected the amount of chow consumed A or the number of trials completed B relative to 
vehicle. Error bars display represent SEM. Veh: Saline Vehicle; Scop: Scopolamine 0.3 mg/kg; 
Bip: Biperiden 3 mg/kg; * p < .05. 
 
5.2.8 Biperiden does not affect extinction behaviour 
The previous results suggest biperiden enhances motivation. It is possible that these effects 
may have been driven by an increase in perseverative-like stimulus responding during a period 
without reinforcement. Therefore, the effects of biperiden on responding in extinction 
conditions  (during which the reinforcer is removed) were evaluated. One animal was removed 
following an outlier analysis (with the number of  touchscreen responses being greater than +2 
standard deviations above the mean).  Figure 5.8A shows that Biperiden did not significantly 
affect the total number of target touches (t(12) = 1.773, p = .102). Biperiden also did not affect 
the decay in responding (figure 5.8B). Neither the predicted peak response rate (t(12) = 1.139, 
p = .277) nor the decay rate (t(12) = 1.808, p = .096; figure 5.8C) were significantly affected 
by biperiden. Therefore, the previous effects of biperiden upon effort output are dependent on 




Figure 5.8: Effects of biperiden under extinction conditions. A Biperiden does not significantly 
affect the total number of target screen touches. B Biperiden does not affect the change in 
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response rates. C The decay rate in responding is not significantly affected by biperiden 
administration. Veh: Saline vehicle, Bip: Biperiden 3mg/kg. Error bars display the SEM.  
 
5.2.9 Biperiden facilitates the effects of amphetamine upon PR performance 
In order to examine whether biperiden interacts with dopaminergic function the potential 
faciliatory effects of biperiden on amphetamine were tested on PR performance.  Sub-effective 
and effective doses of amphetamine (0.1 and 1mg/kg respectively, Heath et al. 2015) were 
applied in isolation and in combination with two sub-effective doses of biperiden (0.3 and 
1mg/kg) which were also applied in isolation. As shown in figure 5.9A, drug administration 
significantly affected breakpoint (F(3.016,42.227) = 14.093,  p < .001; partial eta squared = 
.516). 1mg/kg of amphetamine increased breakpoint relative to vehicle (p<.01). When 1mg/kg 
of amphetamine was applied in combination with the sub-effective 1mg/kg of biperiden, 
breakpoints were increased relative to all other conditions (all p<.05), demonstrating an 
additive effect. No other doses or combination significantly affected breakpoint relative to 
vehicle. 
 
PRPs were also significantly affected by drug administration (F(3.428, 47.993) = 2.773,  p  < 
.05; partial eta squared = .163); however, there were no significant differences between any 
drug condition (all p > .05).  Neither the latency to collect rewards (F(1.899, 26.591) = 1.330,  
p = .280) nor the rate of nontarget screen touches (F(2.834) = 1.294,  p = .290) were 
significantly affected by drug administration. When examining the rate of IR beam breaks, 
which can be seen in figure 5.9B, there was a main effect of drug (F(1.987, 27.696) = 11.337,  
p < .001; partial eta squared = .447). 1mg/kg of amphetamine increased breakpoints relative to 
vehicle (p< .05). The high dose biperiden/amphetamine combination increased beam breaks 
relative to vehicle (p<.05); however, this combination failed to increase the rate of beam breaks 
relative to 1m/kg of amphetamine alone. Together, these results suggest a dose of biperiden 
that does not significantly affect motivated behaviour, is able to enhance the effects of 





Figure 5.9: The effects of biperiden in facilitating the behavioural effects of amphetamine 
upon PR performance. The dose of amphetamine is represented by the graph fill, whereas the 
dose of biperiden is indicated by the graph pattern.  A 1mg/kg of biperiden facilitates the 
enhancement in breakpoints caused by amphetamine but does not affect breakpoint when 
administered in isolation. B 1mg/kg of biperiden does not enhance the general effect of 
amphetamine upon IR beam breaks. Amph: amphetamine; Bip: biperiden. All doses in mg/kg. 
ns p > .05; * p < .05; **p<.01; ***p<.001 
 
Visual inspection of breakpoints (figure 5.9A) suggests that the 1 mg/kg dose of biperiden 
alone, produced a nonsignificant increase in breakpoint. This suggests that the effect of 
biperiden with amphetamine may have been additive rather than synergistic. The presence of 
a significant interaction between treatments would suggest the presence of synergistic effects 
(Slinker 1998).  Therefore, breakpoints following neither treatment (i.e. vehicle), both 
treatments alone (i.e. 1 mg/kg of amphetamine and 1m/kg amphetamine) and the treatments in 
combination were examined. When examining breakpoints there were main effects of both 
amphetamine, figure 5.10 (F(1,14) = 49.182,  p  < .001; partial eta squared = .778) and 
biperiden (F(1,14) = 19.119,  p  < .001; partial eta squared = .577). However, there was no 
significant interaction between the two (F(1,14) = 1.107,  p  = .311; figure 5.10A). This 
suggests the effect of biperiden upon amphetamine was additive, rather than more-than-
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Figure 5.10: The additive effect of biperiden and amphetamine on PR performance. No 
significant interaction was observed between biperiden and amphetamine upon breakpoint, 
suggesting the effects were additive not synergistic. Amph: Amphetamine 1mg/kg; Bip: 
Biperiden 1mg/kg. Veh: Saline vehicle. Error bars represent the SEM. 
 
5.3 Discussion 
Apathy remains a large-scale clinical problem with few effective treatments. Preclinical 
identification of targets is a key step in developing new treatments for such symptoms. 
Progressive ratio (PR) schedules can probe effort-based behaviour in a way believed to model 
activational processes commonly disrupted in clinical populations. Touchscreen-based PR 
tasks in particular are useful assays of motivation as they maintain a high degree of face-
validity across species (Weed et al. 1999; Heath et al. 2015; Bland et al. 2016). PR schedules 
are highly sensitive to pharmacological manipulations; however, are also produce relatively 
unspecific measures of behaviour. Therefore, it is important to follow-up positive results in PR 
with a number of control tasks, to ensure that a change in behaviour is drive by changes in 
motivation rather than a confounding construct. Through this process, this chapter 
demonstrates that muscarinic acetylcholine receptors (mAChRs) can affect motivated 
behaviour in mice, and antagonists of the M1 subtype in particular may provide a new target in 
the treatment of apathy. 
 
5.3.3 Effects of mAChR antagonists upon PR performance 
Several compounds (biperiden, scopolamine and tropicamide) significantly increased 
breakpoint, the typical primary measure of PR performance. However, the overall pattern of 
behaviour was markedly different.  For example, the M1 selective biperiden appeared to 
produce relatively selective effects on motivation, by increasing breakpoint in the absence of 
any significant changes in locomotor measures. In contrast, the nonselective muscarinic 
antagonist scopolamine and the M4 receptor antagonist tropicamide produced concomitant 
increases in nonspecific activity (such as the rate of IR beam breaks and nontarget screen 
touches). Therefore, it is possible that the effects on breakpoint induced by scopolamine and 
tropicamide may have been driven by changes in locomotor activity.  
 
It is possible to obtain complementary measures of behaviour during responding under a PR 
schedule of reinforcement. One such measure is the post reinforcement pause (PRP). The 
length of PRPs reflect, in part, the upcoming work requirement (Felton & Lyon 1966) and 
decrease with an increased motivational state (Powell, 1969). A reduction in the length of PRPs 
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may suggest an animal is more motivated to engage with a task to obtain rewards. Biperiden, 
but neither scopolamine nor tropicamide, reduced the length of PRPs. Similar results were 
observed when examining the pattern of response rates. Over the course of a PR session, the 
rate of operant responding decreases (Killeen et al. 2009). By examining trial-by-trial changes 
response rate it is possible to extract additional parameters of behaviour. The predicted peak 
rate of responding is believed to reflect the maximal energy output of an animal (Kim et al. 
2017; Phillips et al. 2017). In contrast, the rate of decay in responding may reflect the excitatory  
influence of reinforcers upon subsequent bouts of behaviour (Phillips et al. 2017). Biperiden 
alone reduced the rate of decay in responding without affecting the predicted peak response 
rates, again suggesting a motivational effect in the absence of changes to reward value. In 
contrast, neither scopolamine nor tropicamide produced significant effects upon response rates, 
suggesting fewer motivational effects on instrumental behaviour.  
 
Operant responding is also characterised by bouts of successive responses separated by pauses 
(Shull et al. 2001). Biperiden decreased the length of pausing between bouts, without altering 
the mean number of responses within a bout. This result again suggests that biperiden increased 
task engagement in mice, attenuating the effects of increasing work requirements on response 
rates as well as pausing. Together these results highlight the advantages of analysing multiple 
measures of behaviour other than breakpoint. Not only do such analyses provide a richer source 
of data of the effects of manipulations on behaviour but may also reduce the need for additional 
control tasks and could ultimately reduce the number of experimental animal procedures 
conducted. 
 
5.3.4 Effects of biperiden on a battery of control tasks 
A drug induced enhancement in PR performance could be driven by a number of behavioural 
mechanisms. In order to examine potential confounds, previous reports have used a number of 
control tasks to understand the psychological mechanisms underlying a change in behaviour 
(Bailey, Williamson, et al. 2016). We therefore tested the effects of mAChR blockade on a 
battery of control tasks, to investigate whether the effects observed on the PR schedule were 
driven by behavioural changes other than an increase in goal-directed motivation.  
 
PR performance is sensitive to the effects of satiation. The cholinergic system has been 
implicated in the regulation of satiety processes. For example, the slowing of feeding towards 
the end of a feeding bout is accompanied by an increase in striatal acetylcholine levels (Mark 
et al. 1992). Certain appetite suppressing drugs also cause an increase in ACh within the 
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striatum (Rada & Hoebel 2000). It is possible that mAChR antagonists reduce the effects of 
endogenous ACh on satiety, allowing higher breakpoints to be achieved. A separate possibility 
is that the drugs attenuated motor fatigue that may affect PR performance. To account for these 
possibilities, we tested the effects of scopolamine and biperiden upon FR5 performance. At the 
effective doses, neither biperiden nor scopolamine significantly affected the number of FR5 
trials completed, suggesting the effects observed upon PR performance was not mediated by a 
change in motor fatigue. Furthermore, neither compound affected the decay in  response rates, 
which reflect, in part, the onset of satiety (Kim et al. 2017). In humans, anticholinergic drugs, 
including scopolamine, can cause ‘dry-mouth’ symptoms (Scully CBE 2003; Drevets & Furey 
2010). It is possible that such symptoms may cause an increase in the seeking of a liquid 
reinforcer such as milkshake. To further investigate this possibility, the effects of scopolamine 
and biperiden upon free consumption of the strawberry milkshake reinforcer were tested. 
Neither drug significantly increased milkshake consumption during 60-minute free-feeding, 
suggesting that the effects observed on PR were unlikely driven by appetitive changes.  
 
Interpreting enhancements in PR performance can also be confounded by changes in general 
arousal that do not reflect changes goal-directed behaviour (Bailey et al. 2015). Goal directed 
behaviour involves an animal forming action-outcome contingencies (Dickinson & Balleine 
1994). If the effects of a drug are restricted to goal-directed behaviour, then the effects should 
be sensitive to changes in reward value. The effects of biperiden on PR performance were 
replicated in the absence of satiation (prefeeding with water). In contrast, biperiden produced 
no behavioural effects in mice prefed with milkshake. This result suggests the behavioural 
changes induced by biperiden were goal-directed. Scopolamine was still able to produce a 
small, but significant increase in breakpoint in satiated mice. However, the effect upon 
breakpoint was significantly attenuated by prefeeding. This effect of prefeeding suggests, that 
scopolamine may facilitate PR performance through means other than an increase in locomotor 
activity. It should be noted that a dual-reinforcer procedure is necessary to determine whether 
a behaviour is goal-directed or habitual (Dickinson & Balleine 1994). The present study does 
however, suggest that the effects are sensitive to changes in outcome value.  
 
Biperiden also did not significantly affect responding in the absence of reinforcement. This 
finding suggests that the behavioural actions of biperiden on PR performance are unlikely to 
explained by any increase in perseverative or compulsive-like responding. In the present study, 
we did not test the effects scopolamine under extinction; however, previous reports have 
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suggested that higher doses of the drug can reduce extinction behaviour (Morley & Russin 
1978; McKim 1970). 
 
5.3.5 Scopolamine and Biperiden fail to increase effort related choice 
In spite of the effects observed on PR performance, neither biperiden nor scopolamine 
significantly affected ERC performance.  One possibility is that the effort required in a FR5 
schedule is too low to detect the facilitative effects of the compounds. In line with this, previous 
studies investigating the facilitation of ERC behaviour have typically either attempted to 
reverse a motivational deficit following pharmacological pre-treatment (Nunes, Randall, Hart, 
et al. 2013), or have used PR-choice tasks with escalating work requirements (Randall et al. 
2012). A higher ratio employed in an ERC task may be more sensitive to detect any 
enhancements in motivated behaviour following administration of mAChR antagonists.  
 
5.3.6 Biperiden facilitates the effects of amphetamine 
The behavioural effect of amphetamine on breakpoint, but not locomotor activity, was 
facilitated by co-administration of biperiden. It is possible that such an effect could be simply 
additive or synergistic (i.e. more-than-additive). Previous reports have suggested that the 
nonselective antagonist scopolamine can facilitate the locomotor enhancing effects of 
amphetamine (Carlton 1961). Moreover, in a direct test of synergism, scopolamine and cocaine 
were shown to have more-than-additive effects upon locomotor activity when applied in 
combination (Thomsen 2014). However, it is not clear whether these effects also occur for 
effort expenditure or occur through actions at the M1 receptor.  
 
When examining drug combinations there are multiple ways of approaches to assessing 
possible synergistic effects (Foucquier & Guedj 2015). Some approaches require multiple 
combinations of the two drugs at differing ratios (Tallarida 2011). An alternative approach is 
to use null hypothesis testing  and a two-way ANOVA to test for the presence of a significant 
interaction between the two drugs when applied alone and in combination (Slinker 1998). In 
the present study, there was no significant interaction between biperiden and amphetamine 
suggesting an additive effect. This result, coupled with some separate behavioural effects of 
amphetamine (Bailey et al., 2015), suggests that effects of biperiden on effort exertion is 
occurring through a separate physiological pathway than amphetamine. This suggests that the 
previous reports of synergism between scopolamine and stimulants may be dependent on 
actions at receptors other than the M1 subtype. However, in the absence of a direct 
electrophysiological or neurochemical investigation, the effects of biperiden on dopamine 
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function are unknown. Future studies may wish to combine biperiden administration with such 
techniques to fully investigate the effects on dopaminergic function. It should also be noted 
that amphetamine also facilitates other neurotransmitter systems including serotonin and in 
particular noradrenaline (Kuczenski & Segal 1992; Kuczenski & Segal 1997; Rothman et al. 
2000). The present results may therefore represent a facilitation of nondopaminergic 
catecholamine function. 
 
This finding does however, raise the possibility of using combination therapy of muscarinic 
antagonists and stimulants such as amphetamine. Amphetamine has been previously proposed 
as a treatment for apathy (Clark & Mankikar 1979), however the long term use of 
psychostimulants as therapeutics are associated with a number of side effects (reviewed in 
Stotz et al. 1999). The co-administration of biperiden may allow for lower doses to achieve the 
same therapeutic benefits reducing the severity of side effects associated with either drug alone.  
 
5.3.7 Compound selectivity and penetrance 
Muscarinic receptor subtypes are molecular targets for a number of  disorders (Langmead et 
al. 2008). However, due to similarity in the structure of muscarinic binding pockets, it is not 
possible to produce highly selective ligands that act upon the orthosteric binding sites  (Foster 
et al. 2014; Thal et al. 2016). Therefore, orthosteric muscarinic ligands, at best, have preference 
for one receptor subtype. Biperiden has been reported to have preference for the M1 receptor 
over other types (Syvälahti et al. 1987; Bolden et al. 1992; Kimura et al. 1999), and is 
commonly used as a M1 antagonist in the literature (e.g. Salin-Pascual et al. 1993; Klinkenberg 
& Blokland 2011; Roldán et al. 1997; Popelíková et al. 2018). Aside from the M1 subtype, 
biperiden also acts upon M4 receptors (Bolden et al. 1992; Witkin et al. 2014). The M4 receptor 
antagonist tropicamide failed to produce the large PR performance observed following 
scopolamine and biperiden administration. Tropicamide is a potent M4 receptor antagonist, but 
has poor selectivity for the receptor (Lazareno et al. 1990; Croy et al. 2016). There are currently 
a lack of highly selective of M4 receptor antagonists, that cross the blood-brain barrier. 
However, tropicamide can be used to produce M4 receptor-mediated effects on behaviour (Betz 
et al. 2007; Veeraragavan et al. 2011; Aliane et al. 2011; Ztaou et al. 2016). The effects of 
tropicamide upon PR performance are therefore in-line with hypothesis that biperiden and 
scopolamine enhance PR performance through actions at the M1 receptor subtype, however the 




In the present study, all compounds were administered systemically. mAChRs are also 
expressed in peripheral tissues, including the gut, heart and bladder (Caulfield 1993). It is 
possible, therefore, that any drug effects may be driven by actions at peripheral receptors. 
Scopolamine is a highly potent antagonist at all mAChR subtypes that readily crosses the 
blood-brain barrier (Witkin et al. 2014), and produces centrally mediated effects when 
administered systemically (Klinkenberg & Blokland 2010).  Biperiden also readily penetrates 
into the brain (Battaglia et al. 2001; Sudo et al. 1999),  and is prescribed as a centrally acting 
treatment in PD and to treat extrapyramidal symptoms of antipsychotic treatment in 
Schizophrenia (Gjerden et al. 2009). Conversely telenzepine, believed to  have difficulty 
crossing the blood-brain barrier (Ichikawa et al. 2002; Pediani et al. 2016), had little effect on 
PR performance, suggesting the effects of biperiden and scopolamine upon PR performance 
likely occurred through centrally located receptors. 
 
As previously discussed (chapter 1), within the NAc, M1 and M4 receptors are situated upon 
medium spiny neurons (MSNs). M4 receptors are expressed mainly upon the D1 type 
striatonigral MSNs, whereas M4 receptors are expressed upon both striatonigral and the D2 type 
striatopallidal receptors (Goldberg et al. 2012). Suppression of the striatopallidal pathway 
activity, facilitates PR and ERC performance (Randall et al. 2012; Carvalho Poyraz et al. 2016). 
Conversely, compounds that would be expected to enhance striatopallidal MSN excitability, 
disrupt PR performance (Mingote et al. 2008; Bari & Pierce 2005).  Blockade of the Gq-coupled 
M1 receptors would be expected to reduce neuron activity. It is possible that the present 
facilitation of PR performance by biperiden and scopolamine was mediated by striatopallidal 
M1 receptors.  However, further study using disconnection lesions (Mingote et al. 2008) or cell 
specific receptor knock out mice (Jeon et al. 2010) would be needed to investigate this.  
 
5.3.8 Conclusions 
Motivational impairments are a particularly deleterious symptom common to many 
neuropsychiatric and neurodegenerative diseases, yet no therapeutic options are currently 
available. The present results indicate that targeting the M1 mAChR can increase motivation, 
in intact mice, in the absence of a number of potential mediating confounds. Biperiden in 






Chapter 6. Evaluation of ageing as preclinical model of apathy 
 
6.1 Introduction 
The work described in the previous chapter suggested that such muscarinic acetylcholine 
receptor (mAChR) antagonists appear to facilitate effort-based behaviour in intact mice 
(Chapter 5). In order to strengthen the preclinical evidence for muscarinic receptors as 
pharmacological targets, it is useful to test the pharmacological effects of these compounds in 
preclinical models of apathy. Rodent models, which are commonly used in central nervous 
system (CNS) drug discovery, aim to recreate an aspect or aspects of the human condition in a 
preclinical preparation (van der Staay 2006). Therefore, a key stage in preclinical drug 
discovery is evaluating and characterising behavioural profiles in potential animal models, 
which could subsequently be used to test the efficacy of novel therapeutics. As discussed 
previously, apathy can be modelled in rodents by changes in effort-related behaviour 
(Salamone & Correa 2012). Recent preclinical studies have identified a number of potential 
novel targets that can rescue motivated behaviours in deficit models (Simpson et al. 2011; 
Randall, Lee, Podurgiel, et al. 2014; Mingote et al. 2008). The models used include 
pharmacological (Randall, Lee, Nunes, et al. 2014; Farrar et al. 2007); genetic (Simpson et al. 
2011) and developmental manipulations (Amitai et al. 2017). 
 
There is strong evidence that non-pathological ageing is associated with neurophysiological 
changes and an associated decline in a number of cognitive processes (Morrison & Baxter 
2012; Samson & Barnes 2013). Age-related changes in hippocampal and prefrontal structure 
and function, in rodents, have been widely noted (for reviews see, Small et al. 2011; Gray & 
Barnes 2015; McQuail et al. 2015)  Behavioural changes have also been associated with ageing. 
Relative to young rats, older rats display impairments in spatial memory (Barnes 1979; 
Gallagher et al. 1993), working memory (Dunnett et al. 1988; Dunnett et al. 1990), attention 
(Muir et al. 1999) and executive function (Barense et al. 2002). These cognitive changes in rats 
match those seen in normal human ageing (Robbins et al. 1994; De Luca et al. 2003; Mani et 
al. 2005). This has led some to use aged rodents as naturalistic models of cognitive impairment 
to test the efficacy of novel compounds (Ingram et al. 1994; Ye et al. 2000; Foley et al. 2004; 
Cui et al. 2008). 
 
There is also evidence to suggest that motivated behaviour is also susceptible to age-related 
decline. Studies in human subjects have noted an increase in rates of apathy in  healthy older 
age-groups (Onyike et al. 2007).  Furthermore, a longitudinal study of subjects aged 58-85, 
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reported a significant increase in questionnaire-measured apathy scores over a five year period 
(Brodaty et al. 2010). This finding of an increase in apathy with age has since been replicated 
(Guercio et al. 2015). Although less researched than other cognitive domains, two studies have 
also reported an age-related decrease in motivated behaviour in rodents. Motivation is often 
probed in laboratory animals, through examining effort-based behaviour. Studies involving 
both mice (Bordner et al. 2011) and rats (Blokland & Raaijmakers 1993; Amancio-Belmont et 
al. 2017) have reported lower (progressive ratio) PR breakpoints in older groups of rodents. In 
the present study, we sought to confirm and explore any age-related changes in effort-related 
behaviour. Furthermore, ageing is the major risk factor for neurodegenerative disorders (Hindle 
2010), which are commonly associated with motivational impairments. Aged rodents may 
model the ‘baseline’ that a treatment aims to restore.  Therefore, it is important to explore 
whether age-related changes in physiology prevent a given pharmacological treatment from 
working. For example, there are reports of age-related reduction in mAChR expression and 
function in both rodents and humans (Morin & Wasterlain 1980; Rinne 1987; Biegon et al. 
1989; Schwarz et al. 1990; Tayebati et al. 2004). Therefore, it is also important to investigate 
whether this interferes with the effects of mAChR antagonists on behaviour.  
 
In experiment 1, alongside changes in PR performance, age-related changes in locomotor 
activity, a well-established behavioural change associated with age (e.g. Gage et al. 1984; 
Willig et al. 1987; Emerich et al. 1993; Scimonelli et al. 1999), was tested.  Subsequently, in 
experiment 2, any age-related effects on motivation were tested within a touchscreen operant 
system. Additionally, the aged rats in experiment 2 underwent a modified food restriction 
procedure in order to better control for age-related change in weights. Finally, the effects of 
scopolamine, a nonselective mAChR antagonist, on PR performance and effort-related choice 
(ERC) performance were tested in both young and aged rats. 
 
6.2 Experiment 1 
6.2.1 Methods 
Animals and ageing procedures 
Male Sprague-Dawley rats (Envigo, UK) were used in the present study. Table 6.1 provides a 
summary of the ages and number of each group of rats. Across all cohorts and in both 
experiments,  aged rats were approximately 12 months older than the young controls.  
 
The rats in experiment 1 (cohorts 1 and 2) were transferred from the breeding facility (Envigo) 
to the testing facility (Eli Lilly) at 15 months of age, along with the young control groups at 
 
131 
three months of age. Following a week of acclimatisation, they were placed on a schedule of 
controlled feeding and maintained at no less than 85% of their free feeding weight. No 
correction was applied to this 85% body weight to match the expected growth curve. All 
animals were housed in groups of 3-4 in a temperature (20-22°c) and light controlled (12hr 
light/dark cycle; lights on 0700-1900) environment. Young and aged rats were group housed 
separately (i.e. no young and aged rats were mixed). Rats were housed in transparent plastic 
individually ventilated cages, with the bedding changed once weekly. Water was available ad 
libitum throughout the study.  All testing took place within the animals’ light phase. All 
experiments were regulated under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012 and following ethical review by the local Animal Welfare and Ethical 
Review Body (AWERB) at Eli Lilly and Co. 
 
Behavioural Apparatus 
Lever-based Operant chambers 
Progressive ratio testing took place in standard operant chambers (Med-Associates) as 
described in detail in chapter 4.  
 
Open field arenas 
Spontaneous locomotor activity was assessed in 40 x 40 cm open field areas, surrounded by 30 
cm Perspex walls. Testing took place within a dark room containing four infrared tables (100 
x 100 cm). Four open fields were placed on each table. Locomotor activity was monitored by 
overhead infrared cameras (Sanyo VCV-3412P, Tracksys Ltd., UK). Cameras relayed data to 
a computer which ran the analysis software (Ethovision XT v8.5; Noldus, Netherlands). Rats 
were allowed to freely explore the arenas for 120 minutes. Locomotor activity, as distance 
travelled, was measured in 5-minute bins for the total 120-minutes.  
 
Behavioural Assays 
The lever-based PR pre-training and training took place as described in detail in chapter 4.  R 
rats were trained  to respond on the  (5 * e(0.2*n)- 5)  exponential PR schedule for ten sessions . 
Following this, breakpoints were analysed in response to the standard one pellet reward. 
 
Statistics 
Repeated measures ANOVAs  and paired t-tests were used to evaluate age-related differences 
in all tasks. Greenhouse-Geisser corrections were applied to any violations of sphericity. Partial 
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eta squares were reported for all significant results. Bonferroni corrections were applied for 
any post-hoc tests. 
 
6.2.2 Results 
Aged rats display reductions in motivated behaviour and locomotor activity 
Figure 6.1A shows that during the PR testing, breakpoints were significantly lower in aged rats 
(t(38) = 2.610, p < .05). This suggests that young animals are willing to exert significantly 
greater effort for equivalent food rewards. The effects of age on spontaneous locomotor activity 
can be seen in figure 6.1B. The distance travelled within each 5-minute bin was affected by 
both age (F(1,38) = 46.107,  p  < .001; partial eta squared = .542) and time (F(23,897) = 71.480,  
p  < .001; partial eta squared = .647). There was also a significant age x time interaction on the 
distance travelled (F(23,897) = 3.254,  p  < .001; partial eta squared = .077). The young rats 
travelled significantly greater distances in the first 16 bins. Together, this suggests that the aged 
group showed both reduced PR performance and spontaneous locomotor activity 
 
 
Figure 6.1: Effects of ageing on motivation, and locomotor activity in cohort 1. A Aged 
animals show reduced breakpoints on a PR schedule of reinforcement. B Aged rats travel less 
distance in an open field. Young: 6-8 months; Aged: 18-20 months old.  Error bars are ± SEM. 
* A significant difference between aged and young animals p < .05. 
 
Replication of the age-related deficit in motivated behaviour  
As with the first cohort, breakpoints were lower in the aged rats (t(35) = 3.290,  p  <.01; figure 
6.2A). Figure 6.2B shows again, reduced spontaneous locomotor activity in aged rats. The 
open-field distance travelled decreased with time (F(11.298, 395.417) = 61.421, p < .001; 
partial eta squared = .637). Aged rats again showed lower levels of locomotor activity (F(1,35) 
= 39.422, p < .001, partial eta squared = .530). There was also a significant age x time 
interaction on the distance travelled (F(11.298, 395.417) = 6.998, p < .001; partial eta squared 
= .167). Aged rats travelled significantly shorter distances in the first four bins (20 minutes), 
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as well as bins 10, 11 and 21. Together, this suggests that young animals initially show 




Figure 6.2: Replication of the effects of ageing on motivation and locomotor activity in an 
independent cohort  (cohort 2) of rats. A Aged animals show reduced breakpoints on a PR 
schedule of reinforcement. B Aged rats travel less distance in an open field. Young: 3-4 
months. Aged: 15-16 months old. Error bars are ± SEM. * A significant difference between 
aged and young animals p < .05; ** p < .01 
 
Group differences in body-weight 
Body-weights, as shown in table 6.1, were greater in aged rats. In cohort 1, the mean weight 
during testing was significantly greater in aged rats (t(38) = 14.891,  p < .001). Similar 
differences were observed in cohort 2, where aged rats also had significantly greater mean 
body-weights (t(23.263) = 46.009,  p  <.001). 
 
6.2.3 Discussion 
The present results suggest that ageing in the absence of any specific pathology is associated 
with a reduction in both effort-based behaviour and spontaneous locomotor activity. It was 
important to replicate this effect, as the behavioural consequences of ageing may be sensitive 
to effects such as differential life experience. The replication of the age-related deficit raises 
the possibility that ageing may be a useful model to test the effects of mAChR antagonists on 
motivation. However, aged rats were notably heavier than the young controls. It is possible that 
this could confound results, through a reduction in the primary motivation for food rewards. 
PR performance, at least within-subjects, declines with increasing body-weight (Ferguson & 
Paule 1997).  Therefore, an attempt should be made to better control for age-related increases 




6.3 Experiment 2 
 
6.3.1 Methods 
Animals and ageing procedures 
The purpose of experiment 2 was firstly to examine whether the age-related decline in PR 
performance remained in aged animals that were exposed to long-term controlled feeding. To 
achieve this, aged rats were placed on a schedule of controlled feeding from adulthood and 
maintained on this schedule throughout the ageing process.  
  
All rats (male, Sprague-Dawley) in experiment 2 were initially housed in an external holding 
facility (Agenda Life Sciences, Hatfield, UK), having been transferred from the breeding 
facility (Envigo, UK) at four weeks old. All animals (both young and aged) were placed on a 
schedule of controlled feeding at three months of age with body-weights regularly monitored. 
Young and aged were then transferred to the testing facility (Cambridge) for behavioural 
testing (at approximately three and fifteen months of age respectively, as in experiment 1). 
Therefore, all aged rats had restricted feeding for at least twelve months prior to behavioural 
testing (see table 6.1, Young cohort weight at start of training: 408g ± 4.5, start of testing 412g 
± 5.5; aged cohort start of training 477g ± 5.7, start of testing 485g ± 5.6). 
 
There were also some housing and husbandry differences in experiment 2. Rats were group 
housed in standard open top plastic cages (2-3 per cage) in a light- and temperature-controlled 
environment (lights on 1900-0700). All testing took place 5-7 days/week, in the animals’ dark 
phase. Bedding was changed twice weekly. All experiments were regulated under the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations 2012 and following ethical review 
by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 
 
 
 Young Aged 
 Age at 
test (N) 
Weight (g) Age at 
test (N) 
Weight (g) 
Experiment 1 Cohort 1 6-8 (23) 457.59 ± 8.63 18-20 (17) 564.65 ± 7.64 
Cohort 2 3-4 (20) 292.01 ± 2.82 15-16 (17) 690.76 ± 7.72 
Experiment 2 Cohort 3 (PR) 4-7 (15) 404.80 ± 8.27 16-19 (19) 471.84 ± 5.70 
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Cohort 4 (ERC) 7-9 (19) 432.67 ± 11.61 19-21 (18) 484.56 ± 6.14 
Table 6.1: Details of each experimental cohort. Age in months, is accompanied by the numbers 
in each group. The mean bodyweight of each cohort and the SEM in parentheses. PR 
Progressive Ratio; ERC: Effort related Choice 
 
Behavioural Apparatus 
In experiment 2 all testing took place in standard Bussey-Saksida rat touchscreen chambers 
described in detail previously (Chapter 2).  
 
Behavioural Assays 
Touchscreen progressive ratio schedule 
Standard touchscreen pretraining was administered as described in chapter 2. Animals were 
then trained on the PREXP (5 * e(0.2*n)- 5)   schedule described previously (chapter 2). 
 
Effort-Related Choice task 
ERC pretraining was performed as previously described (chapter 3), to a separate cohort of 
young and aged rats. Due to the low number of trials completed previously a FR3 schedule, as 
opposed to a FR5 schedule, was used alongside the freely available chow. Animals initially 
received four FR3 with chow habituation sessions. Subsequently animals received three 
consecutive sessions each of FR3, FR9 and FR15 ERC tests. Performance from the three 
sessions at each ratio were collapsed for data analysis. All behavioural measured were analysed 
as described previously.  
 
Drugs 
Scopolamine hydrobromide was dissolved in physiological saline and administered at a volume 
of 1 mg/ml, via IP injection, 30 minutes prior to testing. Doses of 0.1 and 0.3 mg/kg (PR) and 
0.3 mg/kg (ERC) were utilised. All rats received a single habituation injection of saline prior 
to administration of any compounds. Scopolamine was administered in a within-subject Latin 




Group differences in body-weight 
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As in experiment 1 the mean body-weights during both PR testing (t(32) = 6.881, p < .001) 
and ERC testing (t(20.878) = 3.987, p< .01). However, as shown in table 6.1, the magnitude 
in the age-related differences in weights was substantially smaller in experiment 2. 
 
Aged rats fail to show any motivational deficits on touchscreen PR 
Initially, the previous effect of ageing on PR performance was examined using a touchscreen 
operant system. Figure 6.3A shows that, unlike the previous experiment, there was no 
significant difference in breakpoint between the two age groups (t(32)= .332,  p = .742). PRPs 
were also not affected by the age of the rats (t(32)= .686,  p = .231). Measures of general 




Figure 6.3: Effects of ageing on touchscreen PR performance.  A Aged rats do not any deficit 
in PR. B The predicted peak response rate was not affected by age. C The decay rate did not 
differ between groups. D The pausing between response bouts was not affected by age. Young: 
4-7months; Aged 16-19 months old.  Error bars are ± SEM.  
 
Analysis of response rates suggests that age did not affect the pattern of responding (figures 
6.3B-D). The peak response rate (figure 6.3B) did not differ between the age groups (t(32)= 
.145,  p = .886). The rate of decay in responding (figure 6.3C) was not significantly affected 
by the age group (t(32)= .102,  p = .919). The average length of response bouts was also not 
affected by the age group (t(32)= .265,  p = .279). Figure 6.3D shows that the mean length of 
the inter-bout pausing did not differ between age groups (t(32)= .853,  p = .400). Together, 
these data suggest that this cohort did not display age-related differences in motivated 
behaviour or activity levels.  
 
Progressive ratio Young  Aged 
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Reward Collection latency (s) 1.57 ± .14 1.45 ± .12 
IR Beam Breaks per sec .10 ± .01 .09 ± .01 
Nontarget Touches per sec .03 ± .01 .04 ± .01 
Magazine entries per sec .06 ± .00* .04 ± .00* 
Table 6.2: Effects of ageing on measures of motoric activity during PR performance. Young: 
4-7months; Aged 16-19 months old. * significant group difference (p < .001)   All values are 
expressed as means ± SEM. 
 
Scopolamine facilitates PR performance in both young and aged rats 
The effects of scopolamine administration was subsequently tested in both young and aged 
rats. Figure 6.4A shows how breakpoints were significantly increased following scopolamine 
administration (F(1.567, 50.144) = 8.940,  p  < .001; partial eta squared = .218). There was 
also a significant effect of age group (F(1,32) = 4.523,  p  < .05; partial eta squared = .124). 
However, there was no interaction between age and scopolamine on breakpoint (F(1.567, 
50.144) = 8.940,  p  < .001; partial eta squared = .218).  As seen in figure 6.4B, post 
reinforcement pausing was not significantly affected by scopolamine (F(2,64) = .111,  p  = 
.895; partial eta squared = .126). There were also no effects of age (F(1, 32) = .327,  p  = .571), 
nor any age x scopolamine interaction on the duration of PRPs (F(2,64) = .982, p  = .380). 
Measures of motoric activity are available in table 6.3 
 
 
 Young Aged 
Dose Scopolamine 
(mg/kg) 
Veh 0.1 0.3 Veh 0.1 0.3 
Reward Collection 
latency (s) 
1.66 ± .18 1.76 ± .20 1.53 ± .56 1.50 ± .16 1.60 ± .17 2.47 ± .50 
IR Beam Breaks per 
sec 
.09 ± .01 .14 ± .02 .13 ± .02 .08 ± .01 .09 ± .01 .13 ± .01 
Nontarget Touches per 
sec 
.01 ± .00 .01 ± .00 .01 ± .01 .01 ± .00 .01 ± .00 .02 ± .00 
Magazine entries per 
sec 
.05 ± .01 .08 ± .01 .08 ± .00 .05 ± .01 07 ± .01 .09 ± .01 
 
Table 6.3: Effects of ageing and scopolamine on measures of motoric activity during 
progressive ratio performance. All values are expressed as means ± SEM. Young: 4-7months; 




 The predicted peak response rate was not affected by either scopolamine (F(1.000, 32.001) = 
1.805,  p  = .189) or age (F(1,32) = 1.747,  p  = .196). There was also no interaction between 
age and dose on the peak response rate (F(1.000, 32.001) = 1.735,  p  = .185).  Scopolamine 
did however, significantly increase the rate of decay in responding, as seen in figure 6.4C 
(F(1.322,33.145) = 4.245,  p  < .05; partial eta squared = .117). There was no effect of either 
age on the rate of decay in responding (F(1,32) = 2.274,  p  = .141) or any interaction between 
age and dose (F(2,64) = 2.358,  p  = .103). The mean length of response bouts was significantly 
reduced by administration of scopolamine (F(2,64) = 4.594,  p < .05; partial eta squared = 
.126). However, there were no effects of age (F(1,32) = .185,  p = .670) or any age x 
scopolamine interaction on bout length (F(2,64) = .917,  p  = .405). The length of pausing 
between bouts was not affected by neither scopolamine (F(2,64) = 1.943,  p  = .152), age group 
(F(1,32) = 1.707,  p  = .201), nor any interaction between age and dose (F(2,64) = 1.393,  p  = 
.256) on the length of pausing between response bouts. These data replicate the effects of 
scopolamine on PR performance previously reported in mice, of enhancing effort expenditure 
on a PR schedule of reinforcement. There was no evidence of any differential effects of 
scopolamine with age, as scopolamine enhanced motivated behaviour equally in both young 
and aged rats. This suggests that the efficacy of the drug is not affected by a potential age-
related decline in muscarinic receptors. 
 
 
Figure 6.4: Scopolamine facilitates PR performance in young and aged rats.  A Scopolamine 
dose-dependently increases breakpoint. B Neither scopolamine nor age affect the post 
reinforcement pause (PRP).  C Scopolamine, at high doses, can increase the rate of decay in 
responding. D Neither age nor scopolamine significantly affect the length of pausing between 
response bouts. Young: 4-7 months; Aged 16-19 months old.  Error bars are ± SEM. 
 
Aged rats do not show any motivational deficits on touchscreen ERC 
The previous results suggest that in long-term food controlled aged rats, effort exertion does 
not differ from young controls. We intended to extend these findings by investigating whether 
a separate facet of motivated behaviour, effort-related decision making, was affected by ageing. 
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Performance of a separate group of young and aged rats was compared on the previously 
validated effort related choice (ERC) task, in a new cohort of animals. 
 
The ratio requirement for the food pellet reward was increased across sessions from FR3 to 
FR9 and FR15. Figure 6.5A shows that increasing the ratio requirement significantly reduced 
the number of trials completed (F(1.087,32.623) = 281.100,  p  < .001; partial eta squared = 
.904). In contrast, the number of trials completed did not differ between age groups (F(1,30) = 
1.794, p = .191). There was however, a significant interaction between age and ratio on the 
number of trials completed (F(1.087,32.623) = 4.383,  p  < .05; partial eta squared = .127). In 
both young and aged rats, the number of trials completed within each ratio condition differed 
significantly from each other condition (all p < .05). However, there was no difference, between 
age groups, in the number of trials completed at any ratio (all p >.05).  
 
Increasing the ratio requirement, as seen in figure 6.5B, significantly increased the amount of 
chow consumed (F(2,60) = 27.722,  p  < .001; partial eta squared = .471). Overall, aged animals 
also consumed significantly more chow than the young group (F(1,30) = 4.268,  p  < .05; partial 
eta squared = .125). There was no interaction between the ratio requirement and age group 
(F(2,60) = .747,  p  = .478). Figure 6.5C shows that increasing the ratio requirement 
significantly increased the duration of the mean PRP (F(1.492,44.746) = 34.137,  p  < .001; 
partial eta squared = .532). The duration of PRPs was not affected by either age (F(1.30) = 
.159,  p  = .693) or by any interaction between age and ratio (F(1.492,44.746) = .816,  p  = 
.417).  Measures of general activity also did not differ between age groups, as seen in table 6.4. 
Together, these results suggest that ageing did not affect effort-related decision making, with 
young and aged rats equally affected by increasing the costs associated with a high value 
reward.   
 
Figure 6.5: Age does not affect effort-related choice performance. A Increasing the ratio 
requirement decreases the number of trials completed. B Increasing the ratio requirement 
increases chow consumption. C The length of post reinforcement pausing (PRP) increases at 




 Young Aged 
Ratio FR3 FR9 FR15 FR3 FR9 FR15 
Reward Collection 
latency 
2.69 ± .79 1.87 ± .26 1.55 ± .14 3.43 ± .69 1.70 ± .23 1.50 ± .12 
IR Beam Breaks per 
sec 
.12 ± .01 .08 ± .01 .07 ± .01 .09 ± .01 .06 ± .01 .05 ± .01 
Nontarget Touches 
per sec 
.001 ± .00 .001 ± .00 .001 ± .00 .002 ± .00 .003 ± .00 .002 ± .00 
Magazine entries 
per sec 
.04 ± .00 .01 ± .00 .01 ± .00 .03 ± .00 .01 ± .00 .01 ± .00 
 
Table 6.4: Effects of ageing and ratio requirement on measures of motoric activity during 
effort-related choice performance. All values are expressed as means ± SEM.  Young: 7-9 
months; Aged 19-21 months old 
 
Scopolamine interferes with effort-related choice behaviour in young and aged rats 
The effect of scopolamine (0.3 mg/kg) was tested on the ERC assay using an FR3 schedule of 
reinforcement. Figure 6.6A shows scopolamine administration significantly reduced the 
number of trials completed (F(1,30) = 9.774,  p  <.01; partial eta squared = .240). However, 
the number of trials completed was not affected by either age (F(1,30) = .656,  p  = .424) or by 
any interaction between age and drug (F(1,30) = .305,  p = .583). In contrast, scopolamine 
administration produced no significant effect on chow consumption,  as shown in figure 6.6B 
(F(1,30) = 2.766  p  = .106). Chow consumption was not affected by age group (F(1,30) = .234,  
p = .632) or by any interaction between age and scopolamine (F(1,30) =.200  p = .658). Figure 
6.6C suggests that there were no significant effects on the duration of PRPs [scopolamine 
(F(1,30) =1.586  p = .221); age (F(1,30) =1.284  p = .269); age x scopolamine interaction 
(F(1,30) =.048  p = .827)]. The effects of scopolamine administration on motoric measures can 
be seen in table 6.5. 
 
 Young Aged 
Dose Scopolamine (mg/kg) Veh 0.3  Veh 0.3 
Reward Collection latency 4.76  ± 3.53 2.35 ± 1.50 7.43 ± 4.02 5.24 ± 1.27 
IR Beam Breaks per sec .07 ± .01 .09 ± .02 .07 ± .01 .09 ± .01 
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Nontarget Touches per sec .001 ± .00 .002 ± .00 .001 ± .00 .002 ± .00 
Magazine entries per sec .02 ± .00 .02 ± .00 .02 ± .00 .02 ± .00 
 
Table 6.5: Effects of ageing and scopolamine on measures of motoric activity during effort-
related choice performance. All values are expressed as means ± SEM.  Young: 7-9 months; 
Aged 19-21 months old 
 
Together, these results suggest that scopolamine supresses touchscreen responding equally in 
both young and aged rats. In spite of facilitating unspecific activity levels (indexed by the rate 
of beam breaks and nontarget screen responses) scopolamine reduced the number of trials 
completed and the amount of chow consumption. 
 
Figure 6.6: Effects of scopolamine and ageing on an ERC task. A Scopolamine reduces the 
total number of trials completed in both young and aged rats. B Neither scopolamine nor ageing 
affect the amount of chow consumed. C Scopolamine increases the length of the post 
reinforcement pause (PRP). Young: 7-9 months; Aged 19-21 months old ERC: Effort related 
choice   Error bars are ± SEM. 
 
6.3.3 Discussion 
When tested on the previously validated touchscreen-based assays of motivation (chapters 2 
and 3), aged rats did not show any evidence of a motivational deficit compared to younger 
control animals. Aside from differences in the housing/husbandry conditions (see methods), 
the major difference between experiments 1 (Eli Lilly) and 2 (Cambridge) was the control of 
feeding behaviour throughout the ageing process. When aged animals underwent long term 
(>12 months) controlled feeding, no motivational deficit was observed. The effects of these 
additional feeding controls can be observed by a reduction in size of the group differences in 
body-weights  between the experiments (table 6.1). This raises the possibility that the effects 
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observed in experiment 1 were driven primarily by a reduction in appetite or the value of food 
rewards. 
 
It should also be noted that a separate possibility is that differences  in the results of experiments 
1 and 2 arise from the operant systems used. In the young cohorts, breakpoints were 
substantially higher when tested on the lever-based PR system. Measures of responding (such 
as breakpoint) are substantially lower in rats tested on touchscreen-based tasks (reviewed in 
chapter 2). The lower baseline performance may have reduced the sensitivity of the task to 
detect an age-related change in PR performance. Differences in the rates of responding between 
touchscreen-based and lever-based operant systems may have obscured an age-related effect. 
As shown in table 6.6, there was a tendency across all PR conditions for young animals not to 
reach a breakpoint within the 45-minute session (i.e. not to have undergone 180s without a 
screen response).in other words, the previous results may have reflected in parts differences in 
rates of responding, rather than differences in effort exertion per se. The use of a longer 
touchscreen PR session may have help investigate such an age related-effect. 
 
 Young Aged 
PR Baseline 11/75 4/95 
Veh 0/15 0/19 
0.1 mg/kg scopolamine 3/15 1/19 
0.3 mg/kg scopolamine 6/15 5/19 
 
Table 6.6: Number of sessions ending with rats failing to reach breakpoint during touchscreen 
progressive ratio training and during the scopolamine experiment. 
 
It should also be noted that in the attempt to better control for differences in body-weight aged 
animals were food restricted for a significantly longer period of time. It is possible that the 
chronic food restriction conceals any deficit in effort exertion by an increase in the motivation 
for food. However, if this were the case it may be expected that the aged animals would 
consume significantly more freely available chow in the ERC assay, however this was not the 




Effect of scopolamine on effort-based behaviour in rats 
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In spite of a lack of an age-related deficit in motivation, it was still important to test the effects 
of mAChR antagonism on effort-based behaviour. Firstly, to extend our previous results in 
mice (chapter 5) to a separate species using tasks reinforced with a different (dry) food reward. 
Secondly, as some changes in mAChR function with age have been noted (Morin & Wasterlain 
1980; Rinne 1987; Biegon et al. 1989; Schwarz et al. 1990; Tayebati et al. 2004), it is useful to 
test whether mAChR antagonism was able to affect behaviour.  Scopolamine dose-dependently 
enhanced PR performance. This result replicates those found previously and suggests that age 
related changes in mAChR function or expression do not substantially affect the efficacy of 
mAChR antagonists on behaviour.  
 
Subsequently, the effective dose of scopolamine was found to interfere with ERC performance, 
indexed by the number of touchscreen trials completed. This result was unexpected given that 
scopolamine facilitated effort exertion in PR and previously scopolamine did not suppress the 
number of trials completed by mice (chapter 5). There are other examples of pharmacological 
interventions facilitating PR performance but interfering with effort-related decision making. 
For example, amphetamine increases PR breakpoints (Poncelet et al. 1983). In contrast, 
amphetamine supresses trials completed in an FR/choice ERC task (Cousins et al. 1994), albeit 
at higher doses than those effective in PR. This suppression is likely to be a consequence of 
the appetite supressing effects of amphetamine (MacPhail & Gollub 1974). Similar effects may 
be occurring following scopolamine administration. Scopolamine can supress consumption of 
dry foods, likely due to the peripheral actions given rise to ‘dry-mouth’ type symptoms 
(Drevets & Furey 2010; Hodges et al. 2009). This may limit the rats’ ability to consume large 
amounts of food pellets in ERC. This is less likely to affect PR performance given the low 
amount and frequency of rewards earned.  Furthermore, liquid reinforcers are less susceptible 
to these peripheral effects of scopolamine administration (Hodges et al. 2009), which could 
explain why we previously (chapter 5) did not find a suppression of FR5 performance 
reinforced with milkshake. In line with this explanation, there was a trend for scopolamine to 
decrease the amount of chow consumed. 
 
A related possibility is that scopolamine affects decision-making processes. Scopolamine is 
often used to disrupt cognition in rodents (Klinkenberg & Blokland 2010). Alongside effort, 
the costs of an action can be altered by altering the delay to reinforcement (Thiébot et al. 1985; 
Winstanley et al. 2003) or the probability of a reward being delivered (Richards et al. 1999). 
Increasing the delay or decreasing the probability of reinforcement will shift responding to a 
less preferred reward choice (Winstanley et al. 2003; Richards et al. 1999). Crucially, 
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scopolamine also interferes with both delay-based and probability-based decision making. A 
number of pharmacological interventions have been shown to potentiate the effects of 
increasing costs on behaviour, increasing the rate of discounting (e.g. Winstanley et al. 2003; 
2006; Floresco et al. 2008). Such manipulations typically have little effects when the costs 
associated with the large reward are low. In contrast, scopolamine affects large reward choices, 
even in the absence of any costs (Mendez et al. 2012). Furthermore, scopolamine has been 
shown to affect the time taken to make a choice in a rodent gambling task (Silveira et al. 2015). 
Together, these results suggest that scopolamine may interfere with a rat’s ability to choose 
between multiple actions. Such an effect could explain the reduction in ERC trials completed 
in the present study. Conversely, in PR where there is no choice to be made, disruptions to 
decision-making may not interfere with performance. 
 
6.4  General Discussion 
 
6.4.1 Ageing as an inconsistent model of apathy 
Across species, ageing is associated with a decline in a number of cognitive processes 
(Morrison & Baxter 2012; Samson & Barnes 2013).  Concomitant declines in motivated 
behaviour with age, have also been reported across species (Onyike et al. 2007; Bordner et al. 
2011; Blokland & Raaijmakers 1993). The present chapter sought to establish and explore a 
potential age-related decline in motivated behaviour in rats, in order to test to efficacy of 
putative motivation enhancing compounds. Motivated behaviour was initially tested by 
examining lever pressing for food under a PR schedule of reinforcement. Aged rats had 
significantly lower breakpoints than animals 12 months younger, indicating lower motivation 
to work for food rewards.  This deficit was subsequently replicated in a separate group of aged 
rats. However, both cohorts also had significantly different between-group bodyweights.   It is 
possible that any age-related deficit was confounded by differences in weight. Therefore, an 
attempt was made to better control for weight differences by controlling the feeding of the aged 
rats throughout adulthood. Although the aged rats in the subsequent experiment still had 
significantly higher body-weights than the young controls, the magnitude of the difference was 
smaller. With this additional control, aged rats did not display any differences in motivated 
behaviour compared to their young controls.   
 
The life-extending effects of long-term controlled feeding in rats have been long known 
(McCay et al. 1935). Further research has revealed a dose-dependent effect of calorific 
restriction on life-expectancy in rats (Weindruch et al. 1986). Reducing the calorific intake of 
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rodents has been shown to reduce physiological processes associated with age such as 
development of tumours and myocardial degeneration (Tannenbaum 1942; Yu et al. 1982). In 
addition, long-term calorific restriction reduces age-related neurophysiological changes in 
rodents (Joseph et al. 1983; Levin et al. 1981). Alongside the many physiological benefits, 
calorific restriction has been shown to reduce age-related behavioural changes. Life-long 
calorific restriction improves performance in assays of spatial memory (Stewart et al. 1989; 
Adams et al. 2008; Yang et al. 2014) as well as improving motor coordination (Ingram et al. 
1987). Together, these studies indicate that food restriction reduces the rate of neurocognitive 
ageing in rats (Gallagher et al. 2011). In the present study, it is possible that the long-term 
controlled feeding in experiment 2 preserved the cognitive processes regulating motivation, 
preventing the decline in motivated behaviours seen in aged rats in experiment 1. An alternative 
possibility is that the age-related PR performance did not reflect changes in motivation, but 
instead reflect changes in appetite or satiety. The long-term controlled feeding may have 
prevented or reduced the changes in the primary motivation for food, which may have 
confounded the previous PR results. Whether due to the neuro-protective effects of food 
restriction or differences in appetite, these studies highlight the potential confounding effects 
of food restriction in ageing studies. It should also be noted that previous reports of age-related 
changes in PR performance (Blokland & Raaijmakers 1993; Bordner et al. 2011; Amancio-
Belmont et al. 2017) do not report any methods for controlling for differences in body-weight 
between the groups. The lack of appropriate controls may be the reason why these previous 
studies, like experiment 1, report age-related differences in PR performance. 
 
A separate approach to investigate the effect of ageing on apathy would be to use a within 
subject design to investigate changes in effort exertion across a rodent’s lifespan. PR may be 
especially suited to this, as PR is believed to have fewer effects of repeated testing than other 
rodent assays (Yhnell et al. 2016). Whereas, this would be a useful approach to investigate age-
related changes in motivation, this would not fulfil the primary aim of this chapter in 
characterising a deficit model, against which to test the potential pro-motivational effects of 
mAChR antagonists.  
 
6.4.2 Conclusions 
A series of experiments suggest that the previously reported age-related decline in PR 
performance in rodents is not a robust effect. Aside from concomitant declines in locomotor 
activity could potentially confound PR performance, long-term controlled feeding appears to 
abolish the motivational deficit observed in aged rats. However, this may in part be due to the 
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limitations of the methodology employed. From the data presented in this chapter it is not 
possible to conclude whether the failure to replicate the initial age-related deficit was due to 
differences in the food restriction procedures or the differences in the operant systems 
employed. None of the previous studies reporting age-related deficits in PR performance in 
rodents (Blokland & Raaijmakers 1993; Bordner et al. 2011; Amancio-Belmont et al. 2017) 
, have reported either efforts to control for differences in body weight or response rates between 
groups. Taken together, these results indicate that aged rats may not be a suitable model against 
which to test the pro-motivational effects of muscarinic receptor antagonists, with further 





Chapter 7. Biperiden rescues a model of antipsychotic-induced amotivation 
 
7.1 Introduction 
Previous studies investigating novel therapeutic targets for motivational impairments have 
tested the efficacy of compounds in rescuing the deficits induced by pharmacological 
manipulations (e.g. Farrar et al. 2007; Sommer et al. 2014; Yohn, Collins, et al. 2016). 
Numerous studies have implicated dopamine in supporting effort-based behaviour (Salamone 
1988; Salamone et al. 1991; Salamone & Correa 2012, reviewed in chapter 1). Systemic 
administration of dopamine receptor antagonists can disrupt performance on progressive ratio 
(PR) schedules (Cheeta et al. 1995) and effort related choice (ERC) tasks (Salamone et al. 
1991; Salamone et al. 1994), in the absence of any significant effects upon appetite or motoric 
output (Salamone 1986; Salamone et al. 1991). A number of studies have subsequently tested 
the efficacy of compounds in reversing the motivational deficits induced by dopamine receptor 
blockade (Worden et al. 2009; Nunes et al. 2010). Among the compounds used to induce the 
initial deficit, the dopamine D2 receptor antagonist haloperidol is particularly relevant given its 
use as an antipsychotic treatment. There is evidence to suggest that typical antipsychotics, 
including haloperidol exacerbate symptoms of apathy in patients with schizophrenia 
(Artaloytia et al. 2006) and affect motivation in healthy subjects (Saeedi et al. 2006; Mas et al. 
2013). Systemic haloperidol has been used as a deficit model in both lever- and maze-based 
ERC tasks (Farrar et al. 2007; Mott et al. 2009). In these studies, co-administration of an 
adenosine A2A receptor antagonist was able to rescue the deficit in effort-related decision 
making. 
 
Previous results (Chapter 5) suggest that the M1 receptor antagonist biperiden can facilitate 
motivated behaviour in intact mice. However, the evidence for therapeutic potential of this 
compound would be strengthened by also reversing a deficit. Therefore, in the present chapter 
the efficacy of biperiden in reversing a haloperidol-induced deficit in PR performance was 
examined. Given the previous results, it was hypothesised that biperiden would reverse the PR 
deficit induced by haloperidol. Scopolamine was also included as a positive control. 
Previously, neither scopolamine nor biperiden affected ERC performance. However, as 
discussed, this may have been due to a ceiling effect. Therefore, the effects of scopolamine and 
biperiden following haloperidol administration on ERC performance were also tested. 
 




Sixteen male C57BL/6 mice were used in this study. Mice were aged 8 weeks at the beginning 
of behavioural training.  Animals were maintained at no less than 85% of their free feeding 
body-weight. No correction was applied to this 85% control weight to match the expected 
growth curve (weigh at start of testing: 23.3g ± 0.3).  All husbandry, housing and feeding 
procedures and ethical considerations were identical to those previously described in detail 
(chapter 5).  
 
7.2.2 Apparatus   
All testing took place within Bussey-Saksida mouse touchscreen chambers (chapter 5). 
 
7.2.3 Behavioural procedures 
The experimental timeline can be seen in figure 1. Initially, animals underwent touchscreen PR 
pretraining as described previously (chapter 5). Once stable PR performance has been reached 
animals underwent pharmacological PR challenge.  
 
Subsequently animals trained upon ERC. This consisted of three consecutive days of 
uncapped-FR5 sessions (as described earlier, chapter 5), followed by seven consecutive days 
of ERC sessions where approximately 5g of chow was placed in the chambers and an otherwise 
normal uncapped FR5 session was run. Following this, the drugs were administered as detailed 
below. All behavioural measures for PR and ERC were analysed as detailed earlier (chapter 5). 
 
7.2.4 Drugs 
All compounds were administered via intraperitoneal (IP) injections at a volume of 10ml/kg of 
each animal’s bodyweight. 0.1mg/kg haloperidol (Bio-techne, Abingdon, UK) was dissolved 
in 0.2% tartaric acid and administered 40 minutes prior to testing. This dose was chosen at it 
can reduce effort output in the absence of any significant motoric effects in mice (Pardo et al. 
2013; Correa et al. 2016). In the vehicle only condition, 0.2% tartaric acid was used as a 
vehicle. The pH was checked prior to administration. 0.3 mg/kg scopolamine hydrobromide 
and 3mg/kg biperiden hydrochloride (both Bio-techne, Abingdon, UK) were dissolved in 
physiological saline and administered 30 minutes prior to testing. Doses were selected based 
on those used previously (chapter 5). 
 
7.2.5 Experimental design 
Compound administration was performed identically for both PR and ERC tests, in a within-
subject design.  On each testing day mice received two injections. Initially mice received an 
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injection of either vehicle (0.2% tartaric acid) or haloperidol. These were followed 
approximately 10 minutes later with an injection of either vehicle (saline), scopolamine or 
biperiden. This created the following conditions: Vehicle/vehicle, haloperidol/vehicle, 
haloperidol/scopolamine and haloperidol/biperiden. Injections were administered to 
alternating IP sites to minimise distress to the mice. A single baseline day without drugs was 
administered in between all test days. The behavioural measures and statistical analyses took 
place for PR and ERC as previously described (see chapter 5). 
 
 
Figure 7.1: A timeline summarising the order of the experimental procedures. PR: Progressive 
ratio. ERC Effort related choice 
 
7.3 Results 
7.3.1 Biperiden and scopolamine reverse a haloperidol-induced deficit in PR performance 
Figure 7.2A shows a main effect of drug administration on breakpoint (F(3,45) = 14.680,  p  < 
.001; partial eta squared = .495). Administration of haloperidol significantly reduced 
breakpoints relative the vehicle only condition (p < .001). Co-administration of either 
scopolamine (p < .05) or biperiden (p < .01) with haloperidol, significantly increased 
breakpoint compared to haloperidol alone. No other comparisons were significant (all p > .05). 
In contrast to the effects on breakpoint, PRPs were not significantly affected by drug 
administration (F(3,45) = .304,  p  = .822 figure 7.2B). The latency to collect rewards was 
however, significantly affected by drug administration (F(3,45) = 4.144,  p  < .05; partial eta 
squared = .216; figure 7.2C). Reward collection latencies were significantly longer in the 
haloperidol/scopolamine condition relative to vehicle (p < .01). No other comparisons were 
significant. 
 
Overall, the rate of IR beam breaks, as shown in figure 7.2D, was significantly affected by drug 
administration (F(2.235,33.521) = 4.245, p < .05; partial eta squared = .221); however, there 
were no significant differences between any condition (all p > .05). The rate of nontarget screen 
touches was also affected by drug administration (F(3,45) = 4.484, p < .01; partial eta squared 
= .230; figure 7.2E). Administration of haloperidol significantly reduced the rate of nontarget 
touches compared to the vehicle only condition (p < .01). This reduction was significantly 
reversed by biperiden (p < .05) but not scopolamine (p = .08). The rate of magazine entries was 





also significantly affected by drug administration (F(1.799,26.986) = 11.126, p < .001; partial 
eta squared = .426). The rate of magazine entries was significantly higher in the 
haloperidol/scopolamine condition relative to all other conditions (all p < .05). No other 
comparisons were significant. 
 
The pattern in responding was also somewhat affected by haloperidol. There was no effect 
upon the predicted peak response rate (F(1.013,15.193) = 1.355,  p  = .263). However, the 
decay rate in responding was significantly affected (F(1.399,27.388) = 4.438, p < .05; partial 
eta squared = .228), although there were no significant differences between any condition. The 
average response bout length was not affected by drug administration, although there was a 
trend towards an effect (F(1.974,29.613) = 2.631, p = .089; figure 7.2F). The mean pause 
between response bouts was significantly affected by drug administration (F(1.895,28.422) = 
3.828 p < .05; partial eta squared = .203); however, again there were no significant differences 
between groups. These results suggest that nonspecific antagonism of mAChRs, as well as a 
more selective M1 receptor antagonist can reverse a deficit in motivation arising from dopamine 
receptor blockade.  
 
Figure 7.2: Scopolamine and biperiden reverse a haloperidol induced deficit in PR 
performance. A Haloperidol reduces breakpoint; co-administration of either scopolamine or 
biperiden is able to reverse the effects of haloperidol on breakpoint. B No drug combination 
affects post reinforcement pause (PRP). C Reward collection latency is significantly increased 
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by a combination of haloperidol and scopolamine. D The rate of IR beam breaks were not 
affected by drug administration. E The rate of nontarget (blank) screen responses was reduced 
by haloperidol and partially rescued by co-administration of biperiden. F The mean bout length 
was not affected by any drug condition. Halo: Haloperidol 0.1mg/kg; Scop: Scopolamine 0.3 
mg/kg; Bip: Biperiden 3mg/kg. Error bars display the SEM. *p < .05, **p < .01.  
 
7.3.2 Biperiden, but not scopolamine, reverses a haloperidol induced deficit in effort-related 
choice performance 
Effort -related choice (ERC) behaviour may offer a better test of motivation (Markou et al. 
2013) and can differentiate between directional and activational components of motivation. 
However, in our previous attempts to use a touchscreen-based ERC (chapters 3,5,6), rodents 
showed low baseline levels of operant responding. Therefore, it was initially important to 
demonstrate that mice display a significant preference towards responding for milkshake over 
the freely available chow. As shown in figure 7.3, during baseline ERC performance (the mean 
performance from the final two sessions prior to drug administration) mice consumed 
significantly more milkshake from FR5 responding than chow (t(15) = 5.324, p < .001), 
suggesting a significant preference towards operant responding for milkshake.  
 
Figure 7.3: Mice show a significant preference towards FR5 responding for milkshake 
during baseline ERC testing. Error bars display the SEM. ***p < .001 
 
Drug administration, as shown in 7.4A, significantly affected the number of trials completed 
(F(3,45) = 10.386, p < .001; partial eta squared = .409). Haloperidol significantly reduced the 
number of trials completed relative to vehicle (p < .01). Co-administration of biperiden (p< 
.01), but not scopolamine (p > .05) with haloperidol, was able to increase the number of FR5 
trials completed compared to administration of haloperidol alone. Additionally, when receiving 
biperiden as treatment, mice made significantly more trials compared to when receiving 
scopolamine (p < .01). Chow consumption, as shown in 7.4B, was also affected by drug 
administration (F(3,45) = 4.861, p< .01; partial eta squared = .245). Both biperiden and 
scopolamine reduced the chow consumption following haloperidol administration (p <.05). In 
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contrast, as seen in figure 7.4C, drug administration did not significantly affect the total weight 
of food consumed, (F(1.805,27.705) = 2.879, p = .078), suggesting no changes in overall 
appetite. 
 
PRPs were significantly affected by drug administration (F(3,45) = 10.386,  p  < .001; partial 
eta squared = .409; figure 7.4D). Haloperidol significantly increased the duration of the mean 
PRP (p < .01). The effect of haloperidol upon PRPs was reversed by both scopolamine and 
biperiden (p <.01). There was also a significant effect of drug administration on the latency to 
collect rewards (F(3,45) = 11.011,  p  < .001; partial eta squared = .423, figure 7.4E). 
Haloperidol increased the reward collection latency relative to vehicle only condition (p <.01). 
Reward collection latencies following co-administration scopolamine and biperiden condition 
were also significantly longer compared to the vehicle only condition (both p < .05). The rate 
of nontarget touches was not significantly affected by drug administration (F(3,45) = 42.668,  
p  = .059).  The rate of IR beam breaks, as shown in figure 7.4F, was significantly affected by 
drug administration (F(3,45) = 3.988,  p  < .05; partial eta squared = .210); however, no 
difference between any condition was significant (all  p  > .05). There was also a significant 
effect of drug on the rate of magazine entries (F(3,45) = 11.366,  p < .001; partial eta squared 
= .431). Haloperidol administration reduced the rate of magazine entries relative to vehicle 
(p<.01). This was reversed following co-administration of biperiden (p <.01) but not 
scopolamine (p > .05). The rate of magazine entries in the scopolamine condition was lower 
than both the vehicle only and biperiden conditions (p < .05). Together, these data demonstrate 






Figure 7.4: Biperiden rescues a haloperidol induced deficit in effort-related choice 
performance. A Co-administration of biperiden, but not scopolamine alongside haloperidol 
increases the number of touchscreen trials completed. B Administration of both scopolamine 
and biperiden decrease the amount of freely available chow consumed, C No drug combination 
significantly affects the overall amount of food consumed D The duration of post reinforcement 
pauses (PRP) was significantly increased by haloperidol and reversed by co-administration of 
either scopolamine or biperiden. E Haloperidol increases the reward collection latencies, which 
were not rescued by co-administration of either drug. F No drug combination significantly 
affected the rate of IR beam breaks. Halo: Haloperidol 0.1mg/kg; Scop: Scopolamine 0.3 
mg/kg; Bip: Biperiden 3mg/kg. Error bars display the SEM. *p < .05, **p < .01 
 
7.4 Discussion 
In order to strengthen the evidence of a therapeutic benefit for biperiden, the effects of mAChR 
antagonists upon a dopaminergic deficit model of impaired effort-related behaviour were 
tested. Effort-based behaviour, measured by assays such as progressive ratio (PR) and effort-
related choice (ERC) allows for motivational deficits to be modelled within a preclinical setting 
(Salamone et al. 2015; Salamone, Yohn, et al. 2016). Subsequently, the efficacy of novel 
therapeutics in reversing these deficits could be tested. The preferential M1 antagonist 
biperiden was able to reverse the effects of the dopamine receptor antagonist haloperidol on 
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both PR and ERC performance, strengthening the preclinical evidence for possible therapeutic 
potential. 
 
7.4.1 Haloperidol as a model of amotivation 
Initially, it was important to demonstrate that haloperidol was able to induce a motivational 
deficit upon touchscreen-based assays of motivation, in mice. It was also important to examine 
whether haloperidol produced significant locomotor changes, as at high doses, dopamine D2 
receptor antagonists can impair motor output (Simón et al. 2000). It is possible that the 
subsequent actions of a compound were simply restoring motoric output, as mAChR 
antagonists have also been reported to increase locomotor activity (Meyers & Wilchin 1969; 
Chintoh 2003). At the present dose there was no evidence of any substantial motoric deficits 
following haloperidol administration prior to PR testing. In itself haloperidol did not 
significantly slow reward collection latencies or cause changes in structure of response bouts 
seen as a measure of motoric integrity (Brackney et al. 2011; Phillips et al. 2017). Dopamine 
receptor antagonists have also been observed to affect feeding behaviours (Clifton et al. 1991). 
A disruption of such processes could manifest as a disruption of PR performance resembling 
amotivation (Maccioni et al. 2008). However, haloperidol did not affect the total amount of 
food consumed in the ERC assay, instead the effect was to shift behaviour from touchscreen 
responding towards consumption of freely available chow. This result suggests that the 
suppression in responding was not as a consequence of a reduction in appetite. Haloperidol 
also significantly increased the PRP suggesting a reduction in touchscreen engagement. 
Together, these results suggest that haloperidol was effective at disrupting motivated behaviour 
on both the PR and ERC assays. 
 
It should be noted that only moderate impairments were induced in both assays. This dose of 
haloperidol has been used previously to induce a deficit in lever-based PR in rats (Olarte-
Sánchez et al. 2013), lever-based ERC in rats (Farrar et al. 2007) and maze-based ERC in mice 
(Pardo et al. 2012). Presently, haloperidol reduced breakpoint by approximately 50%, which is 
comparable to the effects of equal doses in rats (Olarte-Sánchez et al. 2013). However,  
haloperidol administration resulted in a ~ 30% reduction in touchscreen responses within the 
present ERC assay, previous studies have reported a ~90% reduction in lever-pressing (Farrar 
et al. 2007). This difference may be a result of the general lower total number of responses and 
rate of responding typically observed in touchscreen operant systems relative to lever-based 
chambers (chapter 2). Indeed, the ~30% reduction in high-effort choices is similar to the 
magnitude induced by this dose of haloperidol on maze versions of ERC tasks in both rats and 
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mice (Mott et al. 2009; Pardo et al. 2012). Taken together, these results suggest administration 
of haloperidol was successful at inducing a motivational deficit. 
 
Previous studies have used other compounds to induce a motivational deficit. The vesicular 
monoamine transport inhibitor, tetrabenazine has been widely used  as a model of amotivation 
(Nunes, Randall, Hart, et al. 2013; Randall, Lee, Nunes, et al. 2014; Yohn, Lopez-Cruz, et al. 
2016). The physiological actions of tetrabenazine are more widespread than haloperidol, 
affecting D1 receptor signalling, as well as the monoamines noradrenaline and serotonin 
(Pettibone et al. 1984). It could be argued that tetrabenazine, as a manipulation, induces a more 
physiological state of amotivation, one that may be particularly relevant to the motivational 
disturbances arising from depression (Nunes, Randall, Hart, et al. 2013). Haloperidol was 
chosen to induce amotivation given the link between motivation and the D2 receptor in 
particular (reviewed in chapter 1). Furthermore, unlike other, more selective D2 receptor 
antagonists, the effects of haloperidol on effort-related behaviour have been well validated 
(Salamone 1986; Salamone et al. 1991). Finally, haloperidol has been shown to induce 
motivational impairments in humans, suggesting a translational model of apathy (Mas et al. 
2013).  
 
7.4.2 Biperiden reverses a haloperidol induced deficit in effort related behaviour 
We previously demonstrated that the M1 receptor antagonist biperiden was effective at 
enhancing motivated behaviour in intact mice. The evidence for a potential therapeutic benefit 
of biperiden was extended by successfully reversing the PR deficit in an antipsychotic induced 
model of amotivation.  Co-administration of biperiden with haloperidol was able to reverse 
breakpoint close to baseline levels (figure 7.2A). This result strengthens the previous argument 
that mAChR antagonists facilitate motivated behaviour. Previously, it was demonstrated, at 
least in rats, that PR performance is related to neural activity within the NAc (Chapter 4). In 
humans, aberrant ventral striatal structure and function has been highlighted as a major 
contribution to apathy (e.g. Kirschner et al. 2016, see chpter 1 for a review). Subsequent studies 
may wish to examine the effects of biperiden upon NAc activity during PR responding. 
 
Biperiden was also found to rescue the effects of haloperidol upon effort-related decision 
making. ERC assays may be less susceptible to non-motivational confounds (Salamone et al. 
2002) and closer resembles some of the decision making assays used in humans (Treadway et 
al. 2009; Chong et al. 2015; Young & Markou 2015). This result demonstrates biperiden 
reverses a dopaminergic deficit in effort-related decision-making. This matches the previous 
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findings of compounds such as dopamine reuptake inhibitors (Sommer et al. 2014) and 
adenosine A2A antagonists (Farrar et al. 2007; Mott et al. 2009) at rescuing the effects of 
dopamine receptor antagonism. There is a previous report of scopolamine, infused into the 
nucleus accumbens (NAc), partially reversing the motivational deficits induced by intra-NAc 
infusion of pilocarpine, a nonselective mAChR agonist (Nunes, Randall, Podurgiel, et al. 
2013). However, the present finding is the first example of a subtype-preferential mAChR 
antagonist reversing a dopaminergic deficit in motivation. This is particularly relevant give the 
previously discussed association between dopamine and apathy. Therefore, biperiden may be 
a useful therapy for apathy in hypodopaminergic conditions.  
 
7.4.3 Scopolamine fails to reverse the deficit in effort related decision making 
Whereas scopolamine, like biperiden, reversed the induced deficit in PR breakpoints, the 
compound did not reverse the effects of haloperidol upon ERC performance. It is noteworthy 
that an effective dose of scopolamine on PR performance did not facilitate ERC behaviour. As 
discussed previously (chapter 6) scopolamine disrupts decision making processes (Mendez et 
al. 2012), which may affect ERC performance. A separate possibility is that scopolamine 
affects feeding behaviour. Whereas, there is some evidence of systemic scopolamine 
supressing food consumption in rats (Hodges et al. 2009), scopolamine at the present dose did 
not significantly affect overall food consumption (Figure 7.4C). 
 
We previously found (chapter 5) that scopolamine enhances locomotor activity, in line with 
previous reports (Meyers & Wilchin 1969; Chintoh 2003; Shannon & Peters 1990). An 
enhancement in locomotor activity would likely facilitate PR performance (Bailey et al. 2015). 
It is possible therefore, that the reversal of the PR deficit was partially mediated by an increase 
in such activity; whereas it is possible ERC performance may be less sensitive to such changes. 
It is also possible that the actions of biperiden, occurred by facilitating motor activity, which 
can be observed at higher doses (Sipos et al. 1999). This is not necessarily problematic, given 
high rates of fatigue that are associated in neurodegenerative and psychiatric conditions 
(Friedman & Friedman 1993; Karlsen et al. 2001; Chaudhuri & Behan 2000; Lou et al. 2003).  
Indeed, many of the other classes of drugs investigated as therapeutic targets for disorders of 
motivation, such as dopamine reuptake inhibitors and both 5-HT2C and adenosine A2A receptor 
antagonists also increase locomotor activity (Marriott 1968; Correa et al. 2004; Fletcher et al. 
2006; Marin et al. 2011; Browne et al. 2017). Therefore, a reduction in fatigue alongside 
motivational effects may be of clinical benefit; however, caution should be adopted that the 




7.4.4 Biperiden as a therapeutic tool 
Numerous studies have reported an association between aberrant dopamine function and 
motivation in disorders including PD (Chong et al. 2015), HD (André et al. 2010) and 
antipsychotic-induced apathy (Artaloytia et al. 2006). Together these studies highlight the 
potential clinical significance of the efficacy of biperiden in reversing a dopaminergic deficit. 
The significance of present results are further enhanced by the fact that biperiden is already 
used as an antiparkinsonian treatment, as well as a treatment for the extrapyramidal side effects 
associated with antipsychotic medication (Gjerden et al. 2009). This suggests that the 
compound can be safely administered to these patient groups, which both display high rates of 
apathy (Foussias et al. 2014; Pedersen et al. 2009). Although there are no reports of the effects 
of biperiden upon motivational function in Parkinson’s disease, there are reports that biperiden 
may reduce negative symptoms in schizophrenia (Tandon et al. 1992). However, as no specific 
measures of motivation were reported, this reduction in overall negative symptoms may be a  
consequence of the mood-enhancing effects of biperiden (Fleischhacker et al. 1987) or by 
affecting some other non-motivational symptom. 
 
There are also a number of problems that could arise from the use of mAChR antagonists as a 
therapy. Aside from peripheral side effects (Guthrie et al. 2000), the use of biperiden in 
schizophrenia has been reported to worsen symptoms such as psychosis (Tandon et al. 1992). 
Furthermore, there are reports of abuse liability (Espi Martinez et al. 2012). However, other 
studies have suggested little evidence for biperiden abuse in clinical populations (Gjerden et 
al. 2009). Another important consideration may be the potential adverse effects upon cognitive 
function. M1 receptor agonists and PAMs have also been evaluated as targets for cognitive 
enhancement (Friedman et al. 1999; Foster et al. 2014). For example, activation of M1 receptors 
improves cognitive performance across species, including humans (e.g. (Brandeis et al. 1990; 
Nathan et al. 2013; Lange et al. 2015). Conversely, biperiden and scopolamine can impair 
cognition, across species (Safer & Allen 1971; Squire 1969; Glick & Jarvik 1969; Talpos et al. 
2014; Sambeth et al. 2015; Klinkenberg & Blokland 2011). There is also some evidence that 
long term biperiden use may adversely affect cognitive functioning (Ogino et al. 2014). The 
putative clinical utility of targeting mAChRs for pro-motivational purposes should therefore 
be tempered by the potential cognitive impairment that could result from treatment. However, 
the dose of biperiden found to be effective in PR here is lower than those required to observe 
cognitive disruptions across several preclinical assays (Klinkenberg & Blokland 2011; Talpos 
et al. 2014; Malikowska et al. 2017). Furthermore, biperiden is currently used as a treatment in 
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PD and for the extrapyramidal side effects associated with antipsychotic treatment in 
Schizophrenia (Gjerden et al. 2009), suggesting that it can be administered in a clinically 
beneficial manner.  
 
7.4.5 Conclusions 
The present results highlight that biperiden can successfully rescue a preclinical model of 
apathy arising from dopamine receptor blockade. The more selective mAChR antagonist 
biperiden demonstrated greater efficacy in reversing the effects of haloperidol than the 
nonselective compound scopolamine. However, it is not clear whether this is due to differences 
in the selectivity profile of the compounds or some other factor. Together, the present results 
strengthen the preclinical evidence for a potential therapeutic benefit of biperiden, particularly 




Chapter 8. General discussion 
 
8.1 Overview 
In recent years, there has been an increased focus on additional symptoms of neurodegenerative 
and psychiatric conditions. These include cognitive impairments such as memory, attention 
and executive functions (Marder 2006; Harvey 2008; Husain & Mehta 2011).  Alongside these 
symptoms, impairments in motivation have been shown, across disorders, to be predictive of 
several key outcome measures such as patient quality of life, disease progression and caregiver 
burden. The aim of this present work was to facilitate the discovery of new approaches for the 
treatment of apathy. This was attempted by two separate approaches. Firstly, to refine the 
approaches used to measure motivated behaviour in rodents to maximise the likelihood of 
results translating across species. Secondly, to identify and interrogate a new pharmacological 
target for apathy. 
 
8.2 Part 1: Facilitating cross-species translation. 
The repeated failure of the effects of drug treatments to translate from rodents to humans is a 
major obstacle in the development of new CNS medicines (Geerts 2009; Cummings et al. 
2014). There are likely a number of contributions to this “translational gap”, ranging from 
inherent species differences and inappropriate experimental design to a lack of formal training 
in behavioural neuroscience  (Zahs & Ashe 2010; Knopp et al. 2015; Bespalov & Steckler 
2018). One key issue is the valid measurement of the constructs of interest in rodent 
preparations. Constructs such as memory and executive function can be readily measured in 
rodents (Keeler & Robbins 2011); however, the ability to model other clinical symptomology 
is more problematic. For example,  attempts at modelling symptoms of psychosis, or depression 
in rodents has been problematic (Bergner et al. 2010; Forrest et al. 2014). Moreover, this has 
given rise to the term “-like” behaviour, which has been criticised as potentially masking a lack 
of validity (Garner 2014). In contrast, numerous studies have reported that motivation, through 
measuring effort, can be accurately measured in rodents (Salamone, Yohn, et al. 2016). 
Furthermore, a review of the literature (chapter 1) suggests that a number of pharmacological 
effects of drugs on effort-based behaviour translate from rodents into the clinic. 
 
It may be possible to further refine the preclinical study of motivation to facilitate the likelihood 
of cross-species translation. One such approach has been to develop touchscreen-based assays 
for rodents (Hvoslef-Eide et al. 2016) that closer resemble the automated batteries used in 
nonhuman primates and humans (Owen et al. 1993; Weed et al. 1999). This approach can allow 
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near-identical tasks to be administered across species (Nithianantharajah et al. 2015).  Effort-
based behaviour can be readily assessed in a number of species (Cagniard et al. 2006; Treadway 
et al. 2009; Varazzani et al. 2015). However, the majority of previous pharmacological studies 
have been conducted in rats (reviewed in chapter 1). We therefore sought to develop and 
validate a battery of touchscreen-tasks to assess effort-based behaviour  and decision making 
in rats. The PR task in particular seemed well suited to application within the rat operant 
touchscreen systems demonstrating sensitivity to detect changes in both outcome value and 
dopaminergic challenge. The key outcome of this study is that highly similar PR touchscreen 
assays can now be administered in rats, as well as mice, nonhuman primates and humans. 
Another observation arising from this study was the demonstration that multiple measures can 
be taken during operant responding to inform of changes in motivation. Through the use of 
such complementary measures, we were able to dissociate the effects of outcome 
manipulations and dopaminergic drugs which produce equivalent effects upon behaviour.  
Such an approach is especially relevant in the study of motivation where motoric changes could 
easily confound results (Bailey et al. 2015). Furthermore, a number of these measures can also 
be assessed in human participants (Williams et al. 2011).  
 
However, the assays of effort-based decision-making, appeared less suited for use in rat 
touchscreen systems, in their current design. For example, high rates of low-effort chow 
consumption in effort-related choice (ERC) and omission rates in effort discounting (EFD), 
suggest that, at least with the current parameters, these tasks may be too effortful. This problem 
was further demonstrated through the use of raclopride, which increased the rates of omissions, 
rather than reward discounting. It is possible, that altering task parameters or training 
procedures may improve performance in these tasks. In particular, it may be necessary to 
reduce the ratio requirements for the high-effort options. A novel rearing effort discounting 
(RED) task, displayed initial promise by demonstrating sensitivity to alterations to the costs 
and benefits of high effort choices. However, there was a clear practice effect from repeated 
task exposure, which reduced the rate of discounting. As a consequence, the actions needed for 
the high value reward were not sufficiently effortful to cause a reliable shift to the low value 
reward. Again, systemic administration of the D2/D3 receptor antagonist raclopride highlighted 
this problem. It would be expected that dopamine antagonists exert greater effects at later, 
higher effort trials (Floresco et al. 2008), which was not observed. 
 
Due to problems with theses effort-based decision-making tasks, an alternative approach would 
be to initially screen for potential effects on behaviour using a PR task, and subsequently 
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follow-up any positive results using a battery of control tasks (e.g. Bailey, Williamson, et al. 
2016). However, it should be noted that this approach would require the use of a greater number 
of experimental animals, which may be ethically and financially disadvantageous.  
 
The use of functional imaging could also facilitate translational research. Such approaches 
could be used to demonstrate that a behavioural assay is engaging equivalent neural circuitry 
across species (Keeler & Robbins 2011). In vivo oxygen amperometry was chosen as it can 
provide a viable and valid proxy measure of fMRI-BOLD, the most widely used functional 
measure in humans. We found that the degree of NAc activity evoked by a food reward was 
correlated with individual differences in motivated behaviour as measured by PR performance. 
To date, no study has combined fMRI (or any other imaging measure) with PR responding in 
humans. However, it would be possible to apply event-related fMRI and PR to investigate 
whether this relationship between performance and NAc activity can also been observed in 
humans. This would further strengthen the argument for the use of PR schedules as preclinical 
assays of motivation It would also be useful to determine whether such a signal is reduced in 
apathetic populations. Furthermore, functional imaging of hemodynamic responses can be used 
to demonstrate that a compound is exerting an expected central pharmacological effect (Wise 
& Tracey 2006; Li et al. 2016). By using a translational technique such as oxygen 
amperometry, such drug effects could subsequently be compared across species. Combining 
functional imaging with pharmacology has been proposed as a method to reduce expensive 
clinical trial failures (Wager & Woo 2015; Duff et al. 2015). Finally, imaging could be used to 
validate preclinical models of amotivation, by demonstrating similar deficits to those observed 
within clinical populations.   
 
There are several potential limitations arising from this study. Amperometry, like fMRI, 
provides only a surrogate measure of neural activity. There are a number of techniques 
available that allow for direct measurement of  neural or neurochemical activity such as 
microdialysis or electrophysiological recordings.  Such measurements may be better suited to 
the study of pharmacological effects on motivated behaviour. This is because a number of 
drugs and disease states can alter the neurovascular coupling processes that allow for 
haemodynamic measures to be proxies of neural activity (D’Esposito et al. 2003; Wise & 
Tracey 2006; Diukova et al. 2012). Furthermore, imaging provides only a correlate of 
behaviour, and does not demonstrate a causal association. Neuromodulatory techniques such 
as optogenetics could be used to demonstrate a causal link between the activity of a given 
population of neurons and behaviour. However, none of the direct measures can be readily 
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performed in humans. Therefore, a major strength of this study is the translatability of the 
results. Nevertheless, it would be useful for future studies to also use more direct measures of 
neurochemical function, particularly when testing the effects of pharmacological interventions. 
 
8.3 Part 2: Muscarinic acetylcholine receptors as novel targets for apathy  
We subsequently aimed to investigate a potential novel target for the facilitation of motivated 
behaviour in rodents. Muscarinic acetylcholine receptors (mAChRs) were chosen based upon 
a review of the literature demonstrating an established interaction with the dopaminergic 
system (Chapter 1). Scopolamine, a nonselective mAChR antagonist, facilitated PR 
performance, but also appeared to increase locomotor activity. Subsequently, through 
administration of more-selective mAChR antagonists, we found that the effects upon effort-
output were likely mediated through the M1 receptor; whereas the effects on locomotor activity 
were likely to be occurring through the M4 receptor subtype. Subsequently, through the use of 
a battery of control tasks, we found that the effects of the M1 receptor antagonist biperiden 
were goal-directed and unlikely to be caused by changes in satiety, appetite, fatigue or 
perseverative behaviour. 
 
One major limitation of the present study was the selectivity of the compounds used. Due to 
the physiological nature of muscarinic receptors, it has not been possible to produce highly 
selective ligands. Compounds with greater selectivity for both the M1 and M4 receptor subtypes 
exist (Sheffler et al. 2009; Croy et al. 2016). However, these drugs have poor brain penetrance. 
The compounds used in the present study were selected as having a balance between selectivity 
and an ability to exert centrally-mediated behavioural effects. In spite of the moderate 
selectivity profiles, a number of other studies support the study’s conclusion of a relationship 
between M1 receptors and motivated behaviour. For example, a more selective M1 antagonist 
is able to reverse the motoric effects associated with high doses of haloperidol (Kharkwal et al. 
2016). Additionally, through the local administration of a number of muscarinic receptor 
antagonists, with varying degrees of subtype selectivity, it affinity for the M1 receptor predicted 
the efficacy in preventing haloperidol-induced catalepsy (Erosa-Rivero et al. 2014). However, 
even on the basis of these studies alone it should not be conclusively claimed that the effects 
of biperiden upon motivation are driven by actions at the M1 receptor. Combining the effects 





Having demonstrated an effect on motivation, we subsequently aimed to test the effects of 
muscarinic receptor antagonists upon a deficit model.  Previous reports had suggested that aged 
rodents display deficits in PR performance relative to young controls (Blokland & Raaijmakers 
1993; Bordner et al. 2011; Amancio-Belmont et al. 2017). Initially, we replicated this age-
related deficit; however, in subsequent cohorts, aged rats showed no difference in motivation. 
This was likely a consequence of a change in feeding protocols that better controlled for the 
bodyweight differences between the age groups. It is possible that the long-term feeding 
schedule reduced age-related changes in feeding behaviours. Therefore, the initial results of an 
age-related decline in PR performance may have been confounded by group differences in 
appetite or satiety. It is also possible that such a confound occurred in the previous reports, 
which did not attempt to control for differences in weight.  Together, this finding suggests that 
aged rats are not a suitable preclinical model of apathy. Aside from the lack of a behavioural 
deficit displayed by the aged rats, there are a number of problems that would have arisen using 
aging as a model, including differential stress reactivity (Buechel et al. 2014) and the effects 
of life experiences (Gallagher et al. 2011) could also confound results. 
 
Given the lack of a deficit in aged animals, we subsequently tested the effects of biperiden and 
scopolamine in a well-validated model of impaired motivation. Haloperidol was chosen as it 
has been shown to be effective across a number of assays of effort-related behaviour, including 
both operant and maze-based effort-related choice (Salamone et al. 1991; Salamone et al. 1994) 
and effort discounting assays (Bardgett et al. 2009). Different classes of drugs, including 
adenosine receptor antagonists and psychostimulants are able to ameliorate the effects of 
haloperidol on effort-related behaviour (Bardgett et al. 2009; Mott et al. 2009). The use of such 
reversal studies has been suggested to be a useful test of potential therapeutic efficacy of 
compounds (Farrar et al. 2007). We found that biperiden was able to reverse the behavioural 
effects of haloperidol upon PR and an effort-related choice (ERC) assay. This finding suggests 
that muscarinic receptor antagonism may be a particularly useful therapeutic approach for 
disorders of motivation arising from hypodopaminergic sates or following dopamine 
antagonist treatments. Haloperidol has also been reported to produce psychomotor slowing 
(Salamone et al. 1993), mirroring the effects of fatigue or anergia frequently reported in clinical 
populations (Friedman & Friedman 1993; Lou et al. 2003). However, such symptoms may be 
more reflective of depression, which is a separate construct from apathy (Levy et al. 1998).  
 
8.4 Enhancing motivation in healthy subjects 
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The focus of the present studies was to investigate a novel pharmacological target for clinical 
apathy. We found that biperiden was effective at facilitating motivation in intact mice in 
addition to those displaying a deficit. It is possible that motivation, as a cognitive process, could 
be enhanced pharmacologically in heathy subjects (Turner et al. 2003). There are already 
reports of otherwise heathy people using psychostimulants such as methylphenidate for 
perceived pro-motivational effects (Ilieva & Farah 2013). Participants self-report that the 
effects on motivation were greater than many perceived effects on other cognitive domains 
(Ilieva & Farah 2013). The effects of psychostimulants on motivation, in healthy subjects, are 
in line with a laboratory study suggesting that amphetamine increases effort expenditure in 
heathy subjects (Wardle et al. 2011). The use of compounds to enhance motivation in the 
general population may raise ethical considerations (Kjærsgaard 2015). The ethical 
considerations of pharmacological enhancement of cognition in the healthy population have 
been debated elsewhere (Farah et al. 2004; Porsdam Mann & Sahakian 2015). It is likely that 
putative pro-motivational drugs deserve a similar level of scrutiny. 
 
8.5 General limitations 
Throughout the present studies, effort was used as a way of operationalising motivation for 
measurement in rodents. Previous studies have suggested that apathy, as seen in clinical 
populations, seems to reflect deficits in behavioural activation (Salamone, Yohn, et al. 2016). 
However, in clinical cases, it is likely that apathy may arise from deficits in a number of 
processes including reward anticipation and decision making (Husain & Roiser 2018). Exertion 
of effort as measured by PR performance likely only captures an aspect of apathy as displayed 
by patient groups. Even within preclinical research there are multiple assays that are used to 
probe different aspects of motivational disruptions (Markou et al. 2013; Barnes et al. 2017). 
Development of novel treatments for apathy may also wish to examine the effects of 
compounds upon other tasks such as assays for ‘cognitive effort’ (Cocker et al. 2012)  
emotional/affective constructs (Robinson 2018) and reward anticipation (Barch et al. 2016).  
 
An additional concern is that the assays used were measuring some construct unrelated to 
effort. In the majority of studies used, a touch sensitive screen was used as a manipulandum. 
As discussed in a previous chapter (chapter 2), no physical effort is needed for a response to 
be recorded. Therefore, the extent to which a touchscreen-based assays can capture effort-based 
behaviours may be questioned. However, the present work (chapter 2), along with a previous 
study (Heath et al., 2015) suggests that the use of touchscreen can support the energetic, 
repetitive responding performed by rodents during effort-based assays. Furthermore, the 
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cognitive processes governing effort are at least partly independent from motoric processes 
(Salamone & Correa, 2012). Therefore, the use of touchscreen as a manipulandum is unlikely 
to have confounded the present results.  
 
In the present studies, time-limited PR sessions were used. The selection of session length and 
no-response periods was somewhat arbitrary but based on previous reports (Wirtshafter & 
Stratford 2010; Klinkenberg & Blokland 2011; Enkel et al. 2014; Heath et al. 2015).  However, 
the choice of these parameters could easily affect breakpoint, particularly when investigating 
the effects of putatively performance enhancing compounds. A further potential issue arises 
from the behavioural measures adopted. Many of the supplementary measures of performance 
other than breakpoint adopted in this thesis have been less commonly used. For example, the 
rate of IR beam breaks and nontarget screen touches were used as measures of general activity. 
The justification for this has been the observation that pharmacological manipulations affect 
these measures similarly to  traditional measures of locomotor activity such as the open field 
and inactive lever-press (Marriott 1968; Pijnenburg et al. 1975; Hillegaart & Ahlenius 1987; 
Heath et al. 2015). However, it is only assumed, rather than known that these measures equate 
to one another. Furthermore, the basis for the response bout-analysis adopted in the present set 
of studies is somewhat arbitrary. A 5s period without responses was taken the signify the end 
of a bout. Previous investigations of response bouts have used a 2s no-response period to define 
the end of a bout (Ko & Wanat 2016; Boekhoudt et al. 2018). However, these have used lever-
based operant systems. The rate of responding is considerably lower within the touchscreen 
system compared to lever-based system (chapter 2). Therefore, based upon differences in 
breakpoints and response rates observed between the two systems, increasing the period to 5s 
seemed justified. A separate approach may have been to define the end of a bout by the 
presence of a separate action (such as a nontarget touch or IR beam break). However, based 
upon visual inspection of rodents performing PR, it was noted that during the sustained 
repetitive responding, rodents would occasionally make nontarget contact either side of the 
response aperture or move in such a way that their hindquarters may have triggered an IR beam 
break. In these cases, the use of such an action-based definition may have confounded 
measurement of response bouts 
 
Another general limitation with the current set of studies is the reliance on systemic 
pharmacology. Whereas, this is not necessarily problematic when investigating the therapeutic 
potential of muscarinic receptor antagonists, it cannot inform us as to the location of the actions 
of these drugs.  Based on a review of the literature (reviewed in chapter 1), it is likely that the 
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effective compounds were acting upon muscarinic receptors within the nucleus accumbens 
core.  However, local administration studies should be used to confirm this. Previous studies 
have also used disconnection lesions to determine the output pathway of pro-motivational 
drugs (Mingote et al. 2008) This approach could also be used to identify regional differences 
within the NAc. The involvement of the core and shell subregions in effort-based behaviour  is 
still not entirely clear (Bailey, Simpson, et al. 2016). Furthermore, it is not known whether 
compounds that enhance motivation are preferentially affecting on one region or another 
(Mingote et al. 2008). Being able to identify the location of a compounds actions would likely 




Through the study of effort exertion in rodents, it may be possible to identify novel 
pharmacological interventions that target motivation-related impairments. Such impairments 
are largely refractory to current treatment approaches. The work described presently outlines 
ways to facilitate cross-species assessment of motivated behaviour by validating translational 
touchscreen testing methods for motivational processes and identifying a translational neural 
signature of motivated behaviour. We were also able to demonstrate that, contrary to previous 
reports,  healthy aging in rats is not reliably associated with any motivational impairments. 
Invalidation, through demonstration of such negative results  is crucial for scientific progress 
(Popper 1959; Rosenthal 1979). Furthermore, through the use of touchscreen tests of 
motivation we identified that the antiparkinsonian drug biperiden was able facilitate motivated 
behaviour in both healthy mice and those displaying a deficit. Future studies can now 
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